<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001765.pub3" GROUP_ID="DEPRESSN" ID="609499092022113083" MERGED_FROM="" MODIFIED="2008-11-06 04:42:49 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Short title (no longer in use): SSRIs compared to placebo in OCD [Protocol]&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-06 03:38:14 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="36" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2008-11-06 04:42:49 +0100" MODIFIED_BY="Rachel Churchill">
<TITLE>Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)</TITLE>
<CONTACT MODIFIED="2008-11-06 04:42:49 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="2D166E2582E26AA200DE9984720A09D8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>G Mustafa</FIRST_NAME><LAST_NAME>Soomro</LAST_NAME><POSITION>Honorary Research Fellow</POSITION><EMAIL_1>gms357@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>St. George's Hospital Medical School</ORGANISATION><ADDRESS_1>University of London</ADDRESS_1><ADDRESS_2>Cranmer Terrace</ADDRESS_2><CITY>London</CITY><ZIP>SW17 0RE</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-06 04:42:49 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="2D166E2582E26AA200DE9984720A09D8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>G Mustafa</FIRST_NAME><LAST_NAME>Soomro</LAST_NAME><POSITION>Honorary Research Fellow</POSITION><EMAIL_1>gms357@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>St. George's Hospital Medical School</ORGANISATION><ADDRESS_1>University of London</ADDRESS_1><ADDRESS_2>Cranmer Terrace</ADDRESS_2><CITY>London</CITY><ZIP>SW17 0RE</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="7126" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Douglas</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Altman</LAST_NAME><POSITION>Convenor</POSITION><EMAIL_1>doug.altman@csm.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Statistics in Medicine</DEPARTMENT><ORGANISATION>Wolfson College Annexe</ORGANISATION><ADDRESS_1>Linton Road</ADDRESS_1><CITY>Oxford</CITY><ZIP>OX2 6UD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 284401</PHONE_1><FAX_1>+44 1865 284424</FAX_1></ADDRESS></PERSON><PERSON ID="399219B082E26AA2010715371D791F39" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sundararajan</FIRST_NAME><LAST_NAME>Rajagopal</LAST_NAME><POSITION>Consultant Psychiatrist</POSITION><EMAIL_1>Sundararajan.Rajogopal@slam.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Adamson Centre for Mental Health</DEPARTMENT><ORGANISATION>South London and Maudsley NHS Trust</ORGANISATION><ADDRESS_1>St Thomas's Hospital</ADDRESS_1><CITY>London</CITY><ZIP>SE1 7EH</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="4885" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Mark</FIRST_NAME><LAST_NAME>Oakley Browne</LAST_NAME><POSITION>Professor and Director</POSITION><EMAIL_1>mark.oakleybrowne@med.monash.edu.au</EMAIL_1><EMAIL_2>markoakleybrowne@dcsi.net.au</EMAIL_2><URL>www.med.monash.edu.au/srh</URL><ADDRESS><DEPARTMENT>Department of Rural and Indigenous Health </DEPARTMENT><ORGANISATION>School of Rural Health </ORGANISATION><ADDRESS_1>Faculty of Medicine, Nursing and Health Sciences </ADDRESS_1><ADDRESS_2>Monash University</ADDRESS_2><CITY>PO Box 973 Moe </CITY><ZIP>3825</ZIP><REGION>Victoria</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 5128 1004 </PHONE_1><FAX_1>+61 3 5128 1080</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-06 04:42:49 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Minor update: 22/10/07&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 12/11/07&lt;/p&gt;">
<UP_TO_DATE>
<DATE DAY="12" MONTH="11" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="11" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="11" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="6" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="10" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>St Georges Hospital Medical School, London SW17 0RE</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Systematic Reviews Training Unit, Institute of Child Health, London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)</TITLE>
<SUMMARY_BODY>
<P>Obsessive compulsive disorder (OCD) is a common and disabling disorder, which frequently follows a chronic course. It is characterised by intrusive thoughts of imagined harm, which are difficult to dispel, and ritualistic behaviour such as repetitive washing of hands and repetitive checking for risk of harm. Individual randomised controlled trials have demonstrated that antidepressants are effective for OCD. This review summarises all the available evidence for one class of antidepressant drugs, the selective serotonin re-uptake inhibitors (SSRIs) (including citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) compared to placebo in the treatment of OCD in adults. The review included 17 studies (3097 participants), and showed that SSRIs were effective in reducing the symptoms of OCD. Based on 13 studies (2697 participants), the review showed that people receiving SSRIs were nearly twice as likely as those receiving placebo to achieve clinical response (defined as a 25% or more reduction in symptoms). Indirect comparisons of effectiveness suggested that although individual SSRI drugs were similar in their effectiveness, they differed in terms of their adverse effects. The most common adverse effect reported by participants was nausea. Further studies involving head to head comparisons between different SSRI drugs are required to obtain more reliable information on differences between SSRIs, both in terms of effectiveness and adverse effects. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Obsessive compulsive disorder is a common and disabling disorder. A significant proportion of patients manifest a chronic course. Individual randomised controlled trials (RCTs) have shown that selective serotonin re-uptake inhibitors (SSRIs) are effective in this condition. Previous systematic reviews or meta-analyses summarising the evidence are methodologically problematic or limited in the scope of their analysis.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To examine the efficacy and adverse effects of serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) in adults. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>CCDANCTR-Studies and CCDANCTR-References were searched on 12/11/2007. Reference lists were checked. Experts in the field were contacted.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All RCTs and quasi-RCTs examining the efficacy of SSRIs compared with placebo for OCD in adults were eligible for inclusion. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Selection of studies and data extraction were carried out by two review authors independently, and quality assessment of studies was undertaken. Data analysis was conducted using Review Manager software. Summary measures were produced using the weighted mean difference (WMD) for continuous data and relative risk (RR) for dichotomous data, with 95% confidence intervals (CI). SSRIs were examined as an overall group of drugs, and as individual drugs. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Seventeen studies were included in the review, involving 3097 participants. Based on all 17 studies, SSRIs as a group were more effective than placebo in reducing the symptoms of OCD between 6 and 13 weeks post-treatment, measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS) (WMD -3.21, 95% CI -3.84 to -2.57). The WMD for individual SSRI drugs were similar and not statistically different. Based on 13 studies (2697 participants), SSRIs were more effective than placebo in achieving clinical response at post-treatment (RR 1.84, 95% CI 1.56 to 2.17). The pooled RR was shown to be similar between individual SSRI drugs. Although reported adverse effects data were more limited, with few exceptions, the overall and individual adverse effects for the different SSRIs were always worse than for placebo and, in the majority of cases, the difference was statistically significant. Nausea, headache and insomnia were always reported amongst the most common adverse effects in trials of each of the drugs. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>SSRIs are more effective than placebo for OCD, at least in the short-term, although there are differences between the adverse effects of individual SSRI drugs. The longer term efficacy and tolerability of different SSRI drugs for OCD has yet to be established. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>
<B>Description of condition</B>
<BR/>Obsessive compulsive disorder (OCD) is characterised by obsessions and compulsions. Obsessions are recurrent intrusive and unwanted thoughts that the sufferer cannot dispel. Common themes of the obsessional thoughts include thoughts that the person may cause harm to others or that harm may befall others, or thoughts that the person or others are contaminated. Other common themes of obsessional thoughts are centred on the need for order, symmetry or perfection. The obsessional thoughts are associated with negative affect, usually anxiety, but other emotions such as disgust, guilt or shame may also be experienced. As a response to the feelings generated by the obsessional thoughts, the person may perform compulsions, and performance of the compulsions temporarily decreases the negative affect. The compulsions are stereotypic, ritualised behaviours that are usually observable but which may include covert mental rituals. Common overt rituals include repetitive checking, washing or cleaning, or repetitive rearranging and ordering of objects. Examples of covert mental rituals include repetitive counting, praying or thinking magical statements (<LINK REF="REF-Gelder-2001" TYPE="REFERENCE">Gelder 2001</LINK>). </P>
<P>Obsessive compulsive disorder is one of the most disabling of anxiety disorders. The obsessions and compulsions may occupy many hours of the person's day and cause severe distress and disruption to the person's life (<LINK REF="REF-Rasmussen-1989" TYPE="REFERENCE">Rasmussen 1989</LINK>), as well as disruption to their families (<LINK REF="REF-Chakrabarti-1993" TYPE="REFERENCE">Chakrabarti 1993</LINK>).</P>
<P>Recent community-based epidemiological studies have shown that the prevalence of OCD is much higher than previous reports based on clinical samples. The cross-sectional prevalence of OCD in the UK was 1% in males and 1.5% in females according to a national survey carried out in 1993 of psychiatric morbidity based on interviews with a nationally representative sample of approximately 10000 people living in private households (<LINK REF="REF-Bebbington-1998" TYPE="REFERENCE">Bebbington 1998</LINK>). In the USA, the lifetime prevalence of OCD was found to be between 1.9% and 3.3% based on the epidemiological catchment area (ECA) study carried out in 1984 of a representative sample of 18500 people from five geographical areas (<LINK REF="REF-Karno-1988" TYPE="REFERENCE">Karno 1988</LINK>). In a cross national study carried out using methodology similar to ECA study, lifetime prevalence was found to be 3% in Canada, 3.1% in Puerto Rico, 0.3 to .9% in Taiwan and 2.2% in New Zealand (<LINK REF="REF-Bebbington-1998" TYPE="REFERENCE">Bebbington 1998</LINK>).</P>
<P>Follow-up studies suggest varied outcome. A one year prospective study of 101 patients showed an episodic course in 46% and a chronic course in 54% of patients (<LINK REF="REF-Ravizza-1997" TYPE="REFERENCE">Ravizza 1997</LINK>). Another follow up study of 144 patients, with a mean follow up of 47 years, showed complete remission in 20% and partial improvement in 63% of participants. It also showed that episodic course was common during first 1-9 years and that chronic course was common in the later years (<LINK REF="REF-Skoog-1999" TYPE="REFERENCE">Skoog 1999</LINK>). A 2-year prospective study of 65 patients showed complete remission in 12% and partial remission in 47% of patients (<LINK REF="REF-Eisen-1999" TYPE="REFERENCE">Eisen 1999</LINK>).</P>
<P>Aetiology of OCD is uncertain. However current hypotheses for aetiology relate to the possible role of genetic, biological, behavioural and cognitive factors. Although controlled family and twin studies provide some support for the genetic hypothesis, it still remains tentative because the results of studies are inconsistent and in some studies there is no evidence for specific inheritance of OCD (<LINK REF="REF-Alsobrook-1998" TYPE="REFERENCE">Alsobrook 1998</LINK>). This may however suggest that OCD is a heterogeneous condition. The evidence that only serotonin reuptake inhibitor (SRI) antidepressants (and not other antidepressants) are effective in OCD led to the development of serotonergic hypothesis (<LINK REF="REF-Barr-1993" TYPE="REFERENCE">Barr 1993</LINK>), which although plausible but has not been proven conclusively. The hypothesis suggests that there is some abnormality (presumably a reduction of function) of serotonergic system in OCD or that serotonergic system is implicated in some way in the pathophysiology of OCD. However, the results from studies of peripheral receptor binding in blood and of the relevant metabolites levels in CSF employing comparisons with control values are inconsistent (<LINK REF="REF-Rauch-1998a" TYPE="REFERENCE">Rauch 1998a</LINK>). Furthermore, serotonin depletion studies do not result in reversal of anti-obsessional drug action or exacerbation of OCD symptoms as would be predicted by the hypothesis (<LINK REF="REF-Delgado-1998" TYPE="REFERENCE">Delgado 1998</LINK>). Thus, it would appear that serotonin plays some part in the disorder, but that perhaps its role may not be primary, but secondary and modulatory. Neuroimaging studies using cross-sectional controlled and pre and post-intervention designs suggest abnormalities of orbito-frontal region and basal ganglia (<LINK REF="REF-Saxena-1998" TYPE="REFERENCE">Saxena 1998</LINK>, <LINK REF="REF-Rauch-1998b" TYPE="REFERENCE">Rauch 1998b</LINK>). The evidence for behavioural (<LINK REF="REF-Baer-1998" TYPE="REFERENCE">Baer 1998</LINK>) and cognitive factors (<LINK REF="REF-Steketee-1998" TYPE="REFERENCE">Steketee 1998</LINK>) is mainly indirect and is based on the observations that specific behavioural and cognitive interventions have been found to be effective in OCD. </P>
<P>
<B>Description of intervention</B>
<BR/>Over the last few decades, a number of treatment strategies have been developed for most anxiety disorders, including OCD, and tested in randomised controlled trials (RCTs). For OCD, a widely used and effective psychological treatment strategy is behavioural therapy, which consists of exposure-in-vivo coupled with response prevention (<LINK REF="REF-Soomro-2003" TYPE="REFERENCE">Soomro 2003</LINK>). Some patients may find difficult to engage in behavioural therapy because of the intense anxiety experienced in carrying it out. Unfortunately about 25% of patients offered this form of treatment refuse it, and of those who do accept, 10-20% make minimal gains. Drug treatment with antidepressants may offer help to some of these patients, and also to other OCD patients as a treatment of first choice. </P>
<P>Evidence from individual RCTs shows that serotonin reuptake inhibitors are effective in OCD. Serotonin reuptake inhibitors include non-selective and selective serotonin reuptake inhibitors (SSRIs), an example of the former being clomipramine, and of the latter being citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline. </P>
<P>
<B>Why it is important to do this review</B>
<BR/>Of twelve previously published systematic reviews or meta-analyses on SSRIs for OCD (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for summary), eight have serious methodological problems (<LINK REF="REF-QAP-1985" TYPE="REFERENCE">QAP 1985</LINK>, <LINK REF="REF-Christensen-1987" TYPE="REFERENCE">Christensen 1987</LINK>, <LINK REF="REF-Jenike-1990d" TYPE="REFERENCE">Jenike 1990d</LINK>, <LINK REF="REF-Jenike-1990c" TYPE="REFERENCE">Jenike 1990c</LINK>, <LINK REF="REF-Cox-1993" TYPE="REFERENCE">Cox 1993</LINK>, <LINK REF="REF-van-Balkom-1994" TYPE="REFERENCE">van Balkom 1994</LINK>, <LINK REF="REF-Greist-1995" TYPE="REFERENCE">Greist 1995</LINK>, <LINK REF="REF-Stein-1995" TYPE="REFERENCE">Stein 1995</LINK>) in that they have used inadequate literature search strategies, have used inappropriate study selection criteria, and/ or when using mixed study designs, did not report separate or adjusted results for RCTs. Although three further reviews (<LINK REF="REF-Piccinelli-1995" TYPE="REFERENCE">Piccinelli 1995</LINK>, <LINK REF="REF-Abramowitz-1997" TYPE="REFERENCE">Abramowitz 1997</LINK>, <LINK REF="REF-Kobak-1998" TYPE="REFERENCE">Kobak 1998</LINK>) were free from these serious flaws, they showed other significant problems, including absence of heterogeneity investigation, using fixed effects models in presence of significant statistical heterogeneity and/or not weighting studies according to sample size. None of these eleven reviews explicitly assessed and or explored the methodological quality of the studies used. The twelfth review (<LINK REF="REF-Ackerman-2002" TYPE="REFERENCE">Ackerman 2002</LINK>) is methodologically sound, however, it did not carry out responder and adverse effects analysis. Furthermore, in relation to sertraline, its analysis was inadequate in the sense that it only analysed this drug versus placebo at a lower dose of 50mg, with findings indicating that it was not superior to placebo, although other RCT evidence has shown sertraline at higher doses to be effective versus placebo. The current review aimed to provide a comprehensive, updating summary and meta-analysis on the effectiveness and adverse effects of SSRIs for OCD.</P>
</BACKGROUND>
<OBJECTIVES>
<P>1) To identify and systematically review evidence of effectiveness of SSRIs in obsessive compulsive disorder in patients of adult age in comparison to placebo<BR/>2) To estimate summary effect sizes (pooled relative risk and weighted or standardised mean differences as appropriate) of the treatments if appropriate<BR/>3) To carry out an assessment of relationship between effect sizes and methodological features of the studies and demographic and clinical features of patients and treatment characteristics<BR/>4) To systematically review and pool data on adverse effects. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All trials described as randomised controlled trials (RCTs) or quasi-randomised trials of SSRIs versus placebo in obsessive compulsive disorder were considered for inclusion in the review, including cross-over trials if the relevant data were available for the trial period before the point of cross-over (post-cross-over data would not be appropriate because there would be a carryover effect of active drug from pre- to post-cross-over phase). Quasi-randomised trials are those where allocation sequence is generated by rules that are not truly random, such as allocation by date of birth, day of the week, medical record number etc. There is greater likelihood of allocation not being adequately concealed in these trials, leading to selection bias. </P>
<P>Both published and unpublished studies were considered for inclusion, as there is evidence of publication bias in favour of studies with positive results (<LINK REF="REF-Dickersin-1992" TYPE="REFERENCE">Dickersin 1992</LINK>; <LINK REF="REF-Easterbrook-1991" TYPE="REFERENCE">Easterbrook 1991</LINK>; <LINK REF="REF-Scherer-1994" TYPE="REFERENCE">Scherer 1994</LINK>), therefore, ignoring unpublished studies could introduce bias into a systematic review. Studies were not excluded on the basis of sample size or duration of follow up.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>RCTs investigating adult patients (aged 18 years and above) of either sex and any cultural background suffering with OCD were considered for inclusion in the review. </P>
<P>Any commonly accepted diagnostic criteria for OCD were considered eligible, such as International Classification of Diseases, 9th or 10th edition (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>) or Diagnostic and Statistical Manual of Mental Disorders (DSM), editions III, IIII-R or IV (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>) or some other accepted /standardised criteria. Studies involving patients with other DSM Axis I disorders were excluded, with the exception of secondary depression.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The intervention of interest was selective serotonin re-uptake inhibitors (SSRIs), at any dose and regimen. The SSRIs include fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram and escitalopram. Only comparisons with placebo were considered. Only those studies where SSRIs were a stand-alone intervention were considered eligible. </P>
<P>RCTs in which SSRIs were used in combination with some other treatment, and which did not allow direct comparison of SSRIs with placebo (i.e. confounded RCTs) were not eligible for inclusion. However, if such RCTs allowed comparison of SSRIs versus placebo, they were considered conceptually eligible for the question of this review. Such trials are likely to show lower (than the true) effectiveness of SSRIs versus placebo, and should not be combined in meta-analysis of trials which used one intervention per arm. However, these trials could be managed as a separate subset within the review, and may be considered for a future update of this review.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>Primary outcome</B>
<BR/>The primary outcome was:<BR/>1) Symptomatic improvement measured as a continuous outcome through reduction in Yale-Brown Obsessive Compulsive Scale (YBOCS) scores (<LINK REF="REF-Goodman-1989a" TYPE="REFERENCE">Goodman 1989a</LINK>; <LINK REF="REF-Kim-1990" TYPE="REFERENCE">Kim 1990</LINK>). Measurement of outcomes was considered in terms of change differences. Where change data for these were not available or calculable, then end point differences were considered.<BR/>2) Response rate as a dichotomous outcome, defined as 25% or more reduction in YBOCS (a common cut off point used in trials)<BR/>It was expected that most trials would use YBOCS, as it is most widely used observer rated severity scale in OCD research and has been investigated for validity and reliability. Range of YBOCS is 0 to 40 (higher score representing more severe symptoms). However, if YBOCS was not used by a trial, then it was decided that some other objective instrument of acceptable reliability and validity would be used. Other observer rated but mainly symptom-related instruments used for obsessive compulsive disorder are Psychopathological Rating Scale (PRS) and Symptom Checklist List 90 (SCL 90) (<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>; <LINK REF="REF-Goodman-1998" TYPE="REFERENCE">Goodman 1998</LINK>). </P>
<P>
<B>Secondary outcomes</B>
<BR/>1) Global assessment of severity of OCD symptoms was used as the main secondary outcome of interest. Scales measuring severity in this way are National Institute of Mental Health Obsessive Compulsive scale (NIMH-OCS), the Clinical Global Impression (CGI) scale for severity and the Clinical Global Impression (CGI) scale for improvement (<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>). It was also decided that self-rated instruments would be considered as secondary measures if used by the majority of the trials. Examples of self-rated instruments are Maudsley Obsessional-Compulsive Inventory (MOCI) (<LINK REF="REF-Hodgson-1977" TYPE="REFERENCE">Hodgson 1977</LINK>) and Padua Inventory (<LINK REF="REF-Goodman-1998" TYPE="REFERENCE">Goodman 1998</LINK>). </P>
<P>Other secondary outcome measures considered were:<BR/>2) Proportion of patients discontinuing treatment (20% or less discontinuers in a trial versus more than 20%)<BR/>3) Adverse events, including overall adverse events, sexual adverse events and three most common adverse events (sexual side effects were considered separately, as these are often a source of great distress to patients, with impact on quality of life and relationships)<BR/>4) Social and occupational functioning<BR/>5) Quality of life<BR/>6) Proportion of relapses (in long term trials)</P>
<P>Depression is usually assessed in OCD research for inclusion criteria, and sometimes as a secondary outcome. Commonly used instruments for measuring depression are the Hamilton Depression Scale (<LINK REF="REF-Hamilton-1967" TYPE="REFERENCE">Hamilton 1967</LINK>, <LINK REF="REF-Hamilton-1969" TYPE="REFERENCE">Hamilton 1969</LINK>), Montgomery Asberg Depression rating scale (<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>) and the Beck Depression Inventory (<LINK REF="REF-Beck-1961" TYPE="REFERENCE">Beck 1961</LINK>). This review did not use change in depression as a secondary outcome, however the information on measurement of depression was used to sub-group trials on the basis of presence or absence of severe secondary depression.<BR/> <BR/>If a study met the inclusion criteria but did not give the data necessary for estimating effect size, and such data were not available from the authors, then it was decided that the study would be excluded from the analysis, but would be commented upon critically and listed as eligible without usable data for meta-analyses (<LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>)</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>
<B>Electronic searches</B>
<BR/>CCDANCTR-Studies - searched on 12/11/2007<BR/>Diagnosis = "Obsessive-Compulsive"<BR/>and<BR/>Intervention = "Selective Serotonin Reuptake Inhibitors" or Alaproclate or Citalopram or Escitalopram or Femoxetine or Fluoxetine or Fluvoxamine or Paroxetine or Sertraline<BR/>and <BR/>Intervention = placebo*<BR/>and<BR/>Age-group = Adult</P>
<P>CCDANCTR-References - searched on 12/11/2007<BR/>Keyword = Obsess* or Compulsi*"<BR/>and<BR/>Free-text = "Selective Serotonin Reuptake Inhibitors" or Alaproclate or Citalopram or Escitalopram or Femoxetine or Fluoxetine or Fluvoxamine or Paroxetine or Sertraline</P>
<P>
<B>Reference Lists</B>
<BR/>Reference lists of the selected studies and previous systematic reviews were searched.</P>
<P>
<B>Personal communication</B>
<BR/>Two active researchers in the area of OCD were contacted personally and asked whether they knew of any unpublished or additional published studies on SSRIs versus placebo in OCD.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Selection of studies</B>
<BR/>Selection of studies was carried out by two review authors independently for reliability. The selection criteria for inclusion of studies in the review were as follows.<BR/>1) The population studied were adults with OCD without co-morbidity of DSM Axis I disorders (except secondary depression)<BR/>2) The studies were RCTs, quasi-randomised trials or cross-over trials <BR/>3) The intervention used was selective serotonin re-uptake inhibitors (SSRIs)<BR/>4) The control group was placebo </P>
<P>
<B>Data extraction</B>
<BR/>Data extraction from the selected studies was carried out by two review authors for reliability. Any disagreements were resolved by discussion (and if necessary through arbitration with a third review author). A specially designed form was used by the reviewers to collect data on methods/quality, participants, intervention and outcome measurements and other relevant features of the trials. The form was piloted by the two reviewers first before data extraction. </P>
<P>
<B>Quality assessment</B>
<BR/>There is some empirical evidence of effect of quality features on trial outcome (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>). There are also logical reasons for suspecting such a relationship. Two of the components for which there is empirical evidence of such an effect are concealment of allocation and double-blinding. Their lack results in exaggeration of effect of size of trials (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>). Thus, it is important to assess quality of studies selected for a systematic review and to use it appropriately to minimise bias in the review. It has been suggested that quality should be used for selecting studies and for sensitivity analysis to investigate how robust the results of a review are to different quality features of the studies. It is not recommended that quality assessment be used for weighting studies as there is no empirical evidence for such approach (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>). Consistent with this approach it has been suggested that quality assessment instruments should not be used as scales with final summation score for the whole scale but as checklists to assess presence or absence of different components of quality (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>). Thus, quality assessment for this review was used for selection of studies and for sensitivity analysis, that is randomised and quasi RCTs were selected (and non-randomised studies were not selected) and a sensitivity analysis was carried out for quality features where data was available. </P>
<P>The checklist for the four quality components (i.e. selection, performance, detection and attrition bias) was developed using Cochrane Reviewers' Handbook 4.1.1 (<LINK REF="REF-Clarke-2002" TYPE="REFERENCE">Clarke 2002</LINK>), the revised CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) and other sources (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>). This quality assessment checklist was pilot tested by the two review authors before use with the trials. </P>
<P>
<B>Statistical analysis</B>
<BR/>Review Manager software was used for data management and relevant statistical analysis for this systematic review. Statistical issues are discussed below in relation to outcome measures, heterogeneity assessment, subgroup and sensitivity analysis, meta-analysis and publication bias. </P>
<P>
<B>
<I>Dealing with missing data</I>
</B>
<BR/>
<I>Continuous/interval data</I>
<BR/>The data required for meta-analysis of continuous data were mean and SD of change from baseline for each treatment group. For some trials only mean and SD of final values could be extracted. Such studies can be pooled with those reporting change from baseline, as they are estimating the same treatment effect. The following assessments were carried out and/or precautions observed while collecting these data and other relevant information. <BR/>1) Efforts were made to spot whether standard error was presented as SD (this mistake is sometimes seen in trial reports).<BR/>2) In the case of missing SD, SE or CI, other statistics were used to calculate SD e.g. t or F statistic.<BR/>3) Where possible, intention to treat analysis data (where relevant, using last observation carried forward [LOCF] data) and completer sample data were extracted separately. Information on the number of discontinuers was also extracted for each group. </P>
<P>
<I>Dichotomous data</I>
<BR/>The data required for the meta-analysis of binary data are number of events in each group and total patients in each group. Precautions were taken to extract intention to treat analysis data (last observation carried forward data [LOCF]) separately and completer sample data separately. Information on the number of discontinuers was also extracted for each group. </P>
<P>
<B>
<I>Measures of treatment effect</I>
</B>
<BR/>For dichotomous data, relative risk (RR) was calculated. The choice of RR instead of odds ratio was mainly based on ease of interpretation. For continuous data, weighted mean difference (WMD) was calculated if the studies used the same scale, however, if they used different scales, the standardised mean difference (SMD) was calculated. These effect sizes (RR, WMD and SMD) were meta-analysed as pooled summary effect sizes (<LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>, <LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>). 95% confidence intervals were also calculated. </P>
<P>To estimate the summary effect sizes, both fixed effects and random effects models were used with RR, WMD and SMD. In absence of clinical and statistical heterogeneity, the fixed effects model would serve as the model of choice, and random effects model would serve to check the robustness of the fixed effects model. However, in the presence of either clinical or statistical heterogeneity, the random effects model would serve as the choice of method for pooling the effect sizes, as in this latter situation, the fixed effect method is not appropriate for summarising the studies (<LINK REF="REF-Egger-1997b" TYPE="REFERENCE">Egger 1997b</LINK>, <LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>, <LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>). </P>
<P>
<B>
<I>Unit of analysis issues</I>
</B>
<BR/>
<I>Continuous/interval data</I>
<BR/>Some studies of SSRIs versus placebo were four arm studies of three fixed dose drug arms and one placebo arm. In such cases for continuous data, mean change (or mean end score) and relevant SDs for three fixed doses were pooled to create one arm for the drug, thus effectively changing the study to a two arm study. This was done to study the effect of mean dose of drug versus placebo. Also, use of one of the drug arms versus placebo would reduce power. However,different dose arms versus placebo could be used in a separate set of meta-analyses to investigate indirect comparison of effect sizes of different dose level. For the purposes of the current review, this has not been done, but will be considered in a future update of the review. </P>
<P>
<I>Dichotomous data</I>
<BR/>Where relevant, the number of events and their denominator were pooled for three fixed doses to create one arm for the study, thus effectively changing the study to a two-arm study (as mentioned above in relation to continuous data). </P>
<P>
<B>
<I>Assessment of publication bias</I>
</B>
<BR/>Funnel plots were generated by plotting relative risk (RR) against the standard error (SE) of log RR. As three of the included studies did not give response rate data, WMD (available for all 17 included studies) was also plotted against SE of WMD. Essentially a funnel plot allows investigation of whether effect size varies by study size (i.e. tendency of small studies to show larger treatment effects), and indirectly investigates influence of such factors as publication bias, heterogeneity of studies or variation in methodological quality of studies (<LINK REF="REF-Egger-1997a" TYPE="REFERENCE">Egger 1997a</LINK>). </P>
<P>
<B>
<I>Assessment of heterogeneity and subgroup differences</I>
</B>
<BR/>For each meta-analysis, the sum of Chi-square values for within sub-categories (strata) heterogeneity was subtracted from the Chi-square value for the whole sample heterogeneity, to find out the residual Chi-square for between sub-category heterogeneity. Thus the significance of the difference between subcategories (strata) was decided from the size of the residual Chi-square and degrees of freedom. For example for one degree of freedom, a Chi-square value of 3.84 and above would prove that there was a statistically significant difference between the sub-categories compared. Criteria for interpreting the heterogeneity test were as follows: no heterogeneity p &gt; 0.1, borderline heterogeneity p = or &lt; 0.1 but &gt; 0.05 and definite heterogeneity p = or &lt; 0.05. Additionally, the I-squared test was used to assess inconsistency between studies due to heterogeneity (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>). If there was evidence of notable clinical heterogeneity or of statistical heterogeneity, further analysis was to be carried out to identify the sources of such heterogeneity in terms of patient, treatment or study design and quality characteristics (<LINK REF="REF-Thompson-1994" TYPE="REFERENCE">Thompson 1994</LINK>) </P>
<P>
<B>Subgroup analyses and exploration of heterogeneity </B>
<BR/>Assessment of studies in terms of clinical heterogeneity was carried out qualitatively (using knowledge of the subject area and study design) with a view to deciding whether the studies were too heterogeneous to carry out statistical synthesis (meta-analysis). It was planned a priori to explore reasons for clinical heterogeneity. It was also decided a priori to explore relationship of effect sizes to clinically meaningful subgroups, even if clinical heterogeneity was not present. <BR/>Subgroups considered a priori for subgroup analysis were as follows:.<BR/>1) different drugs within SSRIs group (citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline)<BR/>2) age of participants <BR/>3) severity of OCD<BR/>4) duration of OCD <BR/>5) presence of severe secondary depression <BR/>6) different dosage levels<BR/>7) duration of trial</P>
<P>
<B>Sensitivity analyses</B>
<BR/>A priori sensitivity analyses were planned in relation to some of the study design characteristics. The following study quality components were identified for exploration in sensitivity analyses: <BR/>1) concealment of allocation<BR/>2) blinding<BR/>3) extent of dropouts. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<B>Results of search</B>
<BR/>A total of 41 studies were identified. Of these, 17 have been included (<LINK REF="STD-Chouinard-1990" TYPE="STUDY">Chouinard 1990</LINK>; <LINK REF="STD-Dominguez-1991" TYPE="STUDY">Dominguez 1991</LINK>; <LINK REF="STD-Goodman-1989" TYPE="STUDY">Goodman 1989</LINK>; <LINK REF="STD-Goodman-1996" TYPE="STUDY">Goodman 1996</LINK>; <LINK REF="STD-Greist-1992b" TYPE="STUDY">Greist 1992b</LINK>; <LINK REF="STD-Hollander-2002" TYPE="STUDY">Hollander 2002</LINK>; <LINK REF="STD-Hollander-2003" TYPE="STUDY">Hollander 2003</LINK>; <LINK REF="STD-Jenike-1990a" TYPE="STUDY">Jenike 1990a</LINK>; <LINK REF="STD-Jenike-1990b" TYPE="STUDY">Jenike 1990b</LINK>; <LINK REF="STD-Jenike-1997" TYPE="STUDY">Jenike 1997</LINK>; <LINK REF="STD-Kamijima-2004" TYPE="STUDY">Kamijima 2004</LINK>; <LINK REF="STD-Kasper-1999" TYPE="STUDY">Kasper 1999</LINK>; <LINK REF="STD-Kronig-1999" TYPE="STUDY">Kronig 1999</LINK>; <LINK REF="STD-Montgomery-1993c" TYPE="STUDY">Montgomery 1993c</LINK>; <LINK REF="STD-Nakajima-1996" TYPE="STUDY">Nakajima 1996</LINK>; <LINK REF="STD-Ushijima-1997" TYPE="STUDY">Ushijima 1997</LINK>; <LINK REF="STD-Zohar-1996" TYPE="STUDY">Zohar 1996</LINK>), 13 excluded (<LINK REF="STD-Ansseau-1996" TYPE="STUDY">Ansseau 1996</LINK>; <LINK REF="STD-Beasley-1992" TYPE="STUDY">Beasley 1992</LINK>; <LINK REF="STD-Cottraux-1990" TYPE="STUDY">Cottraux 1990</LINK>; <LINK REF="STD-George-1991" TYPE="STUDY">George 1991</LINK>; <LINK REF="STD-Greist-1990" TYPE="STUDY">Greist 1990</LINK>; <LINK REF="STD-Hohagen-1998" TYPE="STUDY">Hohagen 1998</LINK>; <LINK REF="STD-Koran-1996" TYPE="STUDY">Koran 1996</LINK>; <LINK REF="STD-Koran-1999" TYPE="STUDY">Koran 1999</LINK>; <LINK REF="STD-Mallya-1993" TYPE="STUDY">Mallya 1993</LINK>; <LINK REF="STD-Peter-1997" TYPE="STUDY">Peter 1997</LINK>; <LINK REF="STD-Romano-1998" TYPE="STUDY">Romano 1998</LINK>; <LINK REF="STD-Turner-1985" TYPE="STUDY">Turner 1985</LINK>; <LINK REF="STD-Zohar-1994" TYPE="STUDY">Zohar 1994</LINK>) and 11 studies are still awaiting assessment (<LINK REF="STD-Bolt-1992" TYPE="STUDY">Bolt 1992</LINK>; <LINK REF="STD-Erzegovesi-2001" TYPE="STUDY">Erzegovesi 2001</LINK>; <LINK REF="STD-Greist-1992a" TYPE="STUDY">Greist 1992a</LINK>; <LINK REF="STD-Hembree-2003-a" TYPE="STUDY">Hembree 2003 a</LINK>; <LINK REF="STD-Jianxun-1998" TYPE="STUDY">Jianxun 1998</LINK>; <LINK REF="STD-Mallya-1992" TYPE="STUDY">Mallya 1992</LINK>; <LINK REF="STD-Nakagawa-2004" TYPE="STUDY">Nakagawa 2004</LINK>; <LINK REF="STD-O_x0027_Connor-2006-a" TYPE="STUDY">O'Connor 2006 a</LINK>; <LINK REF="STD-Perse-1987" TYPE="STUDY">Perse 1987</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>; <LINK REF="STD-Wheadon-1993" TYPE="STUDY">Wheadon 1993</LINK>). </P>
<P>
<B>Settings</B>
<BR/>Fifteen out of 17 studies were multi-centre in location. The remaining two did not give information about whether they were single or multicentre. Six studies selected their patients from outpatient settings, three from inpatients and outpatients, and the rest did not give any information about the source of their samples.</P>
<P>
<B>Participants </B>
<BR/>All studies used similar diagnostic criteria for OCD i.e. DSM III or a later version of this system. All studies included either less than severe or severe secondary depression as a co-morbid disorder (severity of depression of was measured on the basis of guidelines relating to respective depression measurement instruments used in the trials). Age of participants in general was 17 years or above (some studies did not provide information on age range). Thus the studies varied in terms of how they chose to give information on age (e.g. minimum, range or mean etc). All studies included both men and women.</P>
<P>
<B>Interventions</B>
<BR/>Five studies compared sertraline against placebo (<LINK REF="STD-Chouinard-1990" TYPE="STUDY">Chouinard 1990</LINK>, <LINK REF="STD-Greist-1992b" TYPE="STUDY">Greist 1992b</LINK>, <LINK REF="STD-Jenike-1990b" TYPE="STUDY">Jenike 1990b</LINK>, <LINK REF="STD-Kronig-1999" TYPE="STUDY">Kronig 1999</LINK>, <LINK REF="STD-Ushijima-1997" TYPE="STUDY">Ushijima 1997</LINK>). Five studies examined fluvoxamine against placebo (<LINK REF="STD-Goodman-1989" TYPE="STUDY">Goodman 1989</LINK>, <LINK REF="STD-Goodman-1996" TYPE="STUDY">Goodman 1996</LINK>, <LINK REF="STD-Nakajima-1996" TYPE="STUDY">Nakajima 1996</LINK>, <LINK REF="STD-Hollander-2002" TYPE="STUDY">Hollander 2002</LINK>, <LINK REF="STD-Jenike-1990a" TYPE="STUDY">Jenike 1990a</LINK>). A further three studies compared fluoxetine against placebo (<LINK REF="STD-Dominguez-1991" TYPE="STUDY">Dominguez 1991</LINK>, <LINK REF="STD-Jenike-1997" TYPE="STUDY">Jenike 1997</LINK>, <LINK REF="STD-Montgomery-1993c" TYPE="STUDY">Montgomery 1993c</LINK>), with three studies comparing paroxetine against placebo (<LINK REF="STD-Hollander-2003" TYPE="STUDY">Hollander 2003</LINK>, <LINK REF="STD-Zohar-1996" TYPE="STUDY">Zohar 1996</LINK>, <LINK REF="STD-Kamijima-2004" TYPE="STUDY">Kamijima 2004</LINK>) and one study examining citalopram (<LINK REF="STD-Kasper-1999" TYPE="STUDY">Kasper 1999</LINK>).</P>
<P>The duration of trials varied from six to 13 weeks. </P>
<P>
<B>Outcomes</B>
<BR/>All studies used YBOCS as the primary efficacy measure, which was used mainly as a continuous scale. Some studies provided dichotomous response rate data, using a cut-off point of percentage reduction on YBOBS, which commonly was 25%, although one study used a cut-off of 35%. Some studies provided a dichotomous response rate using a global scale such as CGI, or both a global scale and YBOCS. Four studies did not report response rate data. Studies varied widely in terms of choice of other OCD scales. However, all studies included a measure of global improvement. Only one study used a scale related to functioning/quality of life. </P>
<P>
<B>Data available for meta-analysis</B>
</P>
<P>
<B>
<I>Primary outcomes</I>
</B>
<BR/>
<I>Primary continuous outcome (change in YBOCS)</I>
<BR/>The data required for meta-analysis of continuous variables were mean change in the baseline score in each comparison group and standard deviation (SD) of the mean change and sample size of each group. Seven studies provided these data (<LINK REF="STD-Chouinard-1990" TYPE="STUDY">Chouinard 1990</LINK>, <LINK REF="STD-Goodman-1996" TYPE="STUDY">Goodman 1996</LINK>, <LINK REF="STD-Greist-1992b" TYPE="STUDY">Greist 1992b</LINK>, <LINK REF="STD-Hollander-2002" TYPE="STUDY">Hollander 2002</LINK>, <LINK REF="STD-Kasper-1999" TYPE="STUDY">Kasper 1999</LINK>, <LINK REF="STD-Montgomery-1993c" TYPE="STUDY">Montgomery 1993c</LINK>, <LINK REF="STD-Zohar-1996" TYPE="STUDY">Zohar 1996</LINK>). <LINK REF="STD-Kamijima-2004" TYPE="STUDY">Kamijima 2004</LINK>. <LINK REF="STD-Dominguez-1991" TYPE="STUDY">Dominguez 1991</LINK> and <LINK REF="STD-Hollander-2003" TYPE="STUDY">Hollander 2003</LINK> provided mean change in the form of bar charts with standard errors as whisker extensions. A ruler was used to work out the values for mean change and the standard error of mean for each group. The SD for the mean change score was calculated from the standard error of the mean. <LINK REF="STD-Jenike-1997" TYPE="STUDY">Jenike 1997</LINK>, <LINK REF="STD-Goodman-1989" TYPE="STUDY">Goodman 1989</LINK>, <LINK REF="STD-Jenike-1990a" TYPE="STUDY">Jenike 1990a</LINK>, <LINK REF="STD-Jenike-1990b" TYPE="STUDY">Jenike 1990b</LINK>, <LINK REF="STD-Nakajima-1996" TYPE="STUDY">Nakajima 1996</LINK> and <LINK REF="STD-Ushijima-1997" TYPE="STUDY">Ushijima 1997</LINK>only gave baseline scores with SD and end of treatment scores with SD. For these studies, end of treatment mean score and its SD was used for pooling the results. <LINK REF="STD-Kronig-1999" TYPE="STUDY">Kronig 1999</LINK> provided mean change in the form of a figure with no SD or standard error. The standard deviation for this study was calculated using F value for the difference between sertraline and placebo group. Thus it was possible to extract usable data for this outcome for all 17 included studies. </P>
<P>
<I>Primary dichotomous outcome (response rate)</I>
<BR/>Dichotomous response rate data were available in all but four studies (<LINK REF="STD-Jenike-1997" TYPE="STUDY">Jenike 1997</LINK>, <LINK REF="STD-Jenike-1990a" TYPE="STUDY">Jenike 1990a</LINK>, <LINK REF="STD-Jenike-1990b" TYPE="STUDY">Jenike 1990b</LINK> and <LINK REF="STD-Hollander-2003" TYPE="STUDY">Hollander 2003</LINK>). Response was defined as 25% reduction in YBOCS in studies by <LINK REF="STD-Kasper-1999" TYPE="STUDY">Kasper 1999</LINK> and <LINK REF="STD-Ushijima-1997" TYPE="STUDY">Ushijima 1997</LINK>. <LINK REF="STD-Dominguez-1991" TYPE="STUDY">Dominguez 1991</LINK> defined response as 35% reduction in YBOCS. <LINK REF="STD-Montgomery-1993c" TYPE="STUDY">Montgomery 1993c</LINK> defined response rate as 25% reduction in YBOCS and a CGI score of 1 or 2 (i.e. very much improved or much improved respectively). Eight studies defined response as much improved or very much improved on CGI improvement scale (<LINK REF="STD-Goodman-1989" TYPE="STUDY">Goodman 1989</LINK>, <LINK REF="STD-Goodman-1996" TYPE="STUDY">Goodman 1996</LINK>, <LINK REF="STD-Chouinard-1990" TYPE="STUDY">Chouinard 1990</LINK>, <LINK REF="STD-Greist-1992b" TYPE="STUDY">Greist 1992b</LINK>, <LINK REF="STD-Kamijima-2004" TYPE="STUDY">Kamijima 2004</LINK>, <LINK REF="STD-Ushijima-1997" TYPE="STUDY">Ushijima 1997</LINK>, <LINK REF="STD-Nakajima-1996" TYPE="STUDY">Nakajima 1996</LINK>, <LINK REF="STD-Kronig-1999" TYPE="STUDY">Kronig 1999</LINK>). One study gave response rate data using all three criteria i.e. YBOCS reduction of 25%, 35% and CGI score of 1 or 2. The last criterion was used in the meta-analysis as it is the most common criterion used by other studies. </P>
<P>Thus the primary dichotomous variable was differently defined by different studies. The Clinical Global Impression (CGI) scale based definition of response rate (using cut off points of very much or much improved) would be more stringent than 25% reduction in YBOCS. However, studies did not provide information or data on how these two criteria of response rate would compare. Similarly, a 35% reduction in YBOCS is more stringent than the 25% reduction in this scale. Again, there was no information available from the studies as to how this definition compared with the CGI based definition (thus one of the reasons for choosing the random effective model for pooling the data was to take this heterogeneity into account). </P>
<P>
<B>
<I>Secondary continuous outcomes</I>
</B>
<BR/>Secondary continuous outcome measures used by studies included in the review included Clinical Global Impression (CGI) Scales (both severity and improvement scales), National Institute of Mental Health Obsessive Compulsive Scale (NIMH-OCS), Comprehensive Psychopathological Rating Scale Obsessive Compulsive Subscale (CPRS-OCS), Patient Global Improvement Scale (PGIS) Maudsley Obsessive Compulsive Inventory (MOCI) and Symptom Checklist 90 (SCL90) (<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>; <LINK REF="REF-Goodman-1998" TYPE="REFERENCE">Goodman 1998</LINK>). The former three are observer rated and the latter three are self rated. CGI, NIMH-OCS and PGI are one question non-symptom related severity of illness related scales and the other three are symptom related scales (and not so much severity related scales). CPRS-OCS, PGIS and MOCI were used by only two out of the 17 selected studies and SCL-90 was used by only one study. The CGI severity scale was used and appropriate data provided by <LINK REF="STD-Kasper-1999" TYPE="STUDY">Kasper 1999</LINK>, <LINK REF="STD-Montgomery-1993c" TYPE="STUDY">Montgomery 1993c</LINK>, <LINK REF="STD-Dominguez-1991" TYPE="STUDY">Dominguez 1991</LINK>, <LINK REF="STD-Greist-1992b" TYPE="STUDY">Greist 1992b</LINK> and <LINK REF="STD-Chouinard-1990" TYPE="STUDY">Chouinard 1990</LINK>. The CGI improvement scale was used and appropriate data provided by <LINK REF="STD-Hollander-2002" TYPE="STUDY">Hollander 2002</LINK>. However, other studies that used the CGI scale either did not provide usable data, or in the case of <LINK REF="STD-Jenike-1997" TYPE="STUDY">Jenike 1997</LINK>, <LINK REF="STD-Jenike-1990a" TYPE="STUDY">Jenike 1990a</LINK> and <LINK REF="STD-Jenike-1990b" TYPE="STUDY">Jenike 1990b</LINK>, it was not clear whether they had used CGI Improvement Scale, the CGI Severity Scale or some other global assessment scale. </P>
<P>The most commonly available secondary continuous outcome measure was National Institute of Mental Health Obsessive Compulsive Scale (NIMH-OCS). This was used in the studies by <LINK REF="STD-Chouinard-1990" TYPE="STUDY">Chouinard 1990</LINK>, <LINK REF="STD-Goodman-1996" TYPE="STUDY">Goodman 1996</LINK>, <LINK REF="STD-Greist-1992b" TYPE="STUDY">Greist 1992b</LINK>, <LINK REF="STD-Jenike-1990a" TYPE="STUDY">Jenike 1990a</LINK>, <LINK REF="STD-Jenike-1990b" TYPE="STUDY">Jenike 1990b</LINK>, <LINK REF="STD-Jenike-1997" TYPE="STUDY">Jenike 1997</LINK>, <LINK REF="STD-Kasper-1999" TYPE="STUDY">Kasper 1999</LINK>, <LINK REF="STD-Kronig-1999" TYPE="STUDY">Kronig 1999</LINK> and <LINK REF="STD-Zohar-1996" TYPE="STUDY">Zohar 1996</LINK>. With the exception of <LINK REF="STD-Kronig-1999" TYPE="STUDY">Kronig 1999</LINK> (which did not provide any relevant SD or other data to calculate the SD) all other studies provided usable data. For the two studies that did not use this scale (<LINK REF="STD-Montgomery-1993c" TYPE="STUDY">Montgomery 1993c</LINK>, <LINK REF="STD-Dominguez-1991" TYPE="STUDY">Dominguez 1991</LINK>), usable data was available for the other global assessment scale i.e. CGI severity scale. Therefore, it was decided to use the data for NIMH-OCS as the global outcome scale for the eight studies identified above and the data from CGI severity scale for the remaining two studies</P>
<P>For NIMH-OCS, mean change and SD was available for <LINK REF="STD-Kasper-1999" TYPE="STUDY">Kasper 1999</LINK>, <LINK REF="STD-Goodman-1996" TYPE="STUDY">Goodman 1996</LINK>, <LINK REF="STD-Zohar-1996" TYPE="STUDY">Zohar 1996</LINK>, <LINK REF="STD-Chouinard-1990" TYPE="STUDY">Chouinard 1990</LINK> and <LINK REF="STD-Greist-1992b" TYPE="STUDY">Greist 1992b</LINK>. For <LINK REF="STD-Jenike-1997" TYPE="STUDY">Jenike 1997</LINK>, <LINK REF="STD-Jenike-1990a" TYPE="STUDY">Jenike 1990a</LINK> and <LINK REF="STD-Jenike-1990b" TYPE="STUDY">Jenike 1990b</LINK>, the end of treatment score and its SD was used for meta-analysis. <LINK REF="STD-Montgomery-1993c" TYPE="STUDY">Montgomery 1993c</LINK> provided the mean change with SD for CGI severity scale. <LINK REF="STD-Dominguez-1991" TYPE="STUDY">Dominguez 1991</LINK> provided the CGI scale data as the mean change and the standard error of mean in a bar chart with whisker extensions, from which mean change and SD was calculated. In the studies by <LINK REF="STD-Kronig-1999" TYPE="STUDY">Kronig 1999</LINK> and <LINK REF="STD-Goodman-1989" TYPE="STUDY">Goodman 1989</LINK>, CGI severity scale data were not available (and in the case of the former NIMH-OCS data also were not available), therefore, these studies were not included in the meta-analysis of this outcome. For <LINK REF="STD-Hollander-2002" TYPE="STUDY">Hollander 2002</LINK>, NIMH-OCS and CGI severity data were not available. </P>
<P>
<B>Studies awaiting assessment</B>
<BR/>1. <LINK REF="STD-Bolt-1992" TYPE="STUDY">Bolt 1992</LINK> Conference proceeding, two RCTs of Fluvoxamine versus placebo, usable data was not available from the abstract.<BR/>2. <LINK REF="STD-Greist-1992a" TYPE="STUDY">Greist 1992a</LINK> Conference proceeding, RCT of Fluvoxamine versus placebo, usable data was not available from the abstract.<BR/>3. <LINK REF="STD-Jianxun-1998" TYPE="STUDY">Jianxun 1998</LINK> Chinese language trial of Paroxetine versus Clomipramine versus placebo, translation/data extraction of the article is in process<BR/>4. <LINK REF="STD-Mallya-1992" TYPE="STUDY">Mallya 1992</LINK> RCT of fluvoxamine versus placebo, had unusable data (and also perhaps is partial duplicate publication of <LINK REF="STD-Goodman-1996" TYPE="STUDY">Goodman 1996</LINK> RCT of fluvoxamine versus placebo).<BR/>5. <LINK REF="STD-Perse-1987" TYPE="STUDY">Perse 1987</LINK> Cross-over study of Fluvoxamine versus placebo, no relevant data was available from the article on pre-crossover period. <BR/>6. <LINK REF="STD-Wheadon-1993" TYPE="STUDY">Wheadon 1993</LINK> Conference proceeding, RCT of Paroxetine versus placebo, usable data was not available from the abstract</P>
<P>Letters were sent to <LINK REF="STD-Mallya-1992" TYPE="STUDY">Mallya 1992</LINK> and <LINK REF="STD-Perse-1987" TYPE="STUDY">Perse 1987</LINK> to request the relevant information, and contact is being made with <LINK REF="STD-Bolt-1992" TYPE="STUDY">Bolt 1992</LINK>, <LINK REF="STD-Greist-1992a" TYPE="STUDY">Greist 1992a</LINK>, <LINK REF="STD-Wheadon-1993" TYPE="STUDY">Wheadon 1993</LINK> to obtain the relevant information.</P>
<P>An additional five studies were identified from the search, which are potentially relevant to the review (<LINK REF="STD-Erzegovesi-2001" TYPE="STUDY">Erzegovesi 2001</LINK>, <LINK REF="STD-Hembree-2003-a" TYPE="STUDY">Hembree 2003 a</LINK>, <LINK REF="STD-Nakagawa-2004" TYPE="STUDY">Nakagawa 2004</LINK>, <LINK REF="STD-O_x0027_Connor-2006-a" TYPE="STUDY">O'Connor 2006 a</LINK>, <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>). These studies, together with the six studies mentioned above, are listed in 'References to studies awaiting assessment".</P>
<P>
<B>Excluded studies</B>
<BR/>Studies that did not meet all the inclusion criteria (n=13) were categorised as excluded studies, and are presented in the Characteristics of excluded studies table. </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<B>
<BR/>Study design</B>
<BR/>All studies were parallel group randomised controlled trials. </P>
<P>
<B>Allocation concealment</B>
<BR/>
<LINK REF="STD-Hollander-2003" TYPE="STUDY">Hollander 2003</LINK> used computer-generated randomisation by SmithKline and Beecham. None of the other studies gave any description of how randomisation sequence was generated. None of the studies described what precautions were taken to conceal allocation of the patients to study groups. All studies were classified as 'B' according to Cochrane Handbook criteria.</P>
<P>
<B>Blinding</B>
<BR/>All 17 studies described themselves as double blind, however, only one study (<LINK REF="STD-Goodman-1989" TYPE="STUDY">Goodman 1989</LINK>) provided a description of what that meant (and that study in fact was triple blind). <BR/>
<B>
<BR/>Drop-out</B>
<BR/>All but one study (<LINK REF="STD-Jenike-1997" TYPE="STUDY">Jenike 1997</LINK>) analysed the data using intention to treat analysis. Some studies did not give clear reasons for all early withdrawals e.g. 'other reasons' or 'protocol violations' were not explicitly described in each case. Seven studies had an overall dropout of 20% or lower (<LINK REF="STD-Chouinard-1990" TYPE="STUDY">Chouinard 1990</LINK>,<LINK REF="STD-Goodman-1989" TYPE="STUDY">Goodman 1989</LINK>,<LINK REF="STD-Hollander-2003" TYPE="STUDY">Hollander 2003</LINK>, <LINK REF="STD-Jenike-1997" TYPE="STUDY">Jenike 1997</LINK>, <LINK REF="STD-Jenike-1990a" TYPE="STUDY">Jenike 1990a</LINK>, <LINK REF="STD-Jenike-1990b" TYPE="STUDY">Jenike 1990b</LINK>, <LINK REF="STD-Kasper-1999" TYPE="STUDY">Kasper 1999</LINK>). All other studies had a dropout rate of more than 20%.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Some clinical heterogeneity was judged to be present between the studies in terms of duration of trial, duration of illness and presence of severe secondary depression, and how the outcomes were assessed for dichotomous response rate data and continuous secondary outcome data. However, the extent of the heterogeneity was not considered to be so severe such that carrying out meta-analysis would be inappropriate. As stated in the methods, because of the clinical heterogeneity, the random effects model was used as the method of choice for pooling results. Where only one study was involved in a meta-analysis (in sub-group analyses or in some cases, adverse effects outcomes), the fixed effects method was used. <BR/>
<B>
<BR/>SSRIs VERSUS PLACEBO: PRIMARY OUTCOME <BR/>
</B>This comparison presents the meta-analysis of primary outcomes (reduction in symptoms and treatment responders) for included studies across all five SSRI drugs, together with a meta-analysis for each SSRI drug individually, and sub-group and sensitivity analyses across combined SSRI drugs. </P>
<P>
<B>
<I>Reduction in YBOCS scores (Comparison 01 01 and Comparison 01 02)</I>
</B>
<BR/>The results, using weighted mean difference (WMD) and random effects (RE) model, were as follows: overall pooled effect size of all SSRIs against placebo (17 studies, 3097 participants) was -3.21 (95% CI -3.84 to -2.57) in favour of SSRIs. For individual SSRI drugs, WMD for citalopram was -3.63 (95% CI -5.20 to -2.06, n=401), WMD for fluoxetine was -3.07 (95% CI -5.32 to -0.82, n=606), WMD for fluvoxamine was -3.87 (95% CI -5.69 to -2.04, n=566), WMD for paroxetine was -3.36 (95% CI -4.55 to -2.17, n=833) and WMD for sertraline was -2.45 (95% CI -3.54 to -1.35, n=691). Thus, all SSRIs as a group of drugs were shown to be effective for OCD symptoms versus placebo, and all the drugs individually showed significant effect sizes of reasonable magnitude, with narrow confidence intervals for citalopram, fluvoxamine, paroxetine and sertraline, and with slightly wider confidence intervals for fluoxetine studies. All five drugs showed a similar degree of benefit, with the difference between WMD of the five individual SSRI drugs shown not to be significantly different, as indicated by the residual Chi-square.</P>
<P>Heterogeneity tests using random effects model were carried out. The heterogeneity test for all SSRIs as a whole group was not significant (Chi-square 21.61, df 16, p = 0.16; I<SUP>2</SUP> 26.0%). The citalopram sub-category included only one study, therefore heterogeneity assessment was not relevant. The heterogeneity test was not significant for paroxetine studies (Chi-square 2.31, df 2, p=0.31, I<SUP>2</SUP> 13.6%). For fluvoxamine studies, the Chi-square test was not significant, but the I<SUP>2</SUP> was 56%, showing inconsistency due to heterogeneity (Chi-square 9.10, df 4, p=0.06; I<SUP>2</SUP> 56%). Significant heterogeneity was indicated for fluoxetine studies (Chi-square 6.17, df 2, p =0.05; I<SUP>2</SUP> 67.6%). The heterogeneity test was not significant for sertraline studies (Chi-square 1.7, df 4, p=0.79; I<SUP>2</SUP> 0%). </P>
<P>
<B>
<I>Treatment responders (Comparison 01 03 and 01 04)</I>
</B>
<BR/>Results were as follows: the overall relative risk (RR) across all five SSRI studies (13 studies, 2697 participants) was 1.84 (95% CI 1.56 to 2.17). The RR for response rate in the citalopram group was 1.58 (95% CI 1.20 to 2.08), for fluoxetine was 2.41(95% CI 1.18 to 4.91), for fluvoxamine was 2.68 (95% CI 1.58 to 4.56), for paroxetine was 1.74 (95% CI 1.28 to 2.36), and for sertraline was 1.54 (95% CI 1.20 to 1.99). Thus three SSRIs (citalopram, paroxetine, sertraline) showed similar effect sizes of between 1.54 to 1.74, and fluvoxamine and fluoxetine showed larger effect sizes. However, lower limits of the confidence intervals of effect sizes of all five drugs individually were comparable, and the residual chi-square suggested that the difference between the individual drugs was not significant. </P>
<P>There was no statistical heterogeneity across all SSRIs as a whole group (Chi-square 17.28, df 12, p=0.14; I<SUP>2 </SUP>30.5%) or within four of the five SSRIs analysed as subgroups. There was borderline heterogeneity within the fluoxetine subgroup with a high I<SUP>2</SUP> (Chi-square 2.76, df 1, p=0.097; I<SUP>2 </SUP>63.7%).</P>
<P>Number needed to treat (NNTs) for SSRIs as a class of drug were calculated (<LINK REF="REF-Ebrahim2001" TYPE="REFERENCE">Ebrahim2001</LINK>). The base rate for calculating NTTs was chosen as 10% (very conservative) and 20% (conservative). The respective NNTs for these rates were 12 and 6. </P>
<P>
<B>Subgroup analyses </B>
<BR/>Subgroup analyses, using the primary outcome of reduction of symptoms, were carried out for duration of OCD, presence of secondary severe depression and duration of trial. All these categories were identified a priori. Other categories intended a priori for subgroup analysis were age, severity of OCD and dose of SSRIs. Age and severity of OCD were similar across studies, therefore no subgroup analyses were possible. Subgroup analyses for low to medium and high doses of SSRIs and dose-response relationship of SSRIs will be investigated in the next update of the review. </P>
<P>
<B>
<I>Duration of OCD (Comparison 01 05)</I>
</B>
<BR/>Trials with mean duration of OCD of 10 years or less or greater than 10 years were separately meta-analysed. Studies with mean duration of OCD of 10 years or less showed WMD (RE model) of -2.59 (95% CI -3.69 to -1.48). Studies with mean duration of OCD of more than 10 years showed WMD (RE model) of -3.48 (95% CI -4.25 to -2.71). Thus studies using patients with OCD of more than 10 years showed a larger effect size, but this was not significantly different from the effect size of the other sub-group. The test of heterogeneity was non-significant in both subgroups.</P>
<P>
<B>
<I>Presence of severe secondary depression (Comparison 01 06)</I>
</B>
<BR/>The studies were divided into two sub-groups on the basis of whether or not some patients suffered with severe secondary depression (studies were considered as having a proportion of patients with severe secondary depression, where secondary depression was allowed in the inclusion criteria, and no cut off point on depression scales was used for excluding severe depression or the cut-off point fell within the range of severe depression on the scale used). The WMD (RE model) of studies including some patients with severe secondary depression was -3.60 (95% CI -4.89 to -2.30) and the WMD for studies with no severely depressed participants was -2.84 (95% CI -3.59 to -2.09). However, this difference was not significantly significant. Statistically significant heterogeneity was present in the subgroup of studies that included some patients with severe secondary depression (Chi-square 15.06, df 6, p=0.02; I<SUP>2</SUP> 60.2%). <BR/>
<B>
<I>
<BR/>Duration of trial (Comparison 01 07)</I>
</B>
<BR/>The studies were divided into those with duration of trial of less than 12 weeks and those of 12 weeks or more and were meta-analysed separately. For the studies with duration of trial of less than 12 weeks (duration range for these was 6 to 10 weeks) WMD (RE model) was -2.92 (95% CI -4.13 to -1.72); and for those with duration of trial of 12 weeks or more (duration range for these was 12 to 13 weeks) the WMD was -3.38 (95% CI -4.05 to -2.71). Thus the trials of longer duration showed a larger effect size, but the difference between the two sub-groups was not statistically significant. Heterogeneity was non-significant in both sub-groups.</P>
<P>
<B>Sensitivity analyses </B>
<BR/>Sensitivity analysis using the primary outcomes of reduction in symptoms and response rate were carried out for the only available quality component of proportion of discontinuers<BR/>
<B>
<I>
<BR/>Proportion of discontinuers (Comparison 01 08 and 01 09)</I>
</B>
<BR/>Studies with 20% or less discontinuers were compared with those with more than 20% discontinuers in term of effect size. The former showed a WMD of -3.27 (95% CI -4.45 to -2.10) and the latter of -3.18 (95% CI -3.98 to -2.38). Although this difference was not statistically significant (perhaps due to intention to treat analysis), the higher mean effect in the former would be expected, as patients staying in trials would be more likely to continue to improve than those who drop out early, thus their last observation carried forward would tend to minimize effect size. Heterogeneity was non-significant in both subgroups.</P>
<P>This analysis was also carried out using response rate per completers (i.e. using non-intention to treat analysis data) to see whether the magnitude of discontinuers showed any effect on the effect sizes. Effect size (RR) using random effects model were essentially similar between the two subgroups. In studies with 20% or less discontinuers, it was 1.96 (95% CI 0.96 to 4.00) and in more than 20% discontinuers it was 1.90 (95% CI 1.45 to 2.48); however the former group showed statistically non-significant effect size. Heterogeneity was significant in the subgroup of studies with more than 20% discontinuers (Chi-square 25.53, df 8, p= 0.001; I<SUP>2</SUP> 68.7%). </P>
<P>
<B>SSRIs VERSUS PLACEBO: SECONDARY OUTCOMES</B>
<BR/>The most common secondary outcome measure used by studies, and for which usable data was also available, was the National Institute of Mental Health Obsessive Compulsive Scale (NIMH-OCS), which was employed by eight studies. Two studies, <LINK REF="STD-Montgomery-1993c" TYPE="STUDY">Montgomery 1993c</LINK>, <LINK REF="STD-Dominguez-1991" TYPE="STUDY">Dominguez 1991</LINK>, did not use NIMH-OCS. However, <LINK REF="STD-Montgomery-1993c" TYPE="STUDY">Montgomery 1993c</LINK> used Clinical Global Impression Severity Scale (CGI-S scale), and <LINK REF="STD-Dominguez-1991" TYPE="STUDY">Dominguez 1991</LINK> used Clinical Global Impression Improvement Scale (CGI-I scale), and all provided usable data. The remaining two studies did not provide usable data on either of the scales or some other similar scale i.e. observer rated severity related scale.</P>
<P>Meta-analysis was conducted with the eight studies that used the NIMH-OCS and also including the additional two studies that used either NIMH-OCS or CGI scales separately. </P>
<P>
<B>
<I>Using NIMH-OCS (Comparison 02 01)</I>
</B>
<BR/>The overall WMD (RE model) for all SSRI drugs combined was -0.89 (95% CI -1.13 to -0.64). The WMD for the five SSRI drugs individually was as follows: citalopram -1.13 (95% CI -1.67 to -0.59), fluoxetine -0.20 (95% CI -0.98 to 0.58), fluvoxamine -0.99 (95% CI -1.54 to -0.44), paroxetine -1.10 (95% CI -1.80 to -0.40) and sertraline -0.81 (95% CI -1.22 to -0.40).Thus the effect size for fluoxetine did not differ significantly from placebo (however a sensitivity analysis using the fixed effects model was significant at -0.45 (95% CI -0.63 to -0.27). </P>
<P>Test of heterogeneity for the combined SSRIs group was not significant (Chi-square 4.69, df 7, p= 0.70; I<SUP>2</SUP> 0%) and was also not significant for individual SSRIs. </P>
<P>
<B>
<I>Using NIMH-OCS or CGI scales (Comparison 02 02)</I>
</B>
<BR/>Using the standardised mean difference (SMD), the overall SMD (RE model) for the combined SSRI drugs group was -0.42 (95% CI -0.52 to -0.33). Using SMD for the individual SSRI drugs, the findings were as follows: citalopram -0.44 (95% CI -0.67 to -0.21), fluoxetine -0.36 (95% CI -0.80 to 0.08), fluvoxamine -0.42 (95% CI -0.61 to -0.23), paroxetine -0.38 (95% CI -0.62 to -0.14) and sertraline -0.41 (95% CI -0.62 to -0.20). Thus the effect size for fluoxetine only was statistically not significant from placebo (however using fixed effects model this was significant at 0.45 (95% CI -0.63 to -0.27). </P>
<P>Test of heterogeneity for the combined SSRIs group was not significant (Chi-square 10.03, df 10, p=0.44; I<SUP>2</SUP> 0.3%). For individual studies, heterogeneity was significant for fluoxetine (Chi-square 8.89, df 2, p= 0.01; I<SUP>2 </SUP>77.7%). </P>
<P>
<B>
<I>Other secondary outcomes</I>
</B>
<BR/>Only one study provided data on quality of life or social and occupational functioning (<LINK REF="STD-Kasper-1999" TYPE="STUDY">Kasper 1999</LINK>). No studies were long-term trials, therefore the proportion of relapses was not investigated.</P>
<P>
<B>SSRIs VERSUS PLACEBO: ADVERSE EFFECTS<BR/>
</B>Adverse effects were analysed separately for each drug, as this was considered to be clinically more meaningful than combining them across all drugs. These were analysed as overall adverse effects, the three most common adverse effects as reported for each drug by each study, and specific sexual side effects. Not all studies reported adverse effects for each of these three categories. Sexual side effects as a category were analysed separately regardless of whether or not they were reported as the most common side effects, because of their potential impact on patients' lives. Relative risk of adverse effects was calculated using the random effects model.</P>
<P>
<B>Adverse Effects Of Citalopram Versus Placebo (Comparison 03 01 to 03 03)</B>
<BR/>
<B>
<I>Overall adverse effects</I>
</B>
<BR/>Relative risk for overall adverse effects with citalopram compared to placebo was 1.22 (95% CI 1.02 to 1.45), thus the risk for adverse effects with citalopram as an overall rate was not much higher than placebo. Absolute rate for overall adverse effects for citalopram was 71% and for placebo was 58%.</P>
<P>
<B>
<I>Common adverse effects<BR/>
</I>
</B>The most common adverse effects reported for citalopram were nausea, headache and insomnia.<BR/>Relative risk of nausea for citalopram compared to placebo was 2.47 (95% CI 1.28 to 4.77). Thus, the average risk for experiencing nausea was quite high with citalopram as compared to placebo, but wider confidence intervals suggest that some patients would have much lower and others much higher likelihood of getting this side effect. The absolute rate of nausea for citalopram was 22% and for placebo was 9%. The RR of headache for citalopram versus placebo was 1.05 (95% CI 0.63 to 1.76), with an absolute rate of 17% for citalopram and of 16% for placebo. The RR of insomnia for citalopram compared to placebo was 2.26 (95% CI 1.06 to 4.84), with an absolute rate of 16% for citalopram and 7% for placebo.<BR/> <BR/>
<B>
<I>Sexual side effects</I>
</B>
<BR/>Relative risk of reported sexual side effects for citalopram versus placebo was high, at 18.64, with very wide 95% CI of 1.15 to 302.80. In absolute terms, 9% patients on citalopram experienced side effects compared to 0% in the placebo group.</P>
<P>
<B>Adverse Effects Of Fluoxetine Versus Placebo (Comparison 03 04)</B>
<BR/>
<B>
<I>Overall adverse effects</I>
</B>
<BR/>These were not reported by fluoxetine studies.</P>
<P>
<B>
<I>Common adverse effects<BR/>
</I>
</B>The most common adverse effects as reported by different studies were nausea, headache, insomnia and anxiety.<BR/>Risk of these side effects for fluoxetine was similar to placebo, with the RR (RE model) for these three side effects shown to be between 1.11 and 1.42, and 95% confidence intervals crossing 1. </P>
<P>
<B>
<I>Sexual side effects</I>
</B>
<BR/>These were not reported by fluoxetine studies.</P>
<P>
<B>Adverse Effects Of Fluvoxamine (Comparison 03 05 to 03 07)</B>
<BR/>
<B>
<I>Overall adverse effects</I>
</B>
<BR/>Relative risk of overall adverse effects for fluvoxamine versus placebo was 1.14 (95% CI 1.07 to 1.21). Thus the risk of overall adverse effects with fluvoxamine differed little from placebo, with an absolute rate of 95% in fluvoxamine was 95% and 83% for placebo.</P>
<P>
<B>
<I>Common adverse effects</I>
</B>
<BR/>The most common adverse effects across studies were insomnia, nausea, fatigue, headache, somnolence and asthenia.<BR/>Fatigue and headache rates were not significantly different between fluvoxamine and placebo. For fatigue, the absolute rate for 28% in the fluvoxamine group compared to 15% in placebo group. For headache, the absolute rates were 18% in the fluvoxamine group and 22% in the placebo group. For insomnia, RR of insomnia for fluvoxamine compared to placebo was 1.81 (95% CI 1.26 to 2.60), with an absolute rate of 34% for fluvoxamine and 18% for placebo. The RR for nausea was 2.64 (95% CI 1.75 to 3.98), with an absolute rate of 31% in the fluvoxamine group and 12% for placebo. The RR for somnolence in the fluvoxamine group compared to placebo was 2.46 (95% CI 1.59 to 3.79), with an absolute rate of 29% for fluvoxamine and 12% for placebo. The RR of asthenia in fluvoxamine compared to placebo was 2.83 (95% CI 1.74 to 4.60), with an absolute rate of 26% for fluvoxamine and 9% for placebo.</P>
<P>
<B>
<I>Sexual side effects</I>
</B>
<BR/>Relative risk of sexual side effects in fluvoxamine compared to placebo was 4.02 (95% CI 1.85 to 8.73). In absolute terms, the sexual side effects rate in the fluvoxamine group was 14% and in placebo was 3%.</P>
<P>
<B>Adverse Effects Of Paroxetine (Comparison 03 08 to 03 10)</B>
<BR/>
<B>
<I>Overall adverse effects</I>
</B>
<BR/>Relative risk of overall adverse effects for paroxetine was 1.14 (95% CI 0.91 to 1.42), showing a lack of significant difference compared with placebo, and with an absolute rate of 81% in the paroxetine group and 72% in the placebo group.</P>
<P>
<B>
<I>Common adverse effects</I>
</B>
<BR/>The most common side effects reported across studies were asthenia, headache, insomnia and somnolence, nausea and constipation.<BR/>Relative risk for asthenia and headache for paroxetine versus placebo was not statistically significant. However RR for the other four adverse effects was significantly higher for paroxetine than placebo as follows: for insomnia 1.71 (95% CI 1.15 to 2.53), for somnolence 1.85 (95% CI 1.12 to 3.06), for nausea 3.96 (95% CI 1.82 to 8.61) and for constipation 4.29 (95% CI 1.26 to 14.56). The absolute rate of asthenia for paroxetine was 26% and for placebo was 18%, the absolute rate of headache for paroxetine was 24% and for the placebo group was 26%, the absolute rate of insomnia for paroxetine was 23% and for placebo was 14% and the absolute rate of somnolence for paroxetine was 27% and for placebo was 11%.<BR/>
<B>
<I>
<BR/>Sexual side effects</I>
</B>
<BR/>These were reported in usable form for only one study (<LINK REF="STD-Kamijima-2004" TYPE="STUDY">Kamijima 2004</LINK>). The RR of sexual side effects for paroxetine did not significantly differ from placebo (RR 6.93 CI 0.36 to 132.39), with the absolute rate of 3% for paroxetine and of 0% for placebo. </P>
<P>
<B>Adverse Effects Of Sertraline (Comparison 03 11 to 03 13)</B>
<BR/>
<B>
<I>Overall Adverse Effects</I>
</B>
<BR/>Relative risk for overall adverse effects for sertraline was 1.21 (95% CI 1.08 to 1.37). The absolute rate of overall adverse effects for sertraline was 87% and for placebo was 68%. </P>
<P>
<B>
<I>Common adverse effects</I>
</B>
<BR/>The most common adverse effects as reported by different sertraline studies were nausea, insomnia, dyspepsia, constipation, sedation, forgetfulness, headache and diarrhoea.<BR/>Two adverse effects, insomnia and diarrhoea, showed significant RR for sertraline compared to placebo. The RR of insomnia for sertraline compared to placebo was 2.23 (95% CI 1.09 to 4.56), with an absolute rate for sertraline of 31% and for placebo of 13%. Relative risk of diarrhoea for sertraline compared to placebo was 2.16 (95% CI 1.11 to 4.23), with an absolute rate of 25% for sertraline and of 10% for placebo. The RR for nausea, dyspepsia, constipation, sedation, forgetfulness and headache for sertraline compared to placebo were not significant as their confidence intervals crossed 1. </P>
<P>
<B>
<I>Sexual side effects</I>
</B>
<BR/>Relative risk for sexual side effects for sertraline compared to placebo was 5.74 (95% CI 0.68 to 48.31). The confidence interval crossed 1, thus showing no significant risk difference between sertraline and placebo. Absolute rates for sexual side effects for sertraline was 14% and for placebo was 2%. However this difference was not statistically significant. </P>
<P>
<B>Dose response relationship for side effects</B>
<BR/>This was not investigated in the current issue of this systematic review, but will be considered in a future update of this review. </P>
<P>
<B>Funnel Plots</B>
<BR/>These were carried out using both dichotomous measures and continuous measures for YBOCS. It is customary to generate funnel plots only using dichotomous measures but as the binary measures for YBOCS were not available for four of the 17 studies, plots were also generated for the continuous measure. The funnel plots did not show gross asymmetry, although both reflected an absence of small (both negative and positive) studies (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), therefore, the shapes of the funnel plots did not suggest publication bias in the topic reviewed. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>
<B>Summary of findings</B>
<BR/>Seventeen RCTs of SSRIs versus placebo (involving a total of 3097 patients) were included in this systematic review and meta-analysis. Meta-analyses of the available data using a random effects model demonstrated that SSRIs, as a class of drugs, and individually were significantly more effective than placebo for the treatment of OCD, both in terms of continuous (using YBOCS) and dichotomous (response rate using YBOCS and global impression scales) outcomes. The pooled effect sizes of all five individual SSRIs were similar, although it should be noted that these sorts of indirect comparisons of different drugs are unreliable due to the potential effects of confounding (<LINK REF="REF-Bucher-1997" TYPE="REFERENCE">Bucher 1997</LINK>). Results for studies using alternative scales to measure continuous outcome (NIHM-OC scale, CGI-S and CGI-I) broadly supported these findings. Studies using these scales indicated that, with the exception of fluoxetine, all SSRI drugs were more effective than placebo in adults with OCD. The lack of conclusive data for fluoxetine may be due to the insensitivity of the outcome measure, to the fact that this was not the primary outcome measure, or it may simply be a chance finding.</P>
<P>The three most common adverse effects for each SSRI reported in each RCT were analysed. These included nausea, dyspepsia, diarrhoea, constipation, headache, insomnia, anxiety, fatigue, sedation, somnolence, asthenia and forgetfulness. Although reported adverse effect data were limited, with few exceptions, the overall and individual adverse effects for the different SSRIs were always worse than for placebo and, in the majority of cases, the difference was statistically significant. The most common adverse effect was nausea. Included studies were fairly clinically and methodologically homogeneous, although some clinical heterogeneity was observed in terms of trial duration, illness duration, methods for assessing dichotomous and continuous outcomes, and the presence of severe secondary depression in some patients. </P>
<P>The effect of SSRIs in achieving improvement of OCD symptoms is modest, and the clinical utility of these interventions should be weighed against the adverse effects, particularly those that impact on quality of life, such as sexual adverse effects. </P>
<P>
<B>Subgroup analyses</B>
<BR/>It should be noted that this small sample of 17 studies lacks sufficient power for firm conclusions to be drawn from any sub-group analysis, and these analyses should be seen as hypothesis-generating only. Analysis by duration of illness (10 year or more), duration of trials (12 weeks of longer) and presence of severe secondary depression suggested that these drugs might be equally effective under these different conditions However, non-statistically significant increased effect sizes were observed in trials involving patients with more chronic illness, presence of severe secondary depression and for longer duration of trials. These observations appear to be plausible. Of particular interest is the observation that patients with OCD and with co-morbid severe secondary depression respond equally well to SSRIs as those without co-morbid severe secondary depression. Presence of severe secondary depression in OCD is a poor predictor of response to behaviour therapy (<LINK REF="REF-Soomro-2003" TYPE="REFERENCE">Soomro 2003</LINK>). Thus in these patients, drug treatment may be the treatment of choice, at least initially. </P>
<P>
<B>Quality of included studies</B>
<BR/>All studies described themselves as randomised without giving details of how the randomisation sequence was generated and what precautions were taken in relation to concealment of allocation. With the exception of one study (which was described as double blind, but gave a clear description of being triple blind (<LINK REF="STD-Goodman-1989" TYPE="STUDY">Goodman 1989</LINK>), all studies were described as double blind without specifying what this meant. As additional information on risk of bias was limited in these studies, the effects of only one component of study quality, the proportion of people who discontinued, was amenable to sensitivity analysis. Sensitivity analysis of the proportion of patients withdrawing from the trials indicated no differences in the pooled effects size between studies with 20% or less discontinuers and studies with more than 20% discontinuers. This is consistent with previous findings (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>). </P>
<P>
<B>Strengths of this review</B>
<BR/>To limit the potential effects of bias introduced by including observational studies, only randomised or quasi-randomised controlled trials were eligible to be included in the review. The main source of searches for relevant RCTs for this review, the Cochrane Depression, Anxiety and Neurosis Controlled Trials Register (CCDAN-CTR), is the most comprehensive source of trials in this area. Thus, although more recently updated searches have identified some additional trials (included in the Awaiting Assessment category), it is unlikely that relevant trials have been missed. Beyond searches of CCDAN-CTR, no additional published or unpublished reports were identified, either from pharmaceutical companies (through CCDAN) or through direct contact with researchers in the field. Study selection and data extraction process were carried out in duplicate to enhance reliability, with good agreement and few differences between the review co-authors. Sensitivity analysis has been carried out for proportion of discontinuers. Quality assessment was undertaken using a variety of recommendations taken from the Cochrane Reviewer's Handbook, the CONSORT criteria, and other sources.</P>
<P>It should be noted that although primary and secondary outcomes were generally measured using valid instruments, this was not true of adverse effects outcomes. The limited information on adverse effects of SSRIs in general suggests the possible need for a separate systematic review, using Cochrane methodology, of the adverse effects of these drugs across the full range of disorders in which they have been evaluated. Such a review could present a clearer picture of the short-term and common side effects of these drugs. For rare and long-term adverse effects, other designs may need to be considered - such as cohort, case control and case series. It is also worth noting that these studies do not give information about people from different ethnic and cultural backgrounds. Therefore, the generalisability of results to these populations is uncertain. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>This systematic review provides evidence that SSRIs are moderately effective, at least in the short-term, in adults with OCD of varying duration. Although only limited information was available to guide the ethnic and cross-cultural applications of these findings, the patients included in these trials were thought to be representative of those in clinical practice, including both men and women of difference ages who had suffered OCD over varying lengths of time. Numbers needed to treat (NNT) were calculated assuming that a realistic baseline response rate in the clinical setting (that is, the response rate that may be expected even without treatment) would be between 10 to 20%. Based on the data reviewed here, in a group of patients where 10% might be expected to recover without treatment, 12 patients would need to be treated with SSRIs to achieve improvements for one additional patient, whereas in a group of patients where 20% might be expected to recover without treatment, six patients would need to be treated to achieve improvements for one additional patient. The necessary duration of treatment and the long-term outcomes associated with these interventions have yet to be determined. Although SSRIs should be considered as potentially effective treatments for this population, treatment decisions need to take account of the potential adverse effects of these drugs. In some patients, alternative treatments such as cognitive behavioural therapy may need to be considered (<LINK REF="REF-Soomro-2003" TYPE="REFERENCE">Soomro 2003</LINK>). </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Most of the existing studies in this area were found to be poorly reported and lacking sufficient and useable data for the purposes of secondary analyses and summary. Future work in this field needs to conform to the standards laid out in the revised CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). Future trialists might also consider the collection of data on additional, potentially important outcome measures. Whilst symptom severity and change scores may be useful, the value of information on other outcomes that are of direct relevance to patients, such as quality of life, should not be underestimated. Furthermore, particular consideration should be given to the use of valid and reliable methods for collecting adverse effect data. Finally, trials of longer duration are required to establish the necessary length of treatment and longer term outcomes, and trials involving a diverse range of ethnic and cultural groups would ensure greater generalisability of findings. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Authors acknowledge the contribution of C. Doughty to the initial development of the protocol for the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>G Mustafa Soomro: None stated<BR/>D Altman: None stated<BR/>S Rajagopal: None stated<BR/>M Oakley-Browne: None stated</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>G Mustafa Soomro: development of Background and Methods sections, study selection, data extraction, data analysis and writing up</P>
<P>D Altman: development of Methods section and data analysis</P>
<P>S Rajgopal: study selection and data extraction</P>
<P>M Oakley-Browne: development of Background and Methods sections<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1990" NAME="Chouinard 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K et al</AU>
<TI>Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder</TI>
<SO>1990</SO>
<YR>Psychopharmacology Bulletin</YR>
<VL>26</VL>
<NO>3</NO>
<PG>279-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clary CM</AU>
<TI>Sertraline in the treatment of obsessive-compulsive disorder</TI>
<SO>American Family Physician</SO>
<YR>1999</YR>
<VL>59</VL>
<NO>1</NO>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dominguez-1991" NAME="Dominguez 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ackerman DL, Greenland S, Bystritsky A</AU>
<TI>Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>3</NO>
<PG>185-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ackerman DL, Greenland S, Bystritsky A</AU>
<TI>Side effects as predictors of drug response in obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>5</NO>
<PG>459-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dominguez RA, Jacobson AF, Goldstein BJ et al</AU>
<TI>Fixed-dose of fluoxetine in obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1991</YR>
<VL>31</VL>
<PG>843</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dominguez RA</AU>
<TI>Serotonergic antidepressants and their efficacy in obsessive compulsive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1992</YR>
<VL>53 Suppl 10</VL>
<PG>56-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Birkett M, Koran L, Genduso L</AU>
<TI>Continuation treatment of OCD: double-blind and open-label experience with fluoxetine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55 Suppl</VL>
<PG>69-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush AJ, kominguez RA et al</AU>
<TI>A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>7</NO>
<PG>559-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodman-1989" NAME="Goodman 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS</AU>
<TI>Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>1</NO>
<PG>36-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodman-1996" NAME="Goodman 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WK, Kozak MJ, Liebowitz M, White KL</AU>
<TI>Treatment of obsessive-compulsive disorder with fluvoxamine: A multicentre, double-blind, placebo-controlled trial</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>1</NO>
<PG>21-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greist-1992b" NAME="Greist 1992b" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clary CM</AU>
<TI>Sertraline in the treatment of obsessive-compulsive disorder</TI>
<SO>American Family Physician</SO>
<YR>1999</YR>
<VL>59</VL>
<NO>1</NO>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L et al</AU>
<TI>Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>4</NO>
<PG>289-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greist J</AU>
<TI>Double-blind comparison of three doses of sertraline and placebo in the treatment of outpatients with obsessive compulsive disorder</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>1 Pt B</NO>
<PG>316</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A et al</AU>
<TI>A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>2</NO>
<PG>57-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran L et al</AU>
<TI>Long-term sertraline treatment of obsessive compulsive disorder: A 2 year study.</TI>
<SO>8th ECNP (European College of Neuropsychopharmacology) Congress, Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM et al</AU>
<TI>A 2-year study of sertraline in the treatment of obsessive-compulsive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>6</NO>
<PG>309-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-2002" NAME="Hollander 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander E, Kaplan A, Schmeidler J, Yang H, Li D, Koran LM et al</AU>
<TI>Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder</TI>
<SO>Journal of Neuropsychiatry and Clinical Neurosciences</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>4</NO>
<PG>472-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H et al</AU>
<TI>A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>6</NO>
<PG>640-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander E, Yang H, Li D, Barbato LM, Gerritsen van der Hoop R</AU>
<TI>Fluvoxamine controlled release in the treatment of adult outpatients with obsessive-compulsive disorder</TI>
<SO>International Journal of Neuropsychopharmacology 5[Suppl 1], 133. 2002</SO>
<YR>2002</YR>
<VL>5 Suppl 1</VL>
<PG>133</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-2003" NAME="Hollander 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB</AU>
<TI>Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>9</NO>
<PG>1113-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenike-1990a" NAME="Jenike 1990a" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L et al</AU>
<TI>A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>9</NO>
<PG>1209-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenike-1990b" NAME="Jenike 1990b" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jenike MA, Baer L, Summergrad P, Minichiello WE, Holland A, Seymour R</AU>
<TI>Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>7</NO>
<PG>923-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenike MA, Baer L.</AU>
<TI>Erratum: Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>10</NO>
<PG>1393</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenike-1997" NAME="Jenike 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML</AU>
<TI>Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>9</NO>
<PG>1261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamijima-2004" NAME="Kamijima 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamijima K, Murasaki M, Asai M, Higuchi T, Nakajima T, Taga C et al</AU>
<TI>Paroxetine in the treatment of obsessive-compulsive disorder: randomized double-blind, placebo-controlled study in Japanese patients</TI>
<SO>Psychiatry and Clinical Neurosciences</SO>
<YR>2004</YR>
<VL>58</VL>
<PG>427-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasper-1999" NAME="Kasper 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasper S, Note ID, Montgomery S</AU>
<TI>Citalopram is effective in obsessive compulsive disorder: results of a double-blind, placebo-controlled trial</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9 Suppl 5</VL>
<PG>217</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM</AU>
<TI>Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>2</NO>
<PG>75-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein DJ, Montgomery SA, Kasper S, Tanghoj P</AU>
<TI>Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>6</NO>
<PG>357-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kronig-1999" NAME="Kronig 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J et al</AU>
<TI>Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>2</NO>
<PG>172-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montgomery-1993c" NAME="Montgomery 1993c" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meszaros K, Zitterl W, Dossenbach M, Zitterl-Eglseer K, Klech H</AU>
<TI>A double-blind, placebo-controlled trial of fluoxetine in patients with obsessive-compulsive disorder in Austria</TI>
<SO>8th ECNP (European College of Neuropsychopharmacology) Congress, Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J et al</AU>
<TI>A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>2</NO>
<PG>143-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zitterl W, Meszaros K, Hornik K, Twaroch T, Dossenbach M, Zitterl-Eglseer K et al</AU>
<TI>Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1999</YR>
<VL>111</VL>
<NO>11</NO>
<PG>439-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakajima-1996" NAME="Nakajima 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakajima T, Kudo Y, Yamashita I.</AU>
<TI>Clinical usefulness of Fluvoxamine Maleate (SME3110), a selective serotonin reuptake inhibitor, in the treatment of obsessive compulsive disorder: A dopuble blind, placebo-controlled study investigating the therapeutic dose range and the efficacy of SME3110</TI>
<SO>Journal of clinical therapeutics &amp; medicine (Rinshou Iyaku)</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>3</NO>
<PG>409-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ushijima-1997" NAME="Ushijima 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ushijima S, Kamijima K, Asai M, Murasaki M, Nakajima T, Kudo Y</AU>
<TI>Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor in the treatment of obsessive- compulsive disorder: A double blind placebo controlled trial</TI>
<SO>Japanese Journal of Neuropsychopharmacology</SO>
<YR>1997</YR>
<VL>19</VL>
<NO>6</NO>
<PG>603-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zohar-1996" NAME="Zohar 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Humble M, Bejerot S, Bergqvist PB, Bengtsson F</AU>
<TI>Reactivity of serotonin in whole blood: Relationship with drug response in obsessive-compulsive disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>4</NO>
<PG>360-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zohar J, Judge R</AU>
<TI>Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>169</VL>
<PG>468-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ansseau-1996" NAME="Ansseau 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ansseau MM</AU>
<TI>Serotonergic antidepressants in obsessive personality</TI>
<SO>American Psychiatric Association, 149th Annual Meeting</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beasley-1992" NAME="Beasley 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM Jr, Potvin JH, Masica DN, Wheadon DE, Dornseif BE, Genduso LA</AU>
<TI>Fluoxetine: no association with suicidality in obsessive-compulsive disorder</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1992</YR>
<VL>24</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cottraux-1990" NAME="Cottraux 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cottraux J, Messy P, Marks IM, Mollard E, Bouvard M</AU>
<TI>Predictive factors in the treatment of obsessive-compulsive disorders with fluvoxamine and/or behaviour therapy</TI>
<SO>Behavioural Psychotherapy</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>1</NO>
<PG>45-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cottraux J, Mollard E, Bouvard M, Marks I, Sluys M, Nury AM et al</AU>
<TI>A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>1</NO>
<PG>17-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cottraux J, Mollard E, Bouvard M, Marks I</AU>
<TI>Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup</TI>
<SO>Psychiatry Research</SO>
<YR>1993</YR>
<VL>49</VL>
<NO>1</NO>
<PG>63-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-George-1991" NAME="George 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>George MS, Trimble MR</AU>
<TI>Dystonic reaction associated with fluvoxamine</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>3</NO>
<PG>220-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greist-1990" NAME="Greist 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greist JH, Jefferson JW, Rosenfeld R, Gutzmann LD, March JS, Barklage NE</AU>
<TI>Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1990</YR>
<VL>51</VL>
<NO>7</NO>
<PG>292-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hohagen-1998" NAME="Hohagen 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hohagen F, Winkelmann G, Rasche-Raeuchle H, Hand I, Konig A, Muenchau N</AU>
<TI>Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: Results of a multicentre study</TI>
<SO>British Journal of Psychiatry. Supplement</SO>
<YR>1998</YR>
<VL>35</VL>
<PG>71-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koran-1996" NAME="Koran 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koran LM, Cain JW, Dominguez RA, Rush AJ, Thiemann S</AU>
<TI>Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<NO>11</NO>
<PG>1450-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koran-1999" NAME="Koran 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D</AU>
<TI>Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>1</NO>
<PG>88-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallya-1993" NAME="Mallya 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallya G, White K, &amp; Gunderson C</AU>
<TI>Is there a serotonergic withdrawal syndrome?</TI>
<SO>Biological Psychiatry</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>11-2</NO>
<PG>851-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peter-1997" NAME="Peter 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peter H, Tabrizian S, &amp; Hand IE</AU>
<TI>Serum cholesterol in patents with obsessive compulsive disorder during treatment with behavior therapy and ssri or placebo</TI>
<SO>International Journal of Psychiatry in Medicine</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>1</NO>
<PG>27-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romano-1998" NAME="Romano 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romano S, Goodman W, Tamura R, Gonzales J, Deltito J, DuPont R et al</AU>
<TI>Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1</NO>
<PG>46-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turner-1985" NAME="Turner 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turner SM, Jacob RG, Beidel DC, &amp; Himmelhoch J</AU>
<TI>Fluoxetine treatment of obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>4</NO>
<PG>207-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zohar-1994" NAME="Zohar 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zohar J, Kaplan Z, Benjamin J</AU>
<TI>Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>3</NO>
<PG>86-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bolt-1992" NAME="Bolt 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolt G, Holland R, Vardy A</AU>
<TI>Fluvoxamine (FL): An effective treatment for obsessive compulsive disorder (OCD)</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1992</YR>
<VL>15 Suppl 1, Pt B</VL>
<PG>313</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erzegovesi-2001" NAME="Erzegovesi 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L</AU>
<TI>Clinical predictors of drug response in obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology 21[5], 488-92. 2001</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>5</NO>
<PG>488-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greist-1992a" NAME="Greist 1992a" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greist JH</AU>
<TI>Fluvoxamine in obsessive compulsive disorder: A multicenter parallel design double-blind placebo-controlled trial</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1992</YR>
<VL>15 Suppl 1, Pt B</VL>
<PG>310</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hembree-2003-a" NAME="Hembree 2003 a" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hembree EA, Riggs DS, Kozak MJ, Franklin ME, Foa EB</AU>
<TI>Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder</TI>
<SO>CNS Spectrums</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>5</NO>
<PG>363-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jianxun-1998" NAME="Jianxun 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jianxun L, Hu X, Haiying D</AU>
<TI>Clinical controlled study of paroxetine and clomipramine in treatment of obsessive- compulsive disorder</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>4</NO>
<PG>215-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallya-1992" NAME="Mallya 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallya GK, White K, Waternaux C, Quay S</AU>
<TI>Short and long term treatment of obsessive compulsive disorder with fluvoxamine</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>1992</YR>
<VL>4</VL>
<NO>2</NO>
<PG>77-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakagawa-2004" NAME="Nakagawa 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nakagawa A, Nakatani E, Nakao T, Nabeyama M, Yoshizato C, Kudoh A et al</AU>
<TI>Behavioral therapy (BT) alone vs BT + fluvoxamine for treatment of obsessive- compulsive disorder</TI>
<SO>32nd Congress of the British Association for Behavioural and Cognitive Psychotherapies (jointly with the European Association of Behavioural and Cognitive Therapies); 2004 September 7 - 11; Manchester</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakao T, Nakagawa A, Yoshiura T, Nakatani E, Nabeyama M, Yoshizato C et al</AU>
<TI>Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study</TI>
<SO>Biological Psychiatry</SO>
<YR>2005</YR>
<VL>57</VL>
<NO>8</NO>
<PG>901-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakatani E, Nakagawa A, Nakao T, Yoshizato C, Nabeyama M, Kudo A et al</AU>
<TI>A randomized controlled trial of Japanese patients with obsessive-compulsive disorder - Effectiveness of behavior therapy and fluvoxamine</TI>
<SO>Psychotherapy and Psychosomatics</SO>
<YR>2005</YR>
<VL>74</VL>
<NO>5</NO>
<PG>269-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Connor-2006-a" NAME="O'Connor 2006 a" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Connor KP, Aardema F, Robillard S, Guay S, Pelissier MC, Todorov C et al</AU>
<TI>Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>5</NO>
<PG>408-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perse-1987" NAME="Perse 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jefferson JW, Greist JH, Perse TL, Rosenfeld R</AU>
<TI>Fluvoxamine associated mania/hypomania in patients with obsessive compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>6</NO>
<PG>391-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R</AU>
<TI>Fluvoxamine treatment of obsessive-compulsive disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>144</VL>
<NO>12</NO>
<PG>1643-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-2007" NAME="Stein 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein DJ, Andersen EW, Tonnoir B, Fineberg N</AU>
<TI>Escitalopram in obsessive-compulsive disorder: A randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>4</NO>
<PG>701-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wheadon-1993" NAME="Wheadon 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black DW, Monahan P, Gable J, Blum N, Clancy G, Baker P</AU>
<TI>Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>8</NO>
<PG>420-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Black DW, Monahan PO, Clancy GP, Baker PB, Gabel JM</AU>
<TI>Hoarding predicts poor response in OCD</TI>
<SO>150th Annual Meeting of the American Psychiatric Association. San Diego, CA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wheadon DE, Bushnell WD, Steiner MA</AU>
<TI>A fixed-dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder</TI>
<SO>32nd Annual Meeting of the American college of Neuropsychopharmacology, Honolulu, HI</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Abramowitz-1997" NAME="Abramowitz 1997" TYPE="JOURNAL_ARTICLE">
<AU>Abramowitz JS</AU>
<TI>Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review</TI>
<SO>Journal of Consulting and Clincal Psychology</SO>
<YR>1997</YR>
<VL>65</VL>
<NO>1</NO>
<PG>44-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ackerman-2002" NAME="Ackerman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ackerman DL, Greenland S</AU>
<TI>Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder</TI>
<SO>Journal of Clinical psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>309-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alsobrook-1998" NAME="Alsobrook 1998" TYPE="BOOK_SECTION">
<AU>Alsobrook JP, Pauls DL</AU>
<TI>The genetics of obsessive-compulsive disorder</TI>
<SO>Obsessive-compulsive disorders</SO>
<YR>1998</YR>
<EN>3rd</EN>
<ED>Jenike MA, Baer L, Minichiello WE</ED>
<PB>Mosby</PB>
<CY>St. Louis, MO</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and statistical manual of mental disorders (DSM-IV)</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2000" NAME="APA 2000" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Handbook of psychiatric measures</SO>
<YR>2000</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baer-1998" NAME="Baer 1998" TYPE="BOOK_SECTION">
<AU>Baer L, Minichiello WE</AU>
<TI>Behavior therapy for obsessive-compulsive disorder</TI>
<SO>Obsessive-compulsive disorders</SO>
<YR>1998</YR>
<EN>3rd</EN>
<ED>Jenike MA, Baer L, Minichiello WE</ED>
<PB>Mosby</PB>
<CY>St. Louis, MO</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barr-1993" NAME="Barr 1993" TYPE="JOURNAL_ARTICLE">
<AU>Barr LC, Goodman WK, Price LH</AU>
<TI>The serotonin hypothesis of obsessive compulsive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>8 Suppl 2</VL>
<PG>79-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bebbington-1998" NAME="Bebbington 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bebbington PE</AU>
<TI>Epidemiology of obsessive-compulsive disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>35</VL>
<PG>2-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1961" NAME="Beck 1961" TYPE="JOURNAL_ARTICLE">
<AU>Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J</AU>
<TI>An inventory for measuring depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1961</YR>
<VL>4</VL>
<PG>561-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1988" NAME="Beck 1988" TYPE="JOURNAL_ARTICLE">
<AU>Beck AT, Epstein N, Brown G, Steer RA</AU>
<TI>An inventory for measuring clinical anxiety: psychometric properties</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1988</YR>
<VL>56</VL>
<NO>893</NO>
<PG>893-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bucher-1997" NAME="Bucher 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bucher HC, Guyatt GH, Griffith LE, Walter SD.</AU>
<TI>The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>6</NO>
<PG>683-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chakrabarti-1993" NAME="Chakrabarti 1993" TYPE="JOURNAL_ARTICLE">
<AU>Chakrabarti S, Kulhara P, Verma SK</AU>
<TI>The pattern of burden in families of neurotic patients</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>1993</YR>
<VL>28</VL>
<NO>4</NO>
<PG>172-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Christensen-1987" NAME="Christensen 1987" TYPE="JOURNAL_ARTICLE">
<AU>Christensen H, Hadzi PD, Andrews G, Mattick R</AU>
<TI>Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1987</YR>
<VL>55</VL>
<NO>5</NO>
<PG>701-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2002" NAME="Clarke 2002" TYPE="BOOK">
<AU>Clarke M, Oxman AD</AU>
<SO>Cochrane Reviewers' Handbook 4.1.5 [updated April 2002]</SO>
<YR>2002</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cox-1993" NAME="Cox 1993" TYPE="JOURNAL_ARTICLE">
<AU>Cox BJ, Swinson RP, Morrison B, Lee PS</AU>
<TI>Clomipramine, fluoxetene, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis</TI>
<SO>Journal of Behavior Therapy and Experimental Psychiatry</SO>
<YR>1993</YR>
<VL>1993</VL>
<NO>2</NO>
<PG>149-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG</AU>
<TI>Effect measures for meta-analysis of trials with binary outcomes</TI>
<SO>Systematic reviews in health care</SO>
<YR>2001</YR>
<ED>Egger M, Davey-Smith G, Altman DG</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Delgado-1998" NAME="Delgado 1998" TYPE="JOURNAL_ARTICLE">
<AU>Delgado PL, Moreno FA</AU>
<TI>Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder</TI>
<SO>British Journal of Psychiatry. Supplement</SO>
<YR>1998</YR>
<VL>35</VL>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1992" NAME="Dickersin 1992" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Min YI, Meinert CL</AU>
<TI>Factors influencing the publication of research results: follow-up of applications submitted to two substantial review boards</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>267</VL>
<NO>3</NO>
<PG>374-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Easterbrook-1991" NAME="Easterbrook 1991" TYPE="JOURNAL_ARTICLE">
<AU>Easterbrook PJ, Berlin JA, Gopaian R, Matthews DR</AU>
<TI>Publication bias in clinical research</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<NO>8746</NO>
<PG>867-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebrahim2001" NAME="Ebrahim2001" TYPE="BOOK_SECTION">
<AU>Ebrahim S</AU>
<TI>Numbers needed to treat derived from meta-analysis: pitfalls and cautions</TI>
<SO>Systematic Reviews in Health Care</SO>
<YR>2001</YR>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997a" NAME="Egger 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997b" NAME="Egger 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Phillips AN</AU>
<TI>Meta-analysis: Principles and procedures</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7121</NO>
<PG>1533-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eisen-1999" NAME="Eisen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Eisen JL, Goodman WK, Keller MB, Warshaw MG, DeMarco LM, Luce DD et al</AU>
<TI>Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>69</VL>
<NO>5</NO>
<PG>346-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gelder-2001" NAME="Gelder 2001" TYPE="BOOK">
<AU>Gelder MG, Lopez-Ibor JJ and Andreasen</AU>
<SO>New Oxford Textbook of Psychiatry</SO>
<YR>2001</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodman-1989a" NAME="Goodman 1989a" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL et al</AU>
<TI>The Yale-Brown obsessive compulsive scale1, Development, use, and reliability</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>11</NO>
<PG>1006-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodman-1998" NAME="Goodman 1998" TYPE="BOOK_SECTION">
<AU>Goodman WK, Price LH</AU>
<TI>Rating scales for obsessive-compulsive disorder</TI>
<SO>Obsessive-compulsive disorders</SO>
<YR>1998</YR>
<EN>3rd</EN>
<ED>Jenike MA, Baer L, Minichiello WE</ED>
<PB>Mosby</PB>
<CY>St. Louis, MO</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greist-1995" NAME="Greist 1995" TYPE="JOURNAL_ARTICLE">
<AU>Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC</AU>
<TI>Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis</TI>
<SO>Archive of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>1</NO>
<PG>53-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1959" NAME="Hamilton 1959" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>The assessment of anxiety states by rating</TI>
<SO>British Journal of Medical Psychology</SO>
<YR>1959</YR>
<VL>32</VL>
<PG>50-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1967" NAME="Hamilton 1967" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>Development of a rating scale for primary depressive illness</TI>
<SO>British Journal of Social and Clinical Psychiatry</SO>
<YR>1967</YR>
<VL>6</VL>
<NO>4</NO>
<PG>278-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1969" NAME="Hamilton 1969" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>Standardised assessment and recording of depressive symptoms</TI>
<SO>Psychiatry, Neurology and Neurosurgery</SO>
<YR>1969</YR>
<VL>72</VL>
<PG>201-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]</SO>
<YR>2006</YR>
<PB>http://www.cochrane.org/resources/handbook/hbook.htm (accessed 6th October 2006)</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hodgson-1977" NAME="Hodgson 1977" TYPE="JOURNAL_ARTICLE">
<AU>Hodgson RJ, Rachman S</AU>
<TI>Obsessive-compulsive complaints</TI>
<SO>Behavior Research and Therapy</SO>
<YR>1977</YR>
<VL>15</VL>
<NO>5</NO>
<PG>389-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jenike-1990c" NAME="Jenike 1990c" TYPE="JOURNAL_ARTICLE">
<AU>Jenike MA, Baer L, Greist JH</AU>
<TI>Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>2</NO>
<PG>122-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jenike-1990d" NAME="Jenike 1990d" TYPE="JOURNAL_ARTICLE">
<AU>Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L et al</AU>
<TI>A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>9</NO>
<PG>1209-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" NAME="Juni 2001" TYPE="BOOK_SECTION">
<AU>Juni P</AU>
<TI>Assessing the quality of randomised controlled trials</TI>
<SO>Systematic Reviews in Health Care</SO>
<YR>2001</YR>
<ED>Egger, M., Davey-Smith, G. and Altman, D.G.,</ED>
<PB>BMJ publications</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karno-1988" NAME="Karno 1988" TYPE="JOURNAL_ARTICLE">
<AU>Karno M, Golding JM, Sorenson SB, Burnam MA</AU>
<TI>The epidemiology of obsessive-compulsive disorder in five US communities</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<NO>12</NO>
<PG>1094-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-1990" NAME="Kim 1990" TYPE="JOURNAL_ARTICLE">
<AU>Kim SW, Dysken MW, Kuskowski M</AU>
<TI>The Yale-Brown Obsessive-Compulsive Scale: a reliability and validity study</TI>
<SO>Psychiatry Research</SO>
<YR>1990</YR>
<VL>34</VL>
<NO>1</NO>
<PG>99-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kobak-1998" NAME="Kobak 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ</AU>
<TI>Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis</TI>
<SO>Psychopharmacology</SO>
<YR>1998</YR>
<VL>136</VL>
<NO>3</NO>
<PG>205-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Jadad AR et al</AU>
<TI>Assessing the quality of reports of randomised trials: implications for conduct of meta-analysis</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9263</NO>
<PG>1181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petitti-1994" NAME="Petitti 1994" TYPE="BOOK">
<AU>Petitti DB</AU>
<SO>Meta-analysis, decision analysis and cost-effectiveness analysis: methods for quantitative review in medicine</SO>
<YR>1994</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Piccinelli-1995" NAME="Piccinelli 1995" TYPE="JOURNAL_ARTICLE">
<AU>Piccinelli M, Pini S, Bellantuono C, Wilkinson G</AU>
<TI>Efficacy of drug treatment in obsessive-compulsive disorder. A meta- analytic review</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>166</VL>
<PG>424-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-QAP-1985" NAME="QAP 1985" TYPE="JOURNAL_ARTICLE">
<AU>Quality Assurance Project</AU>
<TI>Treatment outlines for the management of obsessive-compulsive disorders</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>19</VL>
<NO>3</NO>
<PG>240-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rasmussen-1989" NAME="Rasmussen 1989" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen SA, Eisen JL</AU>
<TI>Clinical features and phenomenology of obsessive compulsive disorder</TI>
<SO>Psychiatric Annals</SO>
<YR>1989</YR>
<VL>19</VL>
<NO>1</NO>
<PG>67-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rauch-1998a" NAME="Rauch 1998a" TYPE="BOOK_SECTION">
<AU>Rauch SL, Whalen PJ, Dougherty D, Jenike MA</AU>
<TI>Neurobiologic models of obsessive compulsive disorder</TI>
<SO>Obsessive-compulsive disorders</SO>
<YR>1998</YR>
<EN>3rd</EN>
<ED>Jenike MA, Baer L, Minichiello WE</ED>
<PB>Mosby</PB>
<CY>St. Louis, MO</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rauch-1998b" NAME="Rauch 1998b" TYPE="BOOK_SECTION">
<AU>Rauch SL, Baxter LR Jr</AU>
<TI>Neuroimaging in obsessive-compulsive disorder and related disorders</TI>
<SO>Obsessive-compulsive disorders</SO>
<YR>1998</YR>
<EN>3rd</EN>
<ED>Jenike MA, Baer L, Minichiello WE</ED>
<PB>Mosby</PB>
<CY>St. Louis, MO</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ravizza-1997" NAME="Ravizza 1997" TYPE="JOURNAL_ARTICLE">
<AU>Ravizza L, Maina G, Bogetto F</AU>
<TI>Episodic and chronic obsessive-compulsive disorder</TI>
<SO>Depression and Anxiety</SO>
<YR>1997</YR>
<VL>6</VL>
<NO>4</NO>
<PG>154-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saxena-1998" NAME="Saxena 1998" TYPE="JOURNAL_ARTICLE">
<AU>Saxena S, Brody AL, Schwartz JM, Baxter LR</AU>
<TI>Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder</TI>
<SO>British Journal of Psychiatry. Supplement</SO>
<YR>1998</YR>
<VL>35</VL>
<PG>26-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scherer-1994" NAME="Scherer 1994" TYPE="JOURNAL_ARTICLE">
<AU>Scherer RW, Dickersin K, Langenberg P</AU>
<TI>Full publication of results initially presented in abstracts. A meta-analysis</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<NO>2</NO>
<PG>158-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skoog-1999" NAME="Skoog 1999" TYPE="JOURNAL_ARTICLE">
<AU>Skoog G, Skoog I</AU>
<TI>A 40-year follow-up of patients with obsessive-compulsive disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>2</NO>
<PG>121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soomro-2003" NAME="Soomro 2003" TYPE="JOURNAL_ARTICLE">
<AU>Soomro GM.</AU>
<TI>Obsessive compulsive disorder</TI>
<SO>Clinical Evidence</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>1172-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spielberger-1983" NAME="Spielberger 1983" TYPE="BOOK">
<AU>Spielberger CD, Gorsuch RL, Luchene R, Vagg PR, Jacobs GA</AU>
<SO>Manual for the State-Trait Anxiety Inventory</SO>
<YR>1983</YR>
<PB>Consulting Psychologists Press</PB>
<CY>Palo Alto, CA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stein-1995" NAME="Stein 1995" TYPE="JOURNAL_ARTICLE">
<AU>Stein DJ, Spadaccini E, Hollander E</AU>
<TI>Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>1</NO>
<PG>11-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steketee-1998" NAME="Steketee 1998" TYPE="BOOK_SECTION">
<AU>Steketee GS, Frost RO, Rheaume J, Wilhelm S</AU>
<TI>Cognitive theory and treatment of obsessive-compulsive disorder</TI>
<SO>Obsessive-compulsive disorders</SO>
<YR>1998</YR>
<EN>3rd</EN>
<ED>Jenike MA, Baer L, Minichiello WE</ED>
<PB>Mosby</PB>
<CY>St. Louis, MO</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1994" NAME="Thompson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG</AU>
<TI>Why sources of heterogeneity in meta-analysis should be investigated</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6965</NO>
<PG>1351-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Balkom-1994" NAME="van Balkom 1994" TYPE="JOURNAL_ARTICLE">
<AU>van Balkom AJ, van Oppen P, Vermeulen AW, van Dyck R, Nauta MC, Vorst HC</AU>
<TI>A meta-analysis on the treatment of obsessive compulsive disorder: a comparison of antidepressants, behavior, and cognitive therapy</TI>
<SO>Clinical Psychology Review</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>359 -81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" NAME="WHO 1992" TYPE="BOOK">
<AU>World Health Organisation</AU>
<SO>The ICD-10 Classification of Mental and Behavioural Disorders</SO>
<YR>1992</YR>
<PB>World Health Organisation</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Chouinard-1990">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double Duration of study: 8 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre: Multicentre Diagnostic criteria: DSM III Co-morbidity allowed: Secondary depression mild Setting: Not described Age: Mean(SD) 36.5(10.7) to 38(12.8) Other characteristics: Men and women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: Two Sertraline versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>Proportion of responders (defined as CGI of 1 or 2)</P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dominguez-1991">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double Duration of study: 13 week</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre:<BR/>Multicentre<BR/>Diagnostic criteria: DSM IIIR</P>
<P>Co-morbidity allowed: <BR/>Secondary depression including sever<BR/>Setting: <BR/>Out-patients<BR/>Age: 17-70 yrs</P>
<P>Other characteristics:<BR/>Men and women<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: four (fluoxetine 20mg vs 40mg vs 60mg vs placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Change in YBOCS total score Proportion of responders (defined as 35% reduction in YBOCS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goodman-1989">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double (but in fact triple) Duration of study: 6 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre: Multicentre Diagnostic criteria: DSM III Co-morbidity allowed: Secondary depression including sever Setting: Outpatients Age: Mean (SD) 39(14) to 35(11) Other characteristics: Men and women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: Two - Fluvoxamine versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>Proportion of responders (defined as CGI of 1 or 2)</P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goodman-1996">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double Duration of study: 10 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre: Multicentre Diagnostic criteria: DSM IIIR Co-morbidity allowed: Secondary depression including sever Setting: Outpatients Age: 18 or above Other characteristics: Men and women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: Two- Fluvoxamine versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>Proportion of responders (defined as CGI of 1 or 2)</P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Greist-1992b">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double Duration of study: 12 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre: Multicentre Diagnostic criteria: DSM IIIR Co-morbidity allowed: Secondary depression mild Setting: Outpatients Age: Mean(SD) 35.9(13) to 40.1(12) Other characteristics: Men and women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: Four Sertraline 50, 100 and 200mg versus placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>Proportion of responders (defined as CGI of 1 or 2)</P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hollander-2002">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double Duration of study: 12 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre:<BR/>Multicentre<BR/>Diagnostic criteria: DSM V Co-morbidity allowed: <BR/>HAM-D 16 or less</P>
<P>Setting: Not known</P>
<P>Age: Mean(SE) <BR/>36.7(1.0) to 38.1(1.1) <BR/>Other characteristics: Men and women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No of arms: Two</P>
<P>Fluvoxamine versus palcebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Change in YBOCS total score</P>
<P>Proportion of responders (defined as much improved or very much improved)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>6</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hollander-2003">
<CHAR_METHODS>
<P>Design: RCT parallel group,<BR/>Blindness: double <BR/>Duration of study:<BR/>12 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre:<BR/>Multicentre<BR/>Diagnostic criteria: DSM IIIR Co-morbidity allowed: <BR/>HAM-D 16 or less on first 17 or 21 items scale, and 2 or less on item 1</P>
<P>Setting: outpatients</P>
<P>Age: Mean(SD) <BR/>40.0(15.4) to 42.1(12.7) <BR/>Other characteristics: Men and women; 16 patients from non-white ethnicity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms:<BR/>four, paroxetine 20mg vs 40mg vs 60mg vs placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Change in YBOCS total score</P>
<P>Dichotomous outcome not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>7</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jenike-1990a">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double Duration of study: 10 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre: Not desribed Diagnostic criteria: DSM III Co-morbidity allowed: Secondary depression including severe Setting: Outpatients Age: Mean(SD) 37.5(9.3) to 34.6(12.9) Other characteristics: Men and women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: Two- Fluvoxamine versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>8</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jenike-1990b">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double Duration of study: 10 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre: Multicentre Diagnostic criteria: DSM IIIR Co-morbidity allowed: Secondary depression mild Setting: Not described Age: Mean(SD) 35(14) to 45(13) Other characteristics: Men and women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: Two Sertraline versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>9</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jenike-1997">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double Duration of study: 10 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre: Not described Diagnostic criteria: DSM IIIR Co-morbidity allowed: Secondary depression mild Setting: Not described Age: 18 or above Other characteristics: Men and women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: Three - Phenelzine versus Fluoxetine versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>10</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kamijima-2004">
<CHAR_METHODS>
<P>Design: RCT parallel group,<BR/>Blindness: double <BR/>Duration of study 12 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre:<BR/>Multicenter<BR/>Diagnostic criteria: DSM VI<BR/>Co-morbidity allowed: <BR/>Secondary depression Setting: <BR/>Not described<BR/>Age: <BR/>16 to 71<BR/>Other characteristics:<BR/>Men and women<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms:<BR/>Two<BR/>Paroxentine versus<BR/>placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>11</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kasper-1999">
<CHAR_METHODS>
<P>Design: RCT parallel group,<BR/>Blindness: double <BR/>Duration of study:<BR/>12 wks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre:<BR/>Multicentre<BR/>Diagnostic criteria: DSM IV <BR/>Co-morbidity allowed: <BR/>Secondary depression mild<BR/>Setting: <BR/>not described<BR/>Age: <BR/>18-65 years<BR/>Other characteristics:<BR/>Men and women<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: four (citalopram 20mg vs 40mg vs 60mg vs placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>Proportion of responders (defined as 25% reduction in YBOCS)</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kronig-1999">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double Duration of study: 12 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre: Multicentre Diagnostic criteria: DSM IIIR Co-morbidity allowed: Secondary depression mild Setting: Outpatient Age: Mean(SD) 35.5(11.2) to 38.1(12.0) Other characteristics: Men and women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: Two Sertraline versus<BR/>placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>Proportion of responders (defined as CGI of 1 or 2)</P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>13</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Montgomery-1993c">
<CHAR_METHODS>
<P>Design: RCT parallel group,<BR/>Blindness: double <BR/>Duration of study:<BR/>8 wks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre:<BR/>Multicentre<BR/>Diagnostic criteria: DSM IIIR</P>
<P>Co-morbidity allowed: <BR/> Secondary depression including sever<BR/>Setting: <BR/>Not described<BR/>Age: 18 to 65 years<BR/>Other characteristics:<BR/>Men and women<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms:<BR/>four, fluoxetine 20mg vs 40mg vs 60mg vs placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>Proportion of responders (defined as 25% reduction in YBOCS and a CGI of 1 or 2)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>14</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nakajima-1996">
<CHAR_METHODS>
<P>Design: RCT parallel group,<BR/>Blindness: double <BR/>Duration of study:<BR/>8 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre:<BR/>Multicentre<BR/>Diagnostic criteria: DSM IIIR</P>
<P>Co-morbidity allowed: they did not assess for depression (thus not clear whether some patients were depressed) <BR/>Setting: <BR/>In patients and out patients<BR/>Age: 18 to 69 years<BR/>Other characteristics:<BR/>Men and women<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms:<BR/>Three, fluvoxamine 100-150mg (ie low dose) vs fluvoxamine 200-300mg (medium doese) vs placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>Proportion of responders defined as improved or much improved</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>15</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ushijima-1997">
<CHAR_METHODS>
<P>Design: RCT parallel group,<BR/>Blindness: double <BR/>Duration of study:<BR/>8 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre:<BR/>Multicentre<BR/>Diagnostic criteria: DSM IIIR</P>
<P>Co-morbidity allowed: they did not assess for depression (thus not clear whether some patients were depressed) <BR/>Setting: <BR/>In patients and out patients<BR/>Age: 18 to 66 years<BR/>Other characteristics:<BR/>Men and women<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms: Three, <BR/>Sertraline low dose (25-100mg) vs sertraline high dose (50-200mg) vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>Change in YBOCS total score</P>
<P>Proportion of responders defined as improved or much improved</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>16</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zohar-1996">
<CHAR_METHODS>
<P>Design: RCT parallel group, Blindness: double Duration of study: 12 wks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single or multicentre: Multicentre Diagnostic criteria: DSM IIIR Co-morbidity allowed: Secondary depression including sever Setting: Not described Age: 17 or above Other characteristics: Men and women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>No. of arms:<BR/>Three, Paroxetine versus Phenelzine versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: Change in YBOCS total score Proportion of responders (defined as 25% reduction in YBOCS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>17</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ansseau-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was not selected because the patient group studies is obsessive compulsive personality disorder which is not the condition under study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beasley-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was not selected because the study reports only suicide as an outcome of fluoxetine in OCD and not the impact of fluoxetine on OCD symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cottraux-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Combination trial of Fluvoxamine with exposure versus placebo with exposure - thus not direct one to one comparison of Fluvoxamine versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-George-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was not selected because of co-morbidity Giles de la Tourette Syndrome within OCD patients which was an exclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greist-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was not selected because the intervention is clomipramine which is SRI and not SSRI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hohagen-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Combination trial of Fluvoxamine with behaviour therapy versus placebo with behaviour therapy - thus not direct one to one comparison of Fluvoxamine versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koran-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study does not report of impact of fluoxetine on OCD symtom.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koran-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study is single arm trial in the initial phase and then in the subsequest phase investigates in randomised conrolled manner the withdrawal / discontinuation of sertraline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mallya-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study reports two case reports and is not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peter-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Combination trial of Fluvoxamine and CBT versus placebo and CBT - thus not direct one to one comparison of Fluvoxamine versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Romano-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study is single arm trial in the initial phase and then in the subsequest phase investigates in randomised conrolled manner the withdrawal / discontinuation of fluoxetine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Turner-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study is not selected because it is a single arm trial. The placebo is used in the initial run-in phase and then fluoxetine is used and no parallel placebo arm is used in the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zohar-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial is not selected because the condition under study is exhibitionism and not OCD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Bolt-1992">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Erzegovesi-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Greist-1992a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Hembree-2003-a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Jianxun-1998">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Mallya-1992">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Nakagawa-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-O_x0027_Connor-2006-a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Perse-1987">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Stein-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Wheadon-1993">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dominguez-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Greist-1992b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hollander-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hollander-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jenike-1990a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jenike-1990b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jenike-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kamijima-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kasper-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kronig-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-1993c">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nakajima-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ushijima-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zohar-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Critical appraisal of previous systematic reviews of treatment for OCD</TITLE>
<TABLE COLS="8" ROWS="13">
<TR>
<TH>
<P>Article</P>
</TH>
<TH>
<P>Focused question</P>
</TH>
<TH>
<P>Inclusion criteria</P>
</TH>
<TH>
<P>Comprehen search</P>
</TH>
<TH>
<P>Internal validity</P>
</TH>
<TH>
<P>Study assessment</P>
</TH>
<TH>
<P>Heterogenity examin</P>
</TH>
<TH>
<P>Methods pooling data</P>
</TH>
</TR>
<TR>
<TD>
<P>QAP 1985</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>reasonable</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Jenike 1990</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Cox 1993</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>reasonable</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>van Balkom 1994</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes (but not standardised</P>
</TD>
</TR>
<TR>
<TD>
<P>Greist 1995</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>effect sizes compared only</P>
</TD>
</TR>
<TR>
<TD>
<P>Piccinelli 1995</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>reasonable</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Stein 1995</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>reasonable</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Abramowitz 1996</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>reasonable</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Abramowitz 1997</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>reasonable</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Kobak 1998</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>for some comparisons</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Christensen 1987</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>reasonable</P>
</TD>
<TD>
<P>only partial</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not clear</P>
</TD>
</TR>
<TR>
<TD>
<P>Ackerman 2002</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not clear</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>SSRIs versus Placebo - efficacy using YBOCS</NAME>
<CONT_OUTCOME CHI2="21.613237759594288" CI_END="-2.570078740242418" CI_START="-3.840438035561214" CI_STUDY="95" CI_TOTAL="95" DF="16.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.205258387901816" ESTIMABLE="YES" I2="25.97129510178329" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.15612444342099552" P_Q="1.0" P_Z="4.581198255369756E-23" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.4352527274992721" TOTALS="YES" TOTAL_1="2022" TOTAL_2="1075" UNITS="" WEIGHT="99.99999999999999" Z="9.890416080839492">
<NAME>YBOCS reduction for all SSRI drugs</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.11609582655765038" CI_START="-4.50390417344235" EFFECT_SIZE="-2.31" ESTIMABLE="YES" MEAN_1="-3.79" MEAN_2="-1.48" ORDER="721" SD_1="5.22" SD_2="5.22" SE="1.1193594324934466" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" WEIGHT="6.221117026174276"/>
<CONT_DATA CI_END="-3.1302065819699276" CI_START="-6.1497934180300735" EFFECT_SIZE="-4.640000000000001" ESTIMABLE="YES" MEAN_1="-5.44" MEAN_2="-0.8" ORDER="722" SD_1="7.88" SD_2="5.66" SE="0.7703169190552127" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" WEIGHT="10.210174972634237"/>
<CONT_DATA CI_END="-4.36599387932588" CI_START="-12.834006120674122" EFFECT_SIZE="-8.600000000000001" ESTIMABLE="YES" MEAN_1="19.4" MEAN_2="28.0" ORDER="723" SD_1="7.0" SD_2="7.0" SE="2.160246899469287" STUDY_ID="STD-Goodman-1989" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.058559257977279"/>
<CONT_DATA CI_END="-0.4802687336468672" CI_START="-3.999731266353133" EFFECT_SIZE="-2.24" ESTIMABLE="YES" MEAN_1="-3.95" MEAN_2="-1.71" ORDER="724" SD_1="6.25" SD_2="4.88" SE="0.8978385726644309" STUDY_ID="STD-Goodman-1996" TOTAL_1="78" TOTAL_2="78" WEIGHT="8.460515576832305"/>
<CONT_DATA CI_END="-0.6319658402476978" CI_START="-3.708034159752303" EFFECT_SIZE="-2.1700000000000004" ESTIMABLE="YES" MEAN_1="-5.57" MEAN_2="-3.4" ORDER="725" SD_1="6.19" SD_2="6.19" SE="0.7847257255154277" STUDY_ID="STD-Greist-1992b" TOTAL_1="240" TOTAL_2="84" WEIGHT="9.992513642016037"/>
<CONT_DATA CI_END="-0.9520693587496512" CI_START="-4.84793064125035" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-5.6" ORDER="726" SD_1="7.6" SD_2="7.7" SE="0.9938604263217985" STUDY_ID="STD-Hollander-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="7.38054827144408"/>
<CONT_DATA CI_END="-0.7967067990041288" CI_START="-4.443293200995873" EFFECT_SIZE="-2.620000000000001" ESTIMABLE="YES" MEAN_1="19.13" MEAN_2="21.75" ORDER="727" SD_1="8.87" SD_2="7.07" SE="0.9302687270673218" STUDY_ID="STD-Hollander-2003" TOTAL_1="259" TOTAL_2="89" WEIGHT="8.07487190925848"/>
<CONT_DATA CI_END="0.8090370353940979" CI_START="-6.809037035394098" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="18.8" MEAN_2="21.8" ORDER="728" SD_1="4.0" SD_2="7.6" SE="1.943421953382458" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" WEIGHT="2.493411750794819"/>
<CONT_DATA CI_END="5.947376614646841" CI_START="-9.34737661464684" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="20.6" MEAN_2="22.3" ORDER="729" SD_1="9.2" SD_2="7.8" SE="3.9017944589637215" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.670696334306583"/>
<CONT_DATA CI_END="1.4957169987722234" CI_START="-6.495716998772224" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="18.7" ORDER="730" SD_1="6.3" SD_2="6.1" SE="2.0386685828361792" STUDY_ID="STD-Jenike-1997" TOTAL_1="19" TOTAL_2="18" WEIGHT="2.287440072940826"/>
<CONT_DATA CI_END="-2.616257910757117" CI_START="-6.683742089242882" EFFECT_SIZE="-4.6499999999999995" ESTIMABLE="YES" MEAN_1="-8.11" MEAN_2="-3.46" ORDER="735" SD_1="8.0" SD_2="6.1" SE="1.037642581845779" STUDY_ID="STD-Kamijima-2004" TOTAL_1="94" TOTAL_2="94" WEIGHT="6.946373674107296"/>
<CONT_DATA CI_END="-2.063319892060622" CI_START="-5.196680107939379" EFFECT_SIZE="-3.630000000000001" ESTIMABLE="YES" MEAN_1="-9.23" MEAN_2="-5.6" ORDER="731" SD_1="7.09" SD_2="6.9" SE="0.7993412737668403" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" WEIGHT="9.777146927428449"/>
<CONT_DATA CI_END="-1.2510549303106009" CI_START="-7.4689450696894" EFFECT_SIZE="-4.36" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-4.14" ORDER="732" SD_1="10.15" SD_2="10.15" SE="1.5862256113950874" STUDY_ID="STD-Kronig-1999" TOTAL_1="85" TOTAL_2="79" WEIGHT="3.5585586582150044"/>
<CONT_DATA CI_END="0.2570176836917364" CI_START="-3.517017683691736" EFFECT_SIZE="-1.63" ESTIMABLE="YES" MEAN_1="-5.33" MEAN_2="-3.7" ORDER="733" SD_1="6.75" SD_2="5.98" SE="0.9627818156743139" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="158" TOTAL_2="56" WEIGHT="7.7100216089033715"/>
<CONT_DATA CI_END="-2.167060536766019" CI_START="-8.23293946323398" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-1.9" ORDER="736" SD_1="7.03" SD_2="7.2" SE="1.5474465281798133" STUDY_ID="STD-Nakajima-1996" TOTAL_1="60" TOTAL_2="33" WEIGHT="3.7113725397557307"/>
<CONT_DATA CI_END="1.5390533057735802" CI_START="-5.4790533057735775" EFFECT_SIZE="-1.9699999999999989" ESTIMABLE="YES" MEAN_1="17.73" MEAN_2="19.7" ORDER="737" SD_1="8.99" SD_2="8.5" SE="1.7903662176716224" STUDY_ID="STD-Ushijima-1997" TOTAL_1="56" TOTAL_2="41" WEIGHT="2.8848044286873358"/>
<CONT_DATA CI_END="-1.086010757390319" CI_START="-4.913989242609681" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-5.0" ORDER="734" SD_1="8.0" SD_2="7.9" SE="0.9765430679884854" STUDY_ID="STD-Zohar-1996" TOTAL_1="198" TOTAL_2="99" WEIGHT="7.561873348523883"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="21.61323775959429" CI_END="-2.570078740242418" CI_START="-3.840438035561215" CI_STUDY="95" CI_TOTAL="95" DF="16.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2052583879018166" ESTIMABLE="YES" I2="25.9712951017833" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.15612444342099563" P_Q="0.6751134601357887" P_Z="4.581198255369756E-23" Q="2.3310961092282234" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.4352527274992724" TOTALS="YES" TOTAL_1="2022" TOTAL_2="1075" UNITS="" WEIGHT="99.99999999999997" Z="9.890416080839492">
<NAME>YOBCS reduction (individual SSRI drugs)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.063319892060622" CI_START="-5.196680107939379" DF="0.0" EFFECT_SIZE="-3.630000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="5.592451203791011E-6" STUDIES="1" TAU2="0.0" TOTAL_1="300" TOTAL_2="101" WEIGHT="9.777146927428447" Z="4.541239291815719">
<NAME>Citalopram</NAME>
<CONT_DATA CI_END="-2.063319892060622" CI_START="-5.196680107939379" EFFECT_SIZE="-3.630000000000001" ESTIMABLE="YES" MEAN_1="-9.23" MEAN_2="-5.6" ORDER="738" SD_1="7.09" SD_2="6.9" SE="0.7993412737668403" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" WEIGHT="9.777146927428447"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.165470920634094" CI_END="-0.8248016708834731" CI_START="-5.318165564251742" DF="2.0" EFFECT_SIZE="-3.0714836175676075" ESTIMABLE="YES" I2="67.56127754480904" ID="CMP-001.02.02" NO="2" P_CHI2="0.045833740538951395" P_Z="0.007373092957173802" STUDIES="3" TAU2="2.520200102355511" TOTAL_1="443" TOTAL_2="163" WEIGHT="20.207636654478435" Z="2.67950578337187">
<NAME>Fluoxetine</NAME>
<CONT_DATA CI_END="-3.1302065819699276" CI_START="-6.1497934180300735" EFFECT_SIZE="-4.640000000000001" ESTIMABLE="YES" MEAN_1="-5.44" MEAN_2="-0.8" ORDER="739" SD_1="7.88" SD_2="5.66" SE="0.7703169190552127" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" WEIGHT="10.210174972634237"/>
<CONT_DATA CI_END="1.4957169987722234" CI_START="-6.495716998772224" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="18.7" ORDER="740" SD_1="6.3" SD_2="6.1" SE="2.0386685828361792" STUDY_ID="STD-Jenike-1997" TOTAL_1="19" TOTAL_2="18" WEIGHT="2.2874400729408255"/>
<CONT_DATA CI_END="0.2570176836917364" CI_START="-3.517017683691736" EFFECT_SIZE="-1.63" ESTIMABLE="YES" MEAN_1="-5.33" MEAN_2="-3.7" ORDER="741" SD_1="6.75" SD_2="5.98" SE="0.9627818156743139" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="158" TOTAL_2="56" WEIGHT="7.710021608903372"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.101157709625541" CI_END="-2.042668734266498" CI_START="-5.69039415949431" DF="4.0" EFFECT_SIZE="-3.866531446880404" ESTIMABLE="YES" I2="56.04954745735775" ID="CMP-001.02.03" NO="3" P_CHI2="0.0586202389088637" P_Z="3.2519955810941806E-5" STUDIES="5" TAU2="2.273909762196387" TOTAL_1="294" TOTAL_2="272" WEIGHT="24.104407396804213" Z="4.155061852279549">
<NAME>Fluvoxamine</NAME>
<CONT_DATA CI_END="-4.36599387932588" CI_START="-12.834006120674122" EFFECT_SIZE="-8.600000000000001" ESTIMABLE="YES" MEAN_1="19.4" MEAN_2="28.0" ORDER="742" SD_1="7.0" SD_2="7.0" SE="2.160246899469287" STUDY_ID="STD-Goodman-1989" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.058559257977279"/>
<CONT_DATA CI_END="-0.4802687336468672" CI_START="-3.999731266353133" EFFECT_SIZE="-2.24" ESTIMABLE="YES" MEAN_1="-3.95" MEAN_2="-1.71" ORDER="743" SD_1="6.25" SD_2="4.88" SE="0.8978385726644309" STUDY_ID="STD-Goodman-1996" TOTAL_1="78" TOTAL_2="78" WEIGHT="8.460515576832305"/>
<CONT_DATA CI_END="-0.9520693587496512" CI_START="-4.84793064125035" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-5.6" ORDER="744" SD_1="7.6" SD_2="7.7" SE="0.9938604263217985" STUDY_ID="STD-Hollander-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="7.38054827144408"/>
<CONT_DATA CI_END="0.8090370353940979" CI_START="-6.809037035394098" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="18.8" MEAN_2="21.8" ORDER="745" SD_1="4.0" SD_2="7.6" SE="1.943421953382458" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" WEIGHT="2.4934117507948192"/>
<CONT_DATA CI_END="-2.167060536766019" CI_START="-8.23293946323398" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-1.9" ORDER="746" SD_1="7.03" SD_2="7.2" SE="1.5474465281798133" STUDY_ID="STD-Nakajima-1996" TOTAL_1="60" TOTAL_2="33" WEIGHT="3.7113725397557307"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.3138448945152397" CI_END="-2.1668928906668716" CI_START="-4.55071249904389" DF="2.0" EFFECT_SIZE="-3.3588026948553806" ESTIMABLE="YES" I2="13.563782743570265" ID="CMP-001.02.04" NO="4" P_CHI2="0.3144524805199125" P_Z="3.3291848037741964E-8" STUDIES="3" TAU2="0.1508584205833871" TOTAL_1="551" TOTAL_2="282" WEIGHT="22.583118931889658" Z="5.523179933547601">
<NAME>Paroxetine</NAME>
<CONT_DATA CI_END="-0.7967067990041288" CI_START="-4.443293200995873" EFFECT_SIZE="-2.620000000000001" ESTIMABLE="YES" MEAN_1="19.13" MEAN_2="21.75" ORDER="747" SD_1="8.87" SD_2="7.07" SE="0.9302687270673218" STUDY_ID="STD-Hollander-2003" TOTAL_1="259" TOTAL_2="89" WEIGHT="8.07487190925848"/>
<CONT_DATA CI_END="-2.616257910757117" CI_START="-6.683742089242882" EFFECT_SIZE="-4.6499999999999995" ESTIMABLE="YES" MEAN_1="-8.11" MEAN_2="-3.46" ORDER="749" SD_1="8.0" SD_2="6.1" SE="1.037642581845779" STUDY_ID="STD-Kamijima-2004" TOTAL_1="94" TOTAL_2="94" WEIGHT="6.946373674107296"/>
<CONT_DATA CI_END="-1.086010757390319" CI_START="-4.913989242609681" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-5.0" ORDER="748" SD_1="8.0" SD_2="7.9" SE="0.9765430679884854" STUDY_ID="STD-Zohar-1996" TOTAL_1="198" TOTAL_2="99" WEIGHT="7.561873348523883"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7016681255911927" CI_END="-1.3518721753209497" CI_START="-3.5441646425482674" DF="4.0" EFFECT_SIZE="-2.4480184089346086" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.05" NO="5" P_CHI2="0.7904146099381392" P_Z="1.2022541645228831E-5" STUDIES="5" TAU2="0.0" TOTAL_1="434" TOTAL_2="257" WEIGHT="23.327690089399233" Z="4.377178671850424">
<NAME>Sertraline</NAME>
<CONT_DATA CI_END="-0.11609582655765038" CI_START="-4.50390417344235" EFFECT_SIZE="-2.31" ESTIMABLE="YES" MEAN_1="-3.79" MEAN_2="-1.48" ORDER="750" SD_1="5.22" SD_2="5.22" SE="1.1193594324934466" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" WEIGHT="6.221117026174276"/>
<CONT_DATA CI_END="-0.6319658402476978" CI_START="-3.708034159752303" EFFECT_SIZE="-2.1700000000000004" ESTIMABLE="YES" MEAN_1="-5.57" MEAN_2="-3.4" ORDER="751" SD_1="6.19" SD_2="6.19" SE="0.7847257255154277" STUDY_ID="STD-Greist-1992b" TOTAL_1="240" TOTAL_2="84" WEIGHT="9.992513642016034"/>
<CONT_DATA CI_END="5.947376614646841" CI_START="-9.34737661464684" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="20.6" MEAN_2="22.3" ORDER="752" SD_1="9.2" SD_2="7.8" SE="3.9017944589637215" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.6706963343065832"/>
<CONT_DATA CI_END="-1.2510549303106009" CI_START="-7.4689450696894" EFFECT_SIZE="-4.36" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-4.14" ORDER="753" SD_1="10.15" SD_2="10.15" SE="1.5862256113950874" STUDY_ID="STD-Kronig-1999" TOTAL_1="85" TOTAL_2="79" WEIGHT="3.5585586582150044"/>
<CONT_DATA CI_END="1.5390533057735802" CI_START="-5.4790533057735775" EFFECT_SIZE="-1.9699999999999989" ESTIMABLE="YES" MEAN_1="17.73" MEAN_2="19.7" ORDER="754" SD_1="8.99" SD_2="8.5" SE="1.7903662176716224" STUDY_ID="STD-Ushijima-1997" TOTAL_1="56" TOTAL_2="41" WEIGHT="2.884804428687336"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="17.27597760763258" CI_END="2.167136762999515" CI_START="1.561393603566235" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.839498159770941" ESTIMABLE="YES" EVENTS_1="760" EVENTS_2="215" I2="30.53938669902904" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3358863195070928" LOG_CI_START="0.19351239589354777" LOG_EFFECT_SIZE="0.2646993577003203" METHOD="MH" NO="3" P_CHI2="0.13950767765242345" P_Q="0.0" P_Z="3.148973817855424E-13" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.025119122181514048" TOTALS="YES" TOTAL_1="1745" TOTAL_2="952" WEIGHT="100.00000000000003" Z="7.28786837724202">
<NAME>Responders ITT for all SSRI drugs</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.9383602501925195" CI_START="0.8533894369337812" EFFECT_SIZE="2.2511627906976743" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7736665405023573" LOG_CI_START="-0.06885273704474294" LOG_EFFECT_SIZE="0.3524069017288071" ORDER="755" O_E="0.0" SE="0.49489999416885205" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" VAR="0.2449260042283298" WEIGHT="2.5900000210933807"/>
<DICH_DATA CI_END="7.583542552573936" CI_START="1.7401060482933182" EFFECT_SIZE="3.63265306122449" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="7" LOG_CI_END="0.8798721280108274" LOG_CI_START="0.24057571654993323" LOG_EFFECT_SIZE="0.5602239222803803" ORDER="756" O_E="0.0" SE="0.3755258766604035" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" VAR="0.14101968404156456" WEIGHT="4.209834529318431"/>
<DICH_DATA CI_END="306.79369636339845" CI_START="1.1766864974057147" EFFECT_SIZE="19.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.4868464319955983" LOG_CI_START="0.07066076991005915" LOG_EFFECT_SIZE="1.2787536009528289" ORDER="757" O_E="0.0" SE="1.4192794182209667" STUDY_ID="STD-Goodman-1989" TOTAL_1="21" TOTAL_2="21" VAR="2.014354066985646" WEIGHT="0.3429399743093825"/>
<DICH_DATA CI_END="8.061506373251012" CI_START="1.7113325634925194" EFFECT_SIZE="3.7142857142857144" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="7" LOG_CI_END="0.9064162016641458" LOG_CI_START="0.23333441424897639" LOG_EFFECT_SIZE="0.5698753079565612" ORDER="758" O_E="0.0" SE="0.3953715737362529" STUDY_ID="STD-Goodman-1996" TOTAL_1="80" TOTAL_2="80" VAR="0.1563186813186813" WEIGHT="3.8548575302660515"/>
<DICH_DATA CI_END="1.8679409636344066" CI_START="0.9000097629614652" EFFECT_SIZE="1.296597510373444" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="25" LOG_CI_END="0.2713631462126141" LOG_CI_START="-0.04575277947479254" LOG_EFFECT_SIZE="0.11280518336891078" ORDER="759" O_E="0.0" SE="0.18627546449793142" STUDY_ID="STD-Greist-1992b" TOTAL_1="241" TOTAL_2="84" VAR="0.03469854867392011" WEIGHT="11.69247938101758"/>
<DICH_DATA CI_END="2.7434624275960724" CI_START="1.272084735560918" EFFECT_SIZE="1.8681318681318682" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="28" LOG_CI_END="0.43829901680130423" LOG_CI_START="0.10451604131305649" LOG_EFFECT_SIZE="0.27140752905718035" ORDER="760" O_E="0.0" SE="0.19606577205417253" STUDY_ID="STD-Hollander-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.03844178697119874" WEIGHT="11.00388418638296"/>
<DICH_DATA CI_END="3.208326481631335" CI_START="1.3924576265113724" EFFECT_SIZE="2.1136363636363638" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="22" LOG_CI_END="0.5062785559825755" LOG_CI_START="0.1437819881529199" LOG_EFFECT_SIZE="0.3250302720677477" ORDER="765" O_E="0.0" SE="0.21293227833008987" STUDY_ID="STD-Kamijima-2004" TOTAL_1="94" TOTAL_2="93" VAR="0.04534015515484287" WEIGHT="9.92654068475326"/>
<DICH_DATA CI_END="2.082249668868042" CI_START="1.2038225793730397" EFFECT_SIZE="1.5832432432432433" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="37" LOG_CI_END="0.3185328016927118" LOG_CI_START="0.080562484864458" LOG_EFFECT_SIZE="0.19954764327858487" ORDER="761" O_E="0.0" SE="0.13978494207698267" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" VAR="0.0195398300314654" WEIGHT="15.661291822569568"/>
<DICH_DATA CI_END="2.917358490422569" CI_START="1.1194832768012826" EFFECT_SIZE="1.8071895424836601" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="18" LOG_CI_END="0.46498979931240175" LOG_CI_START="0.04901761033383474" LOG_EFFECT_SIZE="0.25700370482311824" ORDER="762" O_E="0.0" SE="0.24434412290155438" STUDY_ID="STD-Kronig-1999" TOTAL_1="85" TOTAL_2="79" VAR="0.059704050396529915" WEIGHT="8.245587400708713"/>
<DICH_DATA CI_END="2.834825483126874" CI_START="1.119240525169922" EFFECT_SIZE="1.78125" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="15" LOG_CI_END="0.4525263281150327" LOG_CI_START="0.04892342659013821" LOG_EFFECT_SIZE="0.2507248773525854" ORDER="763" O_E="0.0" SE="0.23707834222230673" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="160" TOTAL_2="57" VAR="0.05620614035087719" WEIGHT="8.60024131885326"/>
<DICH_DATA CI_END="6.204869420817852" CI_START="1.269473255211564" EFFECT_SIZE="2.8065843621399176" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" LOG_CI_END="0.7927326463641649" LOG_CI_START="0.10362355575216874" LOG_EFFECT_SIZE="0.4481781010581667" ORDER="766" O_E="0.0" SE="0.4047860909704992" STUDY_ID="STD-Nakajima-1996" TOTAL_1="81" TOTAL_2="44" VAR="0.16385177944317728" WEIGHT="3.701188262766234"/>
<DICH_DATA CI_END="3.1415845720939455" CI_START="0.9026067478372736" EFFECT_SIZE="1.6839285714285714" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.4971487555048756" LOG_CI_START="-0.04450142404261974" LOG_EFFECT_SIZE="0.22632366573112792" ORDER="767" O_E="0.0" SE="0.3181679966778295" STUDY_ID="STD-Ushijima-1997" TOTAL_1="56" TOTAL_2="41" VAR="0.10123087410998335" WEIGHT="5.535551275237566"/>
<DICH_DATA CI_END="2.060431346630637" CI_START="1.1419235593010584" EFFECT_SIZE="1.533901918976546" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="35" LOG_CI_END="0.31395814845235553" LOG_CI_START="0.057637033082462555" LOG_EFFECT_SIZE="0.18579759076740904" ORDER="764" O_E="0.0" SE="0.1505642919782593" STUDY_ID="STD-Zohar-1996" TOTAL_1="201" TOTAL_2="99" VAR="0.022669606018914518" WEIGHT="14.635603612723635"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.27597760763258" CI_END="2.167136762999514" CI_START="1.5613936035662346" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8394981597709403" ESTIMABLE="YES" EVENTS_1="760" EVENTS_2="215" I2="30.53938669902904" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.33588631950709263" LOG_CI_START="0.19351239589354766" LOG_EFFECT_SIZE="0.26469935770032016" METHOD="MH" NO="4" P_CHI2="0.13950767765242345" P_Q="0.0" P_Z="3.1489738178554927E-13" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.025119122181514044" TOTALS="YES" TOTAL_1="1745" TOTAL_2="952" WEIGHT="100.00000000000003" Z="7.287868377242018">
<NAME>Responders ITT (indvidual SSRI drugs)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.082249668868042" CI_START="1.2038225793730397" DF="0.0" EFFECT_SIZE="1.5832432432432433" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="37" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.3185328016927118" LOG_CI_START="0.080562484864458" LOG_EFFECT_SIZE="0.19954764327858487" NO="1" P_CHI2="1.0" P_Z="0.0010125485523723799" STUDIES="1" TAU2="0.0" TOTAL_1="300" TOTAL_2="101" WEIGHT="15.66129182256957" Z="3.287016626600022">
<NAME>Citalopram</NAME>
<DICH_DATA CI_END="2.082249668868042" CI_START="1.2038225793730397" EFFECT_SIZE="1.5832432432432433" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="37" LOG_CI_END="0.3185328016927118" LOG_CI_START="0.080562484864458" LOG_EFFECT_SIZE="0.19954764327858487" ORDER="768" O_E="0.0" SE="0.13978494207698267" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" VAR="0.0195398300314654" WEIGHT="15.66129182256957"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7563353160002366" CI_END="4.912318114029029" CI_START="1.1786245600014351" DF="1.0" EFFECT_SIZE="2.4061959138304894" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="22" I2="63.719943861869595" ID="CMP-001.04.02" LOG_CI_END="0.6912864832743919" LOG_CI_START="0.07137548661656033" LOG_EFFECT_SIZE="0.3813309849454761" NO="2" P_CHI2="0.09686999050556044" P_Z="0.01589586527156162" STUDIES="2" TAU2="0.17319734030385317" TOTAL_1="426" TOTAL_2="146" WEIGHT="12.810075848171692" Z="2.411297753102624">
<NAME>Fluoxetine</NAME>
<DICH_DATA CI_END="7.583542552573936" CI_START="1.7401060482933182" EFFECT_SIZE="3.63265306122449" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="7" LOG_CI_END="0.8798721280108274" LOG_CI_START="0.24057571654993323" LOG_EFFECT_SIZE="0.5602239222803803" ORDER="769" O_E="0.0" SE="0.3755258766604035" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" VAR="0.14101968404156456" WEIGHT="4.209834529318431"/>
<DICH_DATA CI_END="2.834825483126874" CI_START="1.119240525169922" EFFECT_SIZE="1.78125" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="15" LOG_CI_END="0.4525263281150327" LOG_CI_START="0.04892342659013821" LOG_EFFECT_SIZE="0.2507248773525854" ORDER="770" O_E="0.0" SE="0.23707834222230673" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="160" TOTAL_2="57" VAR="0.05620614035087719" WEIGHT="8.60024131885326"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.4464764847750615" CI_END="4.564461944343654" CI_START="1.5788842139853685" DF="3.0" EFFECT_SIZE="2.684540353442495" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="41" I2="44.91851734995787" ID="CMP-001.04.03" LOG_CI_END="0.6593895905505657" LOG_CI_START="0.19835028259157397" LOG_EFFECT_SIZE="0.4288699365710698" NO="3" P_CHI2="0.14187527921712384" P_Z="2.6592750139963563E-4" STUDIES="4" TAU2="0.12448243484192494" TOTAL_1="299" TOTAL_2="265" WEIGHT="18.90286995372463" Z="3.6464119879602155">
<NAME>Fluvoxamine</NAME>
<DICH_DATA CI_END="306.79369636339845" CI_START="1.1766864974057147" EFFECT_SIZE="19.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.4868464319955983" LOG_CI_START="0.07066076991005915" LOG_EFFECT_SIZE="1.2787536009528289" ORDER="771" O_E="0.0" SE="1.4192794182209667" STUDY_ID="STD-Goodman-1989" TOTAL_1="21" TOTAL_2="21" VAR="2.014354066985646" WEIGHT="0.3429399743093825"/>
<DICH_DATA CI_END="8.061506373251012" CI_START="1.7113325634925194" EFFECT_SIZE="3.7142857142857144" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="7" LOG_CI_END="0.9064162016641458" LOG_CI_START="0.23333441424897639" LOG_EFFECT_SIZE="0.5698753079565612" ORDER="772" O_E="0.0" SE="0.3953715737362529" STUDY_ID="STD-Goodman-1996" TOTAL_1="80" TOTAL_2="80" VAR="0.1563186813186813" WEIGHT="3.8548575302660515"/>
<DICH_DATA CI_END="2.7434624275960724" CI_START="1.272084735560918" EFFECT_SIZE="1.8681318681318682" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="28" LOG_CI_END="0.43829901680130423" LOG_CI_START="0.10451604131305649" LOG_EFFECT_SIZE="0.27140752905718035" ORDER="773" O_E="0.0" SE="0.19606577205417253" STUDY_ID="STD-Hollander-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.03844178697119874" WEIGHT="11.00388418638296"/>
<DICH_DATA CI_END="6.204869420817852" CI_START="1.269473255211564" EFFECT_SIZE="2.8065843621399176" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" LOG_CI_END="0.7927326463641649" LOG_CI_START="0.10362355575216874" LOG_EFFECT_SIZE="0.4481781010581667" ORDER="774" O_E="0.0" SE="0.4047860909704992" STUDY_ID="STD-Nakajima-1996" TOTAL_1="81" TOTAL_2="44" VAR="0.16385177944317728" WEIGHT="3.701188262766234"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5149570617833594" CI_END="2.362433948653444" CI_START="1.2788871294369395" DF="1.0" EFFECT_SIZE="1.7381847919820772" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="57" I2="33.9915285240605" ID="CMP-001.04.04" LOG_CI_END="0.3733596749013681" LOG_CI_START="0.10683221670244036" LOG_EFFECT_SIZE="0.24009594580190421" NO="4" P_CHI2="0.21838464070264785" P_Z="4.1369612301428866E-4" STUDIES="2" TAU2="0.017511053393313047" TOTAL_1="295" TOTAL_2="192" WEIGHT="24.562144297476895" Z="3.531188942300928">
<NAME>Paroxetine</NAME>
<DICH_DATA CI_END="3.208326481631335" CI_START="1.3924576265113724" EFFECT_SIZE="2.1136363636363638" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="22" LOG_CI_END="0.5062785559825755" LOG_CI_START="0.1437819881529199" LOG_EFFECT_SIZE="0.3250302720677477" ORDER="776" O_E="0.0" SE="0.21293227833008987" STUDY_ID="STD-Kamijima-2004" TOTAL_1="94" TOTAL_2="93" VAR="0.04534015515484287" WEIGHT="9.92654068475326"/>
<DICH_DATA CI_END="2.060431346630637" CI_START="1.1419235593010584" EFFECT_SIZE="1.533901918976546" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="35" LOG_CI_END="0.31395814845235553" LOG_CI_START="0.057637033082462555" LOG_EFFECT_SIZE="0.18579759076740904" ORDER="775" O_E="0.0" SE="0.1505642919782593" STUDY_ID="STD-Zohar-1996" TOTAL_1="201" TOTAL_2="99" VAR="0.022669606018914518" WEIGHT="14.635603612723635"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.952122683512896" CI_END="1.9905320451065958" CI_START="1.19763469899639" DF="3.0" EFFECT_SIZE="1.5439981368783793" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="58" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="0.29896917358097713" LOG_CI_START="0.07832437030456223" LOG_EFFECT_SIZE="0.1886467719427697" NO="5" P_CHI2="0.5824033355848195" P_Z="8.038727579928968E-4" STUDIES="4" TAU2="0.0" TOTAL_1="425" TOTAL_2="248" WEIGHT="28.06361807805724" Z="3.351457848244658">
<NAME>Sertraline</NAME>
<DICH_DATA CI_END="5.9383602501925195" CI_START="0.8533894369337812" EFFECT_SIZE="2.2511627906976743" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7736665405023573" LOG_CI_START="-0.06885273704474294" LOG_EFFECT_SIZE="0.3524069017288071" ORDER="777" O_E="0.0" SE="0.49489999416885205" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" VAR="0.2449260042283298" WEIGHT="2.5900000210933807"/>
<DICH_DATA CI_END="1.8679409636344066" CI_START="0.9000097629614652" EFFECT_SIZE="1.296597510373444" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="25" LOG_CI_END="0.2713631462126141" LOG_CI_START="-0.04575277947479254" LOG_EFFECT_SIZE="0.11280518336891078" ORDER="778" O_E="0.0" SE="0.18627546449793142" STUDY_ID="STD-Greist-1992b" TOTAL_1="241" TOTAL_2="84" VAR="0.03469854867392011" WEIGHT="11.69247938101758"/>
<DICH_DATA CI_END="2.917358490422569" CI_START="1.1194832768012826" EFFECT_SIZE="1.8071895424836601" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="18" LOG_CI_END="0.46498979931240175" LOG_CI_START="0.04901761033383474" LOG_EFFECT_SIZE="0.25700370482311824" ORDER="779" O_E="0.0" SE="0.24434412290155438" STUDY_ID="STD-Kronig-1999" TOTAL_1="85" TOTAL_2="79" VAR="0.059704050396529915" WEIGHT="8.245587400708713"/>
<DICH_DATA CI_END="3.1415845720939455" CI_START="0.9026067478372736" EFFECT_SIZE="1.6839285714285714" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.4971487555048756" LOG_CI_START="-0.04450142404261974" LOG_EFFECT_SIZE="0.22632366573112792" ORDER="780" O_E="0.0" SE="0.3181679966778295" STUDY_ID="STD-Ushijima-1997" TOTAL_1="56" TOTAL_2="41" VAR="0.10123087410998335" WEIGHT="5.535551275237566"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="14.946028074695136" CI_END="-2.5582026477750848" CI_START="-3.821750281914868" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.1899764648449764" ESTIMABLE="YES" I2="26.40185108026184" I2_Q="41.277919450986474" ID="CMP-001.05" NO="5" P_CHI2="0.1849812019674184" P_Q="0.19190442615413983" P_Z="4.3185358570732285E-23" Q="1.7029369372655836" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1302" TOTAL_2="803" UNITS="" WEIGHT="100.0" Z="9.896324940504593">
<NAME>YBOCS reduction (mean duration of OCD)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.3137141094213254" CI_END="-1.483116744497185" CI_START="-3.6911833603108617" DF="3.0" EFFECT_SIZE="-2.587150052404023" ESTIMABLE="YES" I2="9.467144692096246" ID="CMP-001.05.01" NO="1" P_CHI2="0.3457385225590841" P_Z="4.371165162204994E-6" STUDIES="4" TAU2="0.0" TOTAL_1="399" TOTAL_2="202" WEIGHT="32.74604803880182" Z="4.592905747496418">
<NAME>Mean duration of OCD 10 yrs or less</NAME>
<CONT_DATA CI_END="-0.11609582655765038" CI_START="-4.50390417344235" EFFECT_SIZE="-2.31" ESTIMABLE="YES" MEAN_1="-3.79" MEAN_2="-1.48" ORDER="781" SD_1="5.22" SD_2="5.22" SE="1.1193594324934466" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" WEIGHT="8.292546928143052"/>
<CONT_DATA CI_END="-0.6319658402476978" CI_START="-3.708034159752303" EFFECT_SIZE="-2.1700000000000004" ESTIMABLE="YES" MEAN_1="-5.57" MEAN_2="-3.4" ORDER="782" SD_1="6.19" SD_2="6.19" SE="0.7847257255154277" STUDY_ID="STD-Greist-1992b" TOTAL_1="240" TOTAL_2="84" WEIGHT="16.87296027333544"/>
<CONT_DATA CI_END="-2.167060536766019" CI_START="-8.23293946323398" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-1.9" ORDER="783" SD_1="7.03" SD_2="7.2" SE="1.5474465281798133" STUDY_ID="STD-Nakajima-1996" TOTAL_1="60" TOTAL_2="33" WEIGHT="4.339061069020276"/>
<CONT_DATA CI_END="1.5390533057735802" CI_START="-5.4790533057735775" EFFECT_SIZE="-1.9699999999999989" ESTIMABLE="YES" MEAN_1="17.73" MEAN_2="19.7" ORDER="784" SD_1="8.99" SD_2="8.5" SE="1.7903662176716224" STUDY_ID="STD-Ushijima-1997" TOTAL_1="56" TOTAL_2="41" WEIGHT="3.241479768303053"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.929377028008227" CI_END="-2.7131175768521816" CI_START="-4.253869484965471" DF="7.0" EFFECT_SIZE="-3.4834935309088264" ESTIMABLE="YES" I2="29.502123041004545" ID="CMP-001.05.02" NO="2" P_CHI2="0.19261121363432188" P_Z="7.818063121186946E-19" STUDIES="8" TAU2="0.0" TOTAL_1="903" TOTAL_2="601" WEIGHT="67.25395196119818" Z="8.86258433302235">
<NAME>Mean duration of OCD more than 10 yrs</NAME>
<CONT_DATA CI_END="-4.36599387932588" CI_START="-12.834006120674122" EFFECT_SIZE="-8.600000000000001" ESTIMABLE="YES" MEAN_1="19.4" MEAN_2="28.0" ORDER="785" SD_1="7.0" SD_2="7.0" SE="2.160246899469287" STUDY_ID="STD-Goodman-1989" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.2264876140927297"/>
<CONT_DATA CI_END="-0.4802687336468672" CI_START="-3.999731266353133" EFFECT_SIZE="-2.24" ESTIMABLE="YES" MEAN_1="-3.95" MEAN_2="-1.71" ORDER="786" SD_1="6.25" SD_2="4.88" SE="0.8978385726644309" STUDY_ID="STD-Goodman-1996" TOTAL_1="78" TOTAL_2="78" WEIGHT="12.88933601258576"/>
<CONT_DATA CI_END="-0.9520693587496512" CI_START="-4.84793064125035" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-5.6" ORDER="787" SD_1="7.6" SD_2="7.7" SE="0.9938604263217985" STUDY_ID="STD-Hollander-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="10.51904391402126"/>
<CONT_DATA CI_END="5.947376614646841" CI_START="-9.34737661464684" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="20.6" MEAN_2="22.3" ORDER="788" SD_1="9.2" SD_2="7.8" SE="3.9017944589637215" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.6824931379685194"/>
<CONT_DATA CI_END="-2.616257910757117" CI_START="-6.683742089242882" EFFECT_SIZE="-4.6499999999999995" ESTIMABLE="YES" MEAN_1="-8.11" MEAN_2="-3.46" ORDER="792" SD_1="8.0" SD_2="6.1" SE="1.037642581845779" STUDY_ID="STD-Kamijima-2004" TOTAL_1="94" TOTAL_2="94" WEIGHT="9.650092876678958"/>
<CONT_DATA CI_END="-2.063319892060622" CI_START="-5.196680107939379" EFFECT_SIZE="-3.630000000000001" ESTIMABLE="YES" MEAN_1="-9.23" MEAN_2="-5.6" ORDER="789" SD_1="7.09" SD_2="6.9" SE="0.7993412737668403" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" WEIGHT="16.26157430804538"/>
<CONT_DATA CI_END="-1.2510549303106009" CI_START="-7.4689450696894" EFFECT_SIZE="-4.36" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-4.14" ORDER="790" SD_1="10.15" SD_2="10.15" SE="1.5862256113950874" STUDY_ID="STD-Kronig-1999" TOTAL_1="85" TOTAL_2="79" WEIGHT="4.129496942728343"/>
<CONT_DATA CI_END="-1.086010757390319" CI_START="-4.913989242609681" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-5.0" ORDER="791" SD_1="8.0" SD_2="7.9" SE="0.9765430679884854" STUDY_ID="STD-Zohar-1996" TOTAL_1="198" TOTAL_2="99" WEIGHT="10.895427155077229"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="19.43797549398838" CI_END="-2.504339233479401" CI_START="-3.825199783761277" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.164769508620339" ESTIMABLE="YES" I2="27.976038428848685" I2_Q="26.39268473282972" ID="CMP-001.06" NO="6" P_CHI2="0.14887973965262702" P_Q="0.24378726512194904" P_Z="5.8809722159036114E-21" Q="1.3585606218217983" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.44852330386625466" TOTALS="YES" TOTAL_1="1906" TOTAL_2="1001" UNITS="" WEIGHT="100.00000000000001" Z="9.392110703802434">
<NAME>YBOCS reduction (severe secondary depression)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="15.058553852891496" CI_END="-2.2980065368933333" CI_START="-4.894073644205119" DF="6.0" EFFECT_SIZE="-3.5960400905492262" ESTIMABLE="YES" I2="60.15553645712202" ID="CMP-001.06.01" NO="1" P_CHI2="0.019806185794864706" P_Z="5.640592377880312E-8" STUDIES="7" TAU2="1.7151590383870199" TOTAL_1="833" TOTAL_2="457" WEIGHT="48.650912775267415" Z="5.429835804003481">
<NAME>Studies with some pts with severe sec. depression</NAME>
<CONT_DATA CI_END="-3.1302065819699276" CI_START="-6.1497934180300735" EFFECT_SIZE="-4.640000000000001" ESTIMABLE="YES" MEAN_1="-5.44" MEAN_2="-0.8" ORDER="793" SD_1="7.88" SD_2="5.66" SE="0.7703169190552127" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" WEIGHT="10.897501834206256"/>
<CONT_DATA CI_END="-4.36599387932588" CI_START="-12.834006120674122" EFFECT_SIZE="-8.600000000000001" ESTIMABLE="YES" MEAN_1="19.4" MEAN_2="28.0" ORDER="794" SD_1="7.0" SD_2="7.0" SE="2.160246899469287" STUDY_ID="STD-Goodman-1989" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.219708770937834"/>
<CONT_DATA CI_END="-0.4802687336468672" CI_START="-3.999731266353133" EFFECT_SIZE="-2.24" ESTIMABLE="YES" MEAN_1="-3.95" MEAN_2="-1.71" ORDER="795" SD_1="6.25" SD_2="4.88" SE="0.8978385726644309" STUDY_ID="STD-Goodman-1996" TOTAL_1="78" TOTAL_2="78" WEIGHT="9.049811510809137"/>
<CONT_DATA CI_END="0.8090370353940979" CI_START="-6.809037035394098" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="18.8" MEAN_2="21.8" ORDER="796" SD_1="4.0" SD_2="7.6" SE="1.943421953382458" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" WEIGHT="2.6871300419100033"/>
<CONT_DATA CI_END="-2.616257910757117" CI_START="-6.683742089242882" EFFECT_SIZE="-4.6499999999999995" ESTIMABLE="YES" MEAN_1="-8.11" MEAN_2="-3.46" ORDER="799" SD_1="8.0" SD_2="6.1" SE="1.037642581845779" STUDY_ID="STD-Kamijima-2004" TOTAL_1="94" TOTAL_2="94" WEIGHT="7.44429761523609"/>
<CONT_DATA CI_END="0.2570176836917364" CI_START="-3.517017683691736" EFFECT_SIZE="-1.63" ESTIMABLE="YES" MEAN_1="-5.33" MEAN_2="-3.7" ORDER="797" SD_1="6.75" SD_2="5.98" SE="0.9627818156743139" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="158" TOTAL_2="56" WEIGHT="8.254788888614293"/>
<CONT_DATA CI_END="-1.086010757390319" CI_START="-4.913989242609681" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-5.0" ORDER="798" SD_1="8.0" SD_2="7.9" SE="0.9765430679884854" STUDY_ID="STD-Zohar-1996" TOTAL_1="198" TOTAL_2="99" WEIGHT="8.097674113553808"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.0208610192750864" CI_END="-2.088601443584449" CI_START="-3.5853721577878597" DF="7.0" EFFECT_SIZE="-2.8369868006861543" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="0.8830657552210281" P_Z="1.0871979185720862E-13" STUDIES="8" TAU2="0.0" TOTAL_1="1073" TOTAL_2="544" WEIGHT="51.3490872247326" Z="7.429851347565475">
<NAME>Studies with no pts with severe sec. depression</NAME>
<CONT_DATA CI_END="-0.11609582655765038" CI_START="-4.50390417344235" EFFECT_SIZE="-2.31" ESTIMABLE="YES" MEAN_1="-3.79" MEAN_2="-1.48" ORDER="800" SD_1="5.22" SD_2="5.22" SE="1.1193594324934466" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" WEIGHT="6.673115777080613"/>
<CONT_DATA CI_END="-0.6319658402476978" CI_START="-3.708034159752303" EFFECT_SIZE="-2.1700000000000004" ESTIMABLE="YES" MEAN_1="-5.57" MEAN_2="-3.4" ORDER="801" SD_1="6.19" SD_2="6.19" SE="0.7847257255154277" STUDY_ID="STD-Greist-1992b" TOTAL_1="240" TOTAL_2="84" WEIGHT="10.668084647614327"/>
<CONT_DATA CI_END="-0.9520693587496512" CI_START="-4.84793064125035" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-5.6" ORDER="802" SD_1="7.6" SD_2="7.7" SE="0.9938604263217985" STUDY_ID="STD-Hollander-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="7.9052952146471815"/>
<CONT_DATA CI_END="-0.7967067990041288" CI_START="-4.443293200995873" EFFECT_SIZE="-2.620000000000001" ESTIMABLE="YES" MEAN_1="19.13" MEAN_2="21.75" ORDER="803" SD_1="8.87" SD_2="7.07" SE="0.9302687270673218" STUDY_ID="STD-Hollander-2003" TOTAL_1="259" TOTAL_2="89" WEIGHT="8.641473085941875"/>
<CONT_DATA CI_END="5.947376614646841" CI_START="-9.34737661464684" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="20.6" MEAN_2="22.3" ORDER="804" SD_1="9.2" SD_2="7.8" SE="3.9017944589637215" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.7244673893580488"/>
<CONT_DATA CI_END="1.4957169987722234" CI_START="-6.495716998772224" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="18.7" ORDER="805" SD_1="6.3" SD_2="6.1" SE="2.0386685828361792" STUDY_ID="STD-Jenike-1997" TOTAL_1="19" TOTAL_2="18" WEIGHT="2.465795722477724"/>
<CONT_DATA CI_END="-2.063319892060622" CI_START="-5.196680107939379" EFFECT_SIZE="-3.630000000000001" ESTIMABLE="YES" MEAN_1="-9.23" MEAN_2="-5.6" ORDER="806" SD_1="7.09" SD_2="6.9" SE="0.7993412737668403" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" WEIGHT="10.440963321589301"/>
<CONT_DATA CI_END="-1.2510549303106009" CI_START="-7.4689450696894" EFFECT_SIZE="-4.36" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-4.14" ORDER="807" SD_1="10.15" SD_2="10.15" SE="1.5862256113950874" STUDY_ID="STD-Kronig-1999" TOTAL_1="85" TOTAL_2="79" WEIGHT="3.829892066023532"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="21.68759340579282" CI_END="-2.5744412737010145" CI_START="-3.8102584076186674" CI_STUDY="95" CI_TOTAL="95" DF="16.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.192349840659841" ESTIMABLE="YES" I2="26.22510160243805" I2_Q="29.658476495073053" ID="CMP-001.07" NO="7" P_CHI2="0.1535682377857277" P_Q="0.23313465594237948" P_Z="4.239866839794112E-24" Q="1.4216354013571468" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.41290931502604894" TOTALS="YES" TOTAL_1="2022" TOTAL_2="1075" UNITS="" WEIGHT="100.0" Z="10.125916759076738">
<NAME>YBOCS reduction (duration of trial)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.953716254812498" CI_END="-1.7184949295116743" CI_START="-4.125075651971432" DF="8.0" EFFECT_SIZE="-2.9217852907415534" ESTIMABLE="YES" I2="33.07520582329997" ID="CMP-001.07.01" NO="1" P_CHI2="0.15328102168473934" P_Z="1.9444624825733467E-6" STUDIES="9" TAU2="1.0365562084768192" TOTAL_1="463" TOTAL_2="320" WEIGHT="34.96495202867333" Z="4.7591122848845915">
<NAME>Duration of trials less than 12 wks</NAME>
<CONT_DATA CI_END="-0.11609582655765038" CI_START="-4.50390417344235" EFFECT_SIZE="-2.31" ESTIMABLE="YES" MEAN_1="-3.79" MEAN_2="-1.48" ORDER="808" SD_1="5.22" SD_2="5.22" SE="1.1193594324934466" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" WEIGHT="5.966365823120408"/>
<CONT_DATA CI_END="-4.36599387932588" CI_START="-12.834006120674122" EFFECT_SIZE="-8.600000000000001" ESTIMABLE="YES" MEAN_1="19.4" MEAN_2="28.0" ORDER="809" SD_1="7.0" SD_2="7.0" SE="2.160246899469287" STUDY_ID="STD-Goodman-1989" TOTAL_1="21" TOTAL_2="21" WEIGHT="1.95670245531264"/>
<CONT_DATA CI_END="-0.4802687336468672" CI_START="-3.999731266353133" EFFECT_SIZE="-2.24" ESTIMABLE="YES" MEAN_1="-3.95" MEAN_2="-1.71" ORDER="810" SD_1="6.25" SD_2="4.88" SE="0.8978385726644309" STUDY_ID="STD-Goodman-1996" TOTAL_1="78" TOTAL_2="78" WEIGHT="8.153427286059669"/>
<CONT_DATA CI_END="0.8090370353940979" CI_START="-6.809037035394098" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="18.8" MEAN_2="21.8" ORDER="811" SD_1="4.0" SD_2="7.6" SE="1.943421953382458" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" WEIGHT="2.372242841203681"/>
<CONT_DATA CI_END="5.947376614646841" CI_START="-9.34737661464684" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="20.6" MEAN_2="22.3" ORDER="812" SD_1="9.2" SD_2="7.8" SE="3.9017944589637215" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.6356255315604031"/>
<CONT_DATA CI_END="1.4957169987722234" CI_START="-6.495716998772224" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="18.7" ORDER="813" SD_1="6.3" SD_2="6.1" SE="2.0386685828361792" STUDY_ID="STD-Jenike-1997" TOTAL_1="19" TOTAL_2="18" WEIGHT="2.175322203998851"/>
<CONT_DATA CI_END="0.2570176836917364" CI_START="-3.517017683691736" EFFECT_SIZE="-1.63" ESTIMABLE="YES" MEAN_1="-5.33" MEAN_2="-3.7" ORDER="814" SD_1="6.75" SD_2="5.98" SE="0.9627818156743139" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="158" TOTAL_2="56" WEIGHT="7.4181127847984225"/>
<CONT_DATA CI_END="-2.167060536766019" CI_START="-8.23293946323398" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-1.9" ORDER="815" SD_1="7.03" SD_2="7.2" SE="1.5474465281798133" STUDY_ID="STD-Nakajima-1996" TOTAL_1="60" TOTAL_2="33" WEIGHT="3.54023812584063"/>
<CONT_DATA CI_END="1.5390533057735802" CI_START="-5.4790533057735775" EFFECT_SIZE="-1.9699999999999989" ESTIMABLE="YES" MEAN_1="17.73" MEAN_2="19.7" ORDER="816" SD_1="8.99" SD_2="8.5" SE="1.7903662176716224" STUDY_ID="STD-Ushijima-1997" TOTAL_1="56" TOTAL_2="41" WEIGHT="2.7469149767786254"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.312241749623174" CI_END="-2.7105268227151535" CI_START="-4.0488087403850015" DF="7.0" EFFECT_SIZE="-3.3796677815500775" ESTIMABLE="YES" I2="15.786857374337837" ID="CMP-001.07.02" NO="2" P_CHI2="0.3058677628671508" P_Z="4.1919857387138295E-23" STUDIES="8" TAU2="0.14682058394103767" TOTAL_1="1559" TOTAL_2="755" WEIGHT="65.03504797132666" Z="9.899300056421556">
<NAME>Duration of trials 12 to 13 wks</NAME>
<CONT_DATA CI_END="-3.1302065819699276" CI_START="-6.1497934180300735" EFFECT_SIZE="-4.640000000000001" ESTIMABLE="YES" MEAN_1="-5.44" MEAN_2="-0.8" ORDER="817" SD_1="7.88" SD_2="5.66" SE="0.7703169190552127" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" WEIGHT="9.877018559270622"/>
<CONT_DATA CI_END="-0.6319658402476978" CI_START="-3.708034159752303" EFFECT_SIZE="-2.1700000000000004" ESTIMABLE="YES" MEAN_1="-5.57" MEAN_2="-3.4" ORDER="818" SD_1="6.19" SD_2="6.19" SE="0.7847257255154277" STUDY_ID="STD-Greist-1992b" TOTAL_1="240" TOTAL_2="84" WEIGHT="9.661886147608902"/>
<CONT_DATA CI_END="-1.5193447119810637" CI_START="-4.280655288018937" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-5.6" ORDER="819" SD_1="0.5" SD_2="7.7" SE="0.7044289073214454" STUDY_ID="STD-Hollander-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="10.932677779314115"/>
<CONT_DATA CI_END="-0.7967067990041288" CI_START="-4.443293200995873" EFFECT_SIZE="-2.620000000000001" ESTIMABLE="YES" MEAN_1="19.13" MEAN_2="21.75" ORDER="820" SD_1="8.87" SD_2="7.07" SE="0.9302687270673218" STUDY_ID="STD-Hollander-2003" TOTAL_1="259" TOTAL_2="89" WEIGHT="7.775285230711294"/>
<CONT_DATA CI_END="-2.616257910757117" CI_START="-6.683742089242882" EFFECT_SIZE="-4.6499999999999995" ESTIMABLE="YES" MEAN_1="-8.11" MEAN_2="-3.46" ORDER="824" SD_1="8.0" SD_2="6.1" SE="1.037642581845779" STUDY_ID="STD-Kamijima-2004" TOTAL_1="94" TOTAL_2="94" WEIGHT="6.6723566364432685"/>
<CONT_DATA CI_END="-2.063319892060622" CI_START="-5.196680107939379" EFFECT_SIZE="-3.630000000000001" ESTIMABLE="YES" MEAN_1="-9.23" MEAN_2="-5.6" ORDER="821" SD_1="7.09" SD_2="6.9" SE="0.7993412737668403" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" WEIGHT="9.449221954585374"/>
<CONT_DATA CI_END="-1.2510549303106009" CI_START="-7.4689450696894" EFFECT_SIZE="-4.36" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-4.14" ORDER="822" SD_1="10.15" SD_2="10.15" SE="1.5862256113950874" STUDY_ID="STD-Kronig-1999" TOTAL_1="85" TOTAL_2="79" WEIGHT="3.3933586606023836"/>
<CONT_DATA CI_END="-1.086010757390319" CI_START="-4.913989242609681" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-5.0" ORDER="823" SD_1="8.0" SD_2="7.9" SE="0.9765430679884854" STUDY_ID="STD-Zohar-1996" TOTAL_1="198" TOTAL_2="99" WEIGHT="7.273243002790693"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="21.613237759594295" CI_END="-2.5700787402424172" CI_START="-3.840438035561214" CI_STUDY="95" CI_TOTAL="95" DF="16.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2052583879018157" ESTIMABLE="YES" I2="25.971295101783312" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.15612444342099507" P_Q="0.9042608902323132" P_Z="4.5811982553699216E-23" Q="0.01446741788009831" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.43525272749927274" TOTALS="YES" TOTAL_1="2022" TOTAL_2="1075" UNITS="" WEIGHT="100.00000000000001" Z="9.890416080839488">
<NAME>YBOCS reduction (proportion of discontinuers)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.831228911036207" CI_END="-2.097284021561279" CI_START="-4.450527379459719" DF="6.0" EFFECT_SIZE="-3.273905700510499" ESTIMABLE="YES" I2="23.383672369167197" ID="CMP-001.08.01" NO="1" P_CHI2="0.2507307324998308" P_Z="4.9380640881932996E-8" STUDIES="7" TAU2="0.5660110415185693" TOTAL_1="670" TOTAL_2="302" WEIGHT="31.583243278880715" Z="5.453526291910085">
<NAME>Studies with 20% or less discontinuers</NAME>
<CONT_DATA CI_END="-0.11609582655765038" CI_START="-4.50390417344235" EFFECT_SIZE="-2.31" ESTIMABLE="YES" MEAN_1="-3.79" MEAN_2="-1.48" ORDER="825" SD_1="5.22" SD_2="5.22" SE="1.1193594324934466" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" WEIGHT="6.221117026174277"/>
<CONT_DATA CI_END="-4.36599387932588" CI_START="-12.834006120674122" EFFECT_SIZE="-8.600000000000001" ESTIMABLE="YES" MEAN_1="19.4" MEAN_2="28.0" ORDER="826" SD_1="7.0" SD_2="7.0" SE="2.160246899469287" STUDY_ID="STD-Goodman-1989" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.05855925797728"/>
<CONT_DATA CI_END="-0.7967067990041288" CI_START="-4.443293200995873" EFFECT_SIZE="-2.620000000000001" ESTIMABLE="YES" MEAN_1="19.13" MEAN_2="21.75" ORDER="827" SD_1="8.87" SD_2="7.07" SE="0.9302687270673218" STUDY_ID="STD-Hollander-2003" TOTAL_1="259" TOTAL_2="89" WEIGHT="8.074871909258482"/>
<CONT_DATA CI_END="0.8090370353940979" CI_START="-6.809037035394098" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="18.8" MEAN_2="21.8" ORDER="828" SD_1="4.0" SD_2="7.6" SE="1.943421953382458" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" WEIGHT="2.4934117507948197"/>
<CONT_DATA CI_END="5.947376614646841" CI_START="-9.34737661464684" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="20.6" MEAN_2="22.3" ORDER="829" SD_1="9.2" SD_2="7.8" SE="3.9017944589637215" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.6706963343065834"/>
<CONT_DATA CI_END="1.4957169987722234" CI_START="-6.495716998772224" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="18.7" ORDER="830" SD_1="6.3" SD_2="6.1" SE="2.0386685828361792" STUDY_ID="STD-Jenike-1997" TOTAL_1="19" TOTAL_2="18" WEIGHT="2.287440072940827"/>
<CONT_DATA CI_END="-2.063319892060622" CI_START="-5.196680107939379" EFFECT_SIZE="-3.630000000000001" ESTIMABLE="YES" MEAN_1="-9.23" MEAN_2="-5.6" ORDER="831" SD_1="7.09" SD_2="6.9" SE="0.7993412737668403" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" WEIGHT="9.777146927428449"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="13.767541430677989" CI_END="-2.3818470752216263" CI_START="-3.9848514921517135" DF="9.0" EFFECT_SIZE="-3.18334928368667" ESTIMABLE="YES" I2="34.62885116186797" ID="CMP-001.08.02" NO="2" P_CHI2="0.13083797910574557" P_Z="7.0019835458873884E-15" STUDIES="10" TAU2="0.5572619743215206" TOTAL_1="1352" TOTAL_2="773" WEIGHT="68.4167567211193" Z="7.784445108624262">
<NAME>Studies with more than 20% discontinuers</NAME>
<CONT_DATA CI_END="-3.1302065819699276" CI_START="-6.1497934180300735" EFFECT_SIZE="-4.640000000000001" ESTIMABLE="YES" MEAN_1="-5.44" MEAN_2="-0.8" ORDER="832" SD_1="7.88" SD_2="5.66" SE="0.7703169190552127" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" WEIGHT="10.210174972634238"/>
<CONT_DATA CI_END="-0.4802687336468672" CI_START="-3.999731266353133" EFFECT_SIZE="-2.24" ESTIMABLE="YES" MEAN_1="-3.95" MEAN_2="-1.71" ORDER="833" SD_1="6.25" SD_2="4.88" SE="0.8978385726644309" STUDY_ID="STD-Goodman-1996" TOTAL_1="78" TOTAL_2="78" WEIGHT="8.460515576832305"/>
<CONT_DATA CI_END="-0.6319658402476978" CI_START="-3.708034159752303" EFFECT_SIZE="-2.1700000000000004" ESTIMABLE="YES" MEAN_1="-5.57" MEAN_2="-3.4" ORDER="834" SD_1="6.19" SD_2="6.19" SE="0.7847257255154277" STUDY_ID="STD-Greist-1992b" TOTAL_1="240" TOTAL_2="84" WEIGHT="9.992513642016036"/>
<CONT_DATA CI_END="-0.9520693587496512" CI_START="-4.84793064125035" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-5.6" ORDER="835" SD_1="7.6" SD_2="7.7" SE="0.9938604263217985" STUDY_ID="STD-Hollander-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="7.3805482714440815"/>
<CONT_DATA CI_END="-2.616257910757117" CI_START="-6.683742089242882" EFFECT_SIZE="-4.6499999999999995" ESTIMABLE="YES" MEAN_1="-8.11" MEAN_2="-3.46" ORDER="839" SD_1="8.0" SD_2="6.1" SE="1.037642581845779" STUDY_ID="STD-Kamijima-2004" TOTAL_1="94" TOTAL_2="94" WEIGHT="6.9463736741072974"/>
<CONT_DATA CI_END="-1.2510549303106009" CI_START="-7.4689450696894" EFFECT_SIZE="-4.36" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-4.14" ORDER="836" SD_1="10.15" SD_2="10.15" SE="1.5862256113950874" STUDY_ID="STD-Kronig-1999" TOTAL_1="85" TOTAL_2="79" WEIGHT="3.558558658215006"/>
<CONT_DATA CI_END="0.2570176836917364" CI_START="-3.517017683691736" EFFECT_SIZE="-1.63" ESTIMABLE="YES" MEAN_1="-5.33" MEAN_2="-3.7" ORDER="837" SD_1="6.75" SD_2="5.98" SE="0.9627818156743139" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="158" TOTAL_2="56" WEIGHT="7.710021608903373"/>
<CONT_DATA CI_END="-2.167060536766019" CI_START="-8.23293946323398" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-1.9" ORDER="840" SD_1="7.03" SD_2="7.2" SE="1.5474465281798133" STUDY_ID="STD-Nakajima-1996" TOTAL_1="60" TOTAL_2="33" WEIGHT="3.7113725397557324"/>
<CONT_DATA CI_END="1.5390533057735802" CI_START="-5.4790533057735775" EFFECT_SIZE="-1.9699999999999989" ESTIMABLE="YES" MEAN_1="17.73" MEAN_2="19.7" ORDER="841" SD_1="8.99" SD_2="8.5" SE="1.7903662176716224" STUDY_ID="STD-Ushijima-1997" TOTAL_1="56" TOTAL_2="41" WEIGHT="2.8848044286873376"/>
<CONT_DATA CI_END="-1.086010757390319" CI_START="-4.913989242609681" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-5.0" ORDER="838" SD_1="8.0" SD_2="7.9" SE="0.9765430679884854" STUDY_ID="STD-Zohar-1996" TOTAL_1="198" TOTAL_2="99" WEIGHT="7.561873348523885"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="29.12961489185349" CI_END="2.317153198498659" CI_START="1.487765218348886" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8567121301677805" ESTIMABLE="YES" EVENTS_1="710" EVENTS_2="192" I2="62.23774313241503" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.36495474810293754" LOG_CI_START="0.17253440135736095" LOG_EFFECT_SIZE="0.26874457473014923" METHOD="MH" NO="9" P_CHI2="0.002167166101576523" P_Q="0.0" P_Z="4.38051514066661E-8" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07891751627213163" TOTALS="YES" TOTAL_1="1263" TOTAL_2="649" WEIGHT="100.0" Z="5.474781606210096">
<NAME>Responders per completers (proportion of discontinuers)</NAME>
<GROUP_LABEL_1>Treatement</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.6739677504970567" CI_END="3.9987904951492887" CI_START="0.9624851649593167" DF="2.0" EFFECT_SIZE="1.9618298930747058" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="42" I2="45.56294078168168" ID="CMP-001.09.01" LOG_CI_END="0.6019286511492639" LOG_CI_START="-0.016605955664614373" LOG_EFFECT_SIZE="0.2926613477423248" NO="1" P_CHI2="0.159297242138703" P_Z="0.06363555215267644" STUDIES="3" TAU2="0.19147652998435935" TOTAL_1="315" TOTAL_2="142" WEIGHT="17.958921803857336" Z="1.8547246828972064">
<NAME>Studies with 20% or less discontinuers</NAME>
<DICH_DATA CI_END="5.303883281953166" CI_START="0.7807911260209681" EFFECT_SIZE="2.035" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7245939583527083" LOG_CI_START="-0.10746513123023063" LOG_EFFECT_SIZE="0.30856441356123887" ORDER="842" O_E="0.0" SE="0.4887556279799383" STUDY_ID="STD-Chouinard-1990" TOTAL_1="40" TOTAL_2="37" VAR="0.23888206388206384" WEIGHT="4.019979799487901"/>
<DICH_DATA CI_END="306.79369636339845" CI_START="1.1766864974057147" EFFECT_SIZE="19.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.4868464319955983" LOG_CI_START="0.07066076991005915" LOG_EFFECT_SIZE="1.2787536009528289" ORDER="843" O_E="0.0" SE="1.4192794182209667" STUDY_ID="STD-Goodman-1989" TOTAL_1="21" TOTAL_2="21" VAR="2.014354066985646" WEIGHT="0.6103115824642985"/>
<DICH_DATA CI_END="2.0070364643432597" CI_START="1.2051217492483979" EFFECT_SIZE="1.555224515854437" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="37" LOG_CI_END="0.3025552629305371" LOG_CI_START="0.08103092438455965" LOG_EFFECT_SIZE="0.19179309365754832" ORDER="844" O_E="0.0" SE="0.13012449302506807" STUDY_ID="STD-Kasper-1999" TOTAL_1="254" TOTAL_2="84" VAR="0.016932383685030986" WEIGHT="13.328630421905139"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.52510919702408" CI_END="2.477341119420349" CI_START="1.4536694788870128" DF="8.0" EFFECT_SIZE="1.8976920651394282" ESTIMABLE="YES" EVENTS_1="516" EVENTS_2="150" I2="68.65831233766983" ID="CMP-001.09.02" LOG_CI_END="0.39398581122124293" LOG_CI_START="0.1624656721261535" LOG_EFFECT_SIZE="0.27822574167369823" NO="2" P_CHI2="0.0012658799791330777" P_Z="2.4685198235632775E-6" STUDIES="9" TAU2="0.10319808441656789" TOTAL_1="948" TOTAL_2="507" WEIGHT="82.04107819614266" Z="4.710712730078517">
<NAME>Studies with more than 20% discontinuers</NAME>
<DICH_DATA CI_END="8.140035188628937" CI_START="1.8966771727063352" EFFECT_SIZE="3.9292517006802723" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="7" LOG_CI_END="0.9106262823086535" LOG_CI_START="0.27799341731815974" LOG_EFFECT_SIZE="0.5943098498134066" ORDER="845" O_E="0.0" SE="0.3716116764786032" STUDY_ID="STD-Dominguez-1991" TOTAL_1="210" TOTAL_2="76" VAR="0.13809523809523805" WEIGHT="5.886971465017707"/>
<DICH_DATA CI_END="8.723607631797108" CI_START="1.9319055036518216" EFFECT_SIZE="4.105263157894737" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="7" LOG_CI_END="0.9406961237593092" LOG_CI_START="0.2859858797159937" LOG_EFFECT_SIZE="0.6133410017376515" ORDER="846" O_E="0.0" SE="0.38458003821901965" STUDY_ID="STD-Goodman-1996" TOTAL_1="57" TOTAL_2="63" VAR="0.14790180579654263" WEIGHT="5.6324473631871514"/>
<DICH_DATA CI_END="1.7645711371657191" CI_START="0.9114311631268058" EFFECT_SIZE="1.268181818181818" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="25" LOG_CI_END="0.24663917125692852" LOG_CI_START="-0.04027612635414597" LOG_EFFECT_SIZE="0.10318152245139128" ORDER="847" O_E="0.0" SE="0.16853546607037392" STUDY_ID="STD-Greist-1992b" TOTAL_1="176" TOTAL_2="60" VAR="0.02840420332355816" WEIGHT="11.903908149426542"/>
<DICH_DATA CI_END="2.9392020429360093" CI_START="1.4437217096796346" EFFECT_SIZE="2.059948979591837" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="28" LOG_CI_END="0.46822944082466433" LOG_CI_START="0.1594834871407023" LOG_EFFECT_SIZE="0.3138564639826833" ORDER="848" O_E="0.0" SE="0.1813589015110784" STUDY_ID="STD-Hollander-2002" TOTAL_1="84" TOTAL_2="95" VAR="0.03289105115730503" WEIGHT="11.426207506968314"/>
<DICH_DATA CI_END="2.765367032270293" CI_START="1.152271131646773" EFFECT_SIZE="1.785063752276867" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="18" LOG_CI_END="0.44175278103349935" LOG_CI_START="0.06155468145130667" LOG_EFFECT_SIZE="0.251653731242403" ORDER="849" O_E="0.0" SE="0.22333024570552562" STUDY_ID="STD-Kronig-1999" TOTAL_1="61" TOTAL_2="56" VAR="0.04987639864689044" WEIGHT="9.91931872952886"/>
<DICH_DATA CI_END="2.7086147497777286" CI_START="1.1497341404740653" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="15" LOG_CI_END="0.43274723908867274" LOG_CI_START="0.06059742759410427" LOG_EFFECT_SIZE="0.2466723333413885" ORDER="850" O_E="0.0" SE="0.21860264144318656" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="119" TOTAL_2="42" VAR="0.04778711484593838" WEIGHT="10.082882379532883"/>
<DICH_DATA CI_END="6.100753787865935" CI_START="1.3236183142655777" EFFECT_SIZE="2.841666666666667" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" LOG_CI_END="0.785383498237943" LOG_CI_START="0.12176276765180298" LOG_EFFECT_SIZE="0.4535731329448729" ORDER="852" O_E="0.0" SE="0.38981410212189443" STUDY_ID="STD-Nakajima-1996" TOTAL_1="60" TOTAL_2="33" VAR="0.15195503421309872" WEIGHT="5.533563387334479"/>
<DICH_DATA CI_END="2.94664725039299" CI_START="0.9644865810906841" EFFECT_SIZE="1.685823754789272" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.4693281486163863" LOG_CI_START="-0.015703810320573303" LOG_EFFECT_SIZE="0.22681216914790647" ORDER="853" O_E="0.0" SE="0.28491017362648874" STUDY_ID="STD-Ushijima-1997" TOTAL_1="29" TOTAL_2="22" VAR="0.08117380703587597" WEIGHT="7.980119509960352"/>
<DICH_DATA CI_END="1.5565561864876578" CI_START="0.970884192537655" EFFECT_SIZE="1.2293233082706767" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="35" LOG_CI_END="0.19216480188402457" LOG_CI_START="-0.012832569825586403" LOG_EFFECT_SIZE="0.08966611602921909" ORDER="851" O_E="0.0" SE="0.12041647089558119" STUDY_ID="STD-Zohar-1996" TOTAL_1="152" TOTAL_2="60" VAR="0.014500126462946353" WEIGHT="13.675659705186368"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>SSRIs versus placebo - efficacy using NIMH-OC scale or other measures (individual SSRI drugs)</NAME>
<CONT_OUTCOME CHI2="4.687541469252409" CI_END="-0.63966845629076" CI_START="-1.1341546550442096" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8869115556674848" ESTIMABLE="YES" I2="0.0" I2_Q="9.31878256372667" ID="CMP-002.01" NO="1" P_CHI2="0.6980322560238416" P_Q="0.3532245932395043" P_Z="2.0536504399463532E-12" Q="4.411056791127688" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="906" TOTAL_2="453" UNITS="" WEIGHT="100.00000000000001" Z="7.030791601313766">
<NAME>SSRI versus placebo -efficacy using NIMH-OCS only</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5916960755569669" CI_START="-1.6683039244430333" DF="0.0" EFFECT_SIZE="-1.1300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="3.883077372812422E-5" STUDIES="1" TAU2="0.0" TOTAL_1="300" TOTAL_2="101" WEIGHT="21.09566723877204" Z="4.114328731342254">
<NAME>Cipramil</NAME>
<CONT_DATA CI_END="-0.5916960755569669" CI_START="-1.6683039244430333" EFFECT_SIZE="-1.1300000000000001" ESTIMABLE="YES" MEAN_1="-2.93" MEAN_2="-1.8" ORDER="854" SD_1="2.63" SD_2="2.3" SE="0.2746499061661877" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" WEIGHT="21.09566723877204"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5780170773528369" CI_START="-0.9780170773528373" DF="0.0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="1.0" P_Z="0.6143768238914848" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="10.098807612350626" Z="0.5038357233002474">
<NAME>Fluoxetine</NAME>
<CONT_DATA CI_END="0.5780170773528369" CI_START="-0.9780170773528373" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="7.2" ORDER="855" SD_1="1.1" SD_2="1.3" SE="0.39695478258260686" STUDY_ID="STD-Jenike-1997" TOTAL_1="19" TOTAL_2="18" WEIGHT="10.098807612350626"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.18338136378493966" CI_END="-0.4365609574648661" CI_START="-1.541661905829773" DF="1.0" EFFECT_SIZE="-0.9891114316473195" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" NO="3" P_CHI2="0.6684833168254263" P_Z="4.50642938937131E-4" STUDIES="2" TAU2="0.0" TOTAL_1="96" TOTAL_2="98" WEIGHT="20.021861204197933" Z="3.508498993859266">
<NAME>Fluvoxamine</NAME>
<CONT_DATA CI_END="-0.2833152431696322" CI_START="-1.5566847568303679" EFFECT_SIZE="-0.92" ESTIMABLE="YES" MEAN_1="-1.32" MEAN_2="-0.4" ORDER="856" SD_1="2.25" SD_2="1.78" SE="0.3248451307536546" STUDY_ID="STD-Goodman-1996" TOTAL_1="78" TOTAL_2="78" WEIGHT="15.079934446819204"/>
<CONT_DATA CI_END="-0.08781757779422339" CI_START="-2.312182422205777" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="8.0" ORDER="857" SD_1="1.2" SD_2="2.2" SE="0.5674504383644443" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" WEIGHT="4.941926757378729"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.4003608215437955" CI_START="-1.7996391784562047" DF="0.0" EFFECT_SIZE="-1.1" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.04" NO="4" P_CHI2="1.0" P_Z="0.0020593847215929512" STUDIES="1" TAU2="0.0" TOTAL_1="198" TOTAL_2="99" WEIGHT="12.488207782141828" Z="3.0815318086550194">
<NAME>Paroxetine</NAME>
<CONT_DATA CI_END="-0.4003608215437955" CI_START="-1.7996391784562047" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.4" ORDER="858" SD_1="2.9" SD_2="2.9" SE="0.35696532384006496" STUDY_ID="STD-Zohar-1996" TOTAL_1="198" TOTAL_2="99" WEIGHT="12.488207782141828"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.09310331433978124" CI_END="-0.39666324862352365" CI_START="-1.2174456675452183" DF="2.0" EFFECT_SIZE="-0.8070544580843709" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.05" NO="5" P_CHI2="0.9545152534923744" P_Z="1.1603020372387619E-4" STUDIES="3" TAU2="0.0" TOTAL_1="293" TOTAL_2="137" WEIGHT="36.29545616253758" Z="3.854365383425121">
<NAME>Sertraline</NAME>
<CONT_DATA CI_END="-0.060872674827681994" CI_START="-1.599127325172318" EFFECT_SIZE="-0.83" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-0.57" ORDER="859" SD_1="1.83" SD_2="1.83" SE="0.39241911139138075" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" WEIGHT="10.333605465363988"/>
<CONT_DATA CI_END="-0.28057372195442204" CI_START="-1.279426278045578" EFFECT_SIZE="-0.78" ESTIMABLE="YES" MEAN_1="-1.79" MEAN_2="-1.01" ORDER="860" SD_1="2.01" SD_2="2.01" SE="0.2548140078006477" STUDY_ID="STD-Greist-1992b" TOTAL_1="240" TOTAL_2="84" WEIGHT="24.507870621753945"/>
<CONT_DATA CI_END="0.9504300195009794" CI_START="-3.1504300195009822" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="9.3" ORDER="861" SD_1="2.0" SD_2="2.5" SE="1.046156988431681" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.4539800754196508"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.032505942200645" CI_END="-0.3289872783847953" CI_START="-0.5150971386487628" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4220422085167791" ESTIMABLE="YES" I2="0.32400620929525054" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.43764615458597944" P_Q="0.9925218697501841" P_Z="6.152876710457253E-19" Q="0.255159653099982" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="8.330577875800654E-5" TOTALS="YES" TOTAL_1="1447" TOTAL_2="718" UNITS="" WEIGHT="100.0" Z="8.88923915665076">
<NAME>SSRI v. placebo on NIMH-OCS or other scales (CGI -S for Montgomery 93 &amp; Dominguez 91, &amp; CGI-I Hollander 03)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.285898529471456E-31" CI_END="-0.21451552422337009" CI_START="-0.6696396384445896" DF="0.0" EFFECT_SIZE="-0.44207758133397984" ESTIMABLE="YES" I2="100.0" ID="CMP-002.02.01" NO="1" P_CHI2="0.0" P_Z="1.4034481538507802E-4" STUDIES="1" TAU2="0.0" TOTAL_1="300" TOTAL_2="101" WEIGHT="16.61894672951418" Z="3.8075597873771363">
<NAME>Cipramil</NAME>
<CONT_DATA CI_END="-0.21451552422337014" CI_START="-0.6696396384445896" EFFECT_SIZE="-0.4420775813339799" ESTIMABLE="YES" MEAN_1="-2.93" MEAN_2="-1.8" ORDER="862" SD_1="2.63" SD_2="2.3" SE="0.11610522382328972" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" WEIGHT="16.61894672951418"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.981815032236172" CI_END="0.07735172920765193" CI_START="-0.8020927343486546" DF="2.0" EFFECT_SIZE="-0.36237050257050135" ESTIMABLE="YES" I2="77.7327857140021" ID="CMP-002.02.02" NO="2" P_CHI2="0.011210479262620643" P_Z="0.10627045024147848" STUDIES="3" TAU2="0.11081942822698718" TOTAL_1="443" TOTAL_2="163" WEIGHT="25.639371419993985" Z="1.615185866827369">
<NAME>Fluoxetine</NAME>
<CONT_DATA CI_END="-0.45238131933145237" CI_START="-0.9433750345974645" EFFECT_SIZE="-0.6978781769644584" ESTIMABLE="YES" MEAN_1="-0.88" MEAN_2="-0.04" ORDER="863" SD_1="1.25" SD_2="1.04" SE="0.12525580039707562" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" WEIGHT="14.291801539855033"/>
<CONT_DATA CI_END="0.48297032322816047" CI_START="-0.8087540877318339" EFFECT_SIZE="-0.1628918822518367" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="7.2" ORDER="864" SD_1="1.1" SD_2="1.3" SE="0.32952758855493053" STUDY_ID="STD-Jenike-1997" TOTAL_1="19" TOTAL_2="18" WEIGHT="2.0742733245109686"/>
<CONT_DATA CI_END="0.17805049087188474" CI_START="-0.4320576858810822" EFFECT_SIZE="-0.12700359750459872" ESTIMABLE="YES" MEAN_1="-0.82" MEAN_2="-0.68" ORDER="865" SD_1="1.14" SD_2="0.97" SE="0.1556427009795645" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="158" TOTAL_2="56" WEIGHT="9.273296555627985"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7164811435731652" CI_END="-0.22819566396440882" CI_START="-0.6103452692184524" DF="2.0" EFFECT_SIZE="-0.41927046659143064" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.03" NO="3" P_CHI2="0.6989050278771214" P_Z="1.7026099359771336E-5" STUDIES="3" TAU2="0.0" TOTAL_1="213" TOTAL_2="218" WEIGHT="23.62567719478006" Z="4.300697962276976">
<NAME>Fluvoxamine</NAME>
<CONT_DATA CI_END="-0.1333723320579468" CI_START="-0.7692071663682982" EFFECT_SIZE="-0.4512897492131225" ESTIMABLE="YES" MEAN_1="-1.32" MEAN_2="-0.4" ORDER="866" SD_1="2.25" SD_2="1.78" SE="0.16220574442329946" STUDY_ID="STD-Goodman-1996" TOTAL_1="78" TOTAL_2="78" WEIGHT="8.540380638163578"/>
<CONT_DATA CI_END="-0.10571019706956802" CI_START="-0.6192389751639493" EFFECT_SIZE="-0.36247458611675865" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.6" ORDER="867" SD_1="1.1" SD_2="1.1" SE="0.13100464655091387" STUDY_ID="STD-Hollander-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="13.070921852655957"/>
<CONT_DATA CI_END="0.002160727864056966" CI_START="-1.3086426114258487" EFFECT_SIZE="-0.6532409417808959" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="8.0" ORDER="868" SD_1="1.2" SD_2="2.2" SE="0.3343947515437414" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" WEIGHT="2.0143747039605255"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.13515368762102284" CI_START="-0.6215366694904978" DF="0.0" EFFECT_SIZE="-0.37834517855576033" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.04" NO="4" P_CHI2="1.0" P_Z="0.002294409011245611" STUDIES="1" TAU2="0.0" TOTAL_1="198" TOTAL_2="99" WEIGHT="14.562582802989482" Z="3.0492141022017325">
<NAME>Paroxetine</NAME>
<CONT_DATA CI_END="-0.13515368762102284" CI_START="-0.6215366694904978" EFFECT_SIZE="-0.37834517855576033" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.4" ORDER="869" SD_1="2.9" SD_2="2.9" SE="0.12407957128447304" STUDY_ID="STD-Zohar-1996" TOTAL_1="198" TOTAL_2="99" WEIGHT="14.562582802989482"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.07905011329132546" CI_END="-0.1965220171825971" CI_START="-0.6165532442706103" DF="2.0" EFFECT_SIZE="-0.4065376307266037" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.05" NO="5" P_CHI2="0.9612458688695598" P_Z="1.4824002361353347E-4" STUDIES="3" TAU2="0.0" TOTAL_1="293" TOTAL_2="137" WEIGHT="19.553421852722295" Z="3.7939994133694555">
<NAME>Sertraline</NAME>
<CONT_DATA CI_END="-0.0237268835293854" CI_START="-0.8753494741281413" EFFECT_SIZE="-0.4495381788287634" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-0.57" ORDER="870" SD_1="1.83" SD_2="1.83" SE="0.2172546529722603" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" WEIGHT="4.767366925577468"/>
<CONT_DATA CI_END="-0.13688080667107683" CI_START="-0.6374294601765036" EFFECT_SIZE="-0.3871551334237902" ESTIMABLE="YES" MEAN_1="-1.79" MEAN_2="-1.01" ORDER="871" SD_1="2.01" SD_2="2.01" SE="0.1276933294319923" STUDY_ID="STD-Greist-1992b" TOTAL_1="240" TOTAL_2="84" WEIGHT="13.754125892638976"/>
<CONT_DATA CI_END="0.44869737518793384" CI_START="-1.3830333851282912" EFFECT_SIZE="-0.46716800497017874" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="9.3" ORDER="872" SD_1="2.0" SD_2="2.5" SE="0.46728684168808293" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.0319290345058516"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>SSRIs versus Placebo - adverse effects</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4547437106643941" CI_START="1.0154742926425038" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2154237288135594" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.1627864882715987" LOG_CI_START="0.0066689334475487135" LOG_EFFECT_SIZE="0.0847277108595737" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.03338577875082479" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="300" TOTAL_2="101" WEIGHT="100.0" Z="2.1274130505624047">
<NAME>Citalopram - overall adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4547437106643941" CI_START="1.0154742926425038" EFFECT_SIZE="1.2154237288135594" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="59" LOG_CI_END="0.1627864882715987" LOG_CI_START="0.0066689334475487135" LOG_EFFECT_SIZE="0.0847277108595737" ORDER="873" O_E="0.0" SE="0.09170422449800675" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" VAR="0.008409664790780822" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.126849044115615" CI_END="3.1252657021344463" CI_START="0.9583850914828399" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.730666939606897" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="32" I2="60.98968425264018" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.49488694586104526" LOG_CI_START="-0.018459950732200643" LOG_EFFECT_SIZE="0.23821349756442228" METHOD="MH" NO="2" P_CHI2="0.07704055637191798" P_Q="0.0" P_Z="0.06891091093868801" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1658099790924347" TOTALS="YES" TOTAL_1="900" TOTAL_2="303" WEIGHT="100.0" Z="1.81900340279073">
<NAME>Citalopram - nausea, headache and insomnia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.771696341645001" CI_START="1.2774099417184777" DF="0.0" EFFECT_SIZE="2.468888888888889" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="9" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.6786727985054227" LOG_CI_START="0.10633029182562517" LOG_EFFECT_SIZE="0.39250154516552394" NO="1" P_CHI2="1.0" P_Z="0.007183585199760061" STUDIES="1" TAU2="0.0" TOTAL_1="300" TOTAL_2="101" WEIGHT="32.60954113066963" Z="2.6882116334970534">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="4.771696341645001" CI_START="1.2774099417184777" EFFECT_SIZE="2.468888888888889" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="9" LOG_CI_END="0.6786727985054227" LOG_CI_START="0.10633029182562517" LOG_EFFECT_SIZE="0.39250154516552394" ORDER="874" O_E="0.0" SE="0.33619682156481345" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" VAR="0.11302830283028302" WEIGHT="32.60954113066963"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7622703698113913" CI_START="0.6280984798015088" DF="0.0" EFFECT_SIZE="1.0520833333333333" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="16" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.24607253921185557" LOG_CI_START="-0.20197225772570734" LOG_EFFECT_SIZE="0.02205014074307413" NO="2" P_CHI2="1.0" P_Z="0.8470248358239493" STUDIES="1" TAU2="0.0" TOTAL_1="300" TOTAL_2="101" WEIGHT="38.68026400960833" Z="0.19291589593657138">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.7622703698113913" CI_START="0.6280984798015088" EFFECT_SIZE="1.0520833333333333" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="16" LOG_CI_END="0.24607253921185557" LOG_CI_START="-0.20197225772570734" LOG_EFFECT_SIZE="0.02205014074307413" ORDER="875" O_E="0.0" SE="0.2631837315786384" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" VAR="0.06926567656765678" WEIGHT="38.68026400960833"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.840115931597085" CI_START="1.0557087226676605" DF="0.0" EFFECT_SIZE="2.2604761904761905" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="7" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.6848557640927406" LOG_CI_START="0.02354410987614101" LOG_EFFECT_SIZE="0.3541999369844408" NO="3" P_CHI2="1.0" P_Z="0.035770927497855654" STUDIES="1" TAU2="0.0" TOTAL_1="300" TOTAL_2="101" WEIGHT="28.710194859722044" Z="2.099521807575715">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="4.840115931597085" CI_START="1.0557087226676605" EFFECT_SIZE="2.2604761904761905" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="7" LOG_CI_END="0.6848557640927406" LOG_CI_START="0.02354410987614101" LOG_EFFECT_SIZE="0.3541999369844408" ORDER="876" O_E="0.0" SE="0.388457739232314" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" VAR="0.15089941516948047" WEIGHT="28.710194859722044"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="302.79600231932505" CI_START="1.1472091289679782" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="18.637873754152828" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="2.481150137069388" LOG_CI_START="0.05964259425524852" LOG_EFFECT_SIZE="1.270396365662318" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.039733074478320134" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="300" TOTAL_2="101" WEIGHT="100.0" Z="2.056513208210009">
<NAME>Citalopram - sexual side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="302.79600231932505" CI_START="1.1472091289679782" EFFECT_SIZE="18.637873754152825" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="0" LOG_CI_END="2.481150137069388" LOG_CI_START="0.05964259425524852" LOG_EFFECT_SIZE="1.270396365662318" ORDER="877" O_E="0.0" SE="1.4224055173046806" STUDY_ID="STD-Kasper-1999" TOTAL_1="300" TOTAL_2="101" VAR="2.023237455658796" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.339957461556256" CI_END="1.4922143081084827" CI_START="0.9306423829620184" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1784387466423945" ESTIMABLE="YES" EVENTS_1="325" EVENTS_2="91" I2="18.255657046711978" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.17383119990955684" LOG_CI_START="-0.0312171728779827" LOG_EFFECT_SIZE="0.07130701351578703" METHOD="MH" NO="4" P_CHI2="0.2905488486044717" P_Q="0.0" P_Z="0.17282499615988484" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.018486939285504097" TOTALS="YES" TOTAL_1="1430" TOTAL_2="491" WEIGHT="100.0" Z="1.363182515775092">
<NAME>Fluoxetine - nausea, headache, insomnia and anxiety</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.368172816374693" CI_END="3.249056649287634" CI_START="0.43818751470727224" DF="1.0" EFFECT_SIZE="1.1931873525538585" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="23" I2="81.37168764482263" ID="CMP-003.04.01" LOG_CI_END="0.5117572836006129" LOG_CI_START="-0.35834000096742824" LOG_EFFECT_SIZE="0.07670864131659237" NO="1" P_CHI2="0.020507518384397905" P_Z="0.7296548124389767" STUDIES="2" TAU2="0.42546237725723635" TOTAL_1="424" TOTAL_2="145" WEIGHT="25.450746131263475" Z="0.34558474540731715">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="3.4284467519211037" CI_START="1.1110994157919283" EFFECT_SIZE="1.9517543859649122" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="12" LOG_CI_END="0.5350974087156656" LOG_CI_START="0.045752919245290055" LOG_EFFECT_SIZE="0.2904251639804778" ORDER="878" O_E="0.0" SE="0.28744337540918774" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" VAR="0.08262369406662724" WEIGHT="14.347988754043177"/>
<DICH_DATA CI_END="1.366636283729703" CI_START="0.36767908355148465" EFFECT_SIZE="0.7088607594936709" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.13565294691089536" LOG_CI_START="-0.4345310754793773" LOG_EFFECT_SIZE="-0.149439064284241" ORDER="879" O_E="0.0" SE="0.33492891720847706" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="158" TOTAL_2="56" VAR="0.11217737958244287" WEIGHT="11.102757377220298"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8524401032737623" CI_END="1.5795380883412444" CI_START="0.78684703471001" DF="1.0" EFFECT_SIZE="1.1148340060398345" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="32" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.1985301027685419" LOG_CI_START="-0.104109687511621" LOG_EFFECT_SIZE="0.047210207628460406" NO="2" P_CHI2="0.35586304138318947" P_Z="0.5408765346638691" STUDIES="2" TAU2="0.0" TOTAL_1="424" TOTAL_2="145" WEIGHT="34.55939176858163" Z="0.611488043715484">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.8872951213823128" CI_START="0.8183282400165317" EFFECT_SIZE="1.242749731471536" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="21" LOG_CI_END="0.275839817264135" LOG_CI_START="-0.08707246132332117" LOG_EFFECT_SIZE="0.09438367797040689" ORDER="880" O_E="0.0" SE="0.2131764688870234" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" VAR="0.04544420688714006" WEIGHT="22.69213547858033"/>
<DICH_DATA CI_END="1.6356454869943446" CI_START="0.4627163637627158" EFFECT_SIZE="0.8699654775604143" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" LOG_CI_END="0.21368917969836082" LOG_CI_START="-0.3346851415932807" LOG_EFFECT_SIZE="-0.06049798094745991" ORDER="881" O_E="0.0" SE="0.3221177908233795" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="158" TOTAL_2="56" VAR="0.10375987116493446" WEIGHT="11.867256290001297"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8075906428501867" CI_END="1.6831424554683134" CI_START="0.8311420596990015" DF="1.0" EFFECT_SIZE="1.1827639186265233" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="31" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.22612087474326217" LOG_CI_START="-0.08032473978926423" LOG_EFFECT_SIZE="0.07289806747699899" NO="3" P_CHI2="0.36883359351021294" P_Z="0.3510872361482077" STUDIES="2" TAU2="0.0" TOTAL_1="424" TOTAL_2="145" WEIGHT="34.051547825388326" Z="0.9324825027464927">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="2.027394799608469" CI_START="0.8615343606071184" EFFECT_SIZE="1.3216165413533834" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="20" LOG_CI_END="0.30693832816808797" LOG_CI_START="-0.06472739688747602" LOG_EFFECT_SIZE="0.12110546564030598" ORDER="882" O_E="0.0" SE="0.21831828667264885" STUDY_ID="STD-Dominguez-1991" TOTAL_1="266" TOTAL_2="89" VAR="0.04766287429568089" WEIGHT="21.931040341785575"/>
<DICH_DATA CI_END="1.7431209500478402" CI_START="0.5008930237138344" EFFECT_SIZE="0.9344073647871116" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="11" LOG_CI_END="0.2413275225752491" LOG_CI_START="-0.3002550169902314" LOG_EFFECT_SIZE="-0.02946374720749116" ORDER="883" O_E="0.0" SE="0.31812826461757066" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="158" TOTAL_2="56" VAR="0.10120559274858706" WEIGHT="12.120507483602747"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.598162253525952" CI_START="0.5586002419513401" DF="0.0" EFFECT_SIZE="1.4177215189873418" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" I2="0.0" ID="CMP-003.04.04" LOG_CI_END="0.5560807432847392" LOG_CI_START="-0.2528988805252588" LOG_EFFECT_SIZE="0.15159093137974017" NO="4" P_CHI2="1.0" P_Z="0.46262147452384594" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="56" WEIGHT="5.938314274766571" Z="0.7345370813862557">
<NAME>Anxiety</NAME>
<DICH_DATA CI_END="3.598162253525951" CI_START="0.5586002419513401" EFFECT_SIZE="1.4177215189873418" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="0.556080743284739" LOG_CI_START="-0.2528988805252588" LOG_EFFECT_SIZE="0.15159093137974017" ORDER="884" O_E="0.0" SE="0.4751986355397146" STUDY_ID="STD-Montgomery-1993c" TOTAL_1="158" TOTAL_2="56" VAR="0.2258137432188065" WEIGHT="5.938314274766571"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0766861640516454" CI_END="1.2136408323988301" CI_START="1.0697120182534172" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1394060664487047" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="186" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.08409017966659205" LOG_CI_START="0.02926687514587911" LOG_EFFECT_SIZE="0.056678527406235614" METHOD="MH" NO="5" P_CHI2="0.583714727386305" P_Q="0.0" P_Z="5.065622019178914E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="222" TOTAL_2="224" WEIGHT="100.0" Z="4.052578493185059">
<NAME>Fluvoxamine - overall adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2647468664068056" CI_START="1.0173583808850146" EFFECT_SIZE="1.1343283582089552" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="67" LOG_CI_END="0.10200361205457706" LOG_CI_START="0.007473967105352685" LOG_EFFECT_SIZE="0.0547387895799649" ORDER="885" O_E="0.0" SE="0.05552718137246355" STUDY_ID="STD-Goodman-1996" TOTAL_1="80" TOTAL_2="80" VAR="0.003083267871170463" WEIGHT="33.63522719272586"/>
<DICH_DATA CI_END="1.2255418884231357" CI_START="1.0457373066778575" EFFECT_SIZE="1.1320754716981132" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="106" LOG_CI_END="0.08832815981504459" LOG_CI_START="0.019422601750664487" LOG_EFFECT_SIZE="0.05387538078285457" ORDER="886" O_E="0.0" SE="0.040475465895030295" STUDY_ID="STD-Hollander-2002" TOTAL_1="124" TOTAL_2="124" VAR="0.0016382633394197606" WEIGHT="63.30265278327074"/>
<DICH_DATA CI_END="1.9614708216924224" CI_START="0.9534246800642765" EFFECT_SIZE="1.3675213675213675" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.2925818520667659" LOG_CI_START="-0.0207136102472396" LOG_EFFECT_SIZE="0.13593412090976315" ORDER="887" O_E="0.0" SE="0.18403130540079687" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" VAR="0.03386752136752137" WEIGHT="3.0621200240034154"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.325423882178335" CI_END="2.654356251031784" CI_START="1.6194705375754863" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.073319016643434" ESTIMABLE="YES" EVENTS_1="280" EVENTS_2="135" I2="34.51720365568119" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.4239592107191409" LOG_CI_START="0.20937305146025575" LOG_EFFECT_SIZE="0.3166661310896983" METHOD="MH" NO="6" P_CHI2="0.10616091910192271" P_Q="0.0" P_Z="7.265822675314738E-9" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06564494116032195" TOTALS="YES" TOTAL_1="968" TOTAL_2="976" WEIGHT="100.0" Z="5.784662106847877">
<NAME>Fluvoxamine - insomnia, nausea, fatigue, headache, somnolence and asthenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1718334885332986" CI_END="2.5975060699466437" CI_START="1.262907816270433" DF="2.0" EFFECT_SIZE="1.8111904147674562" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="41" I2="7.911908967263539" ID="CMP-003.06.01" LOG_CI_END="0.41455657110553945" LOG_CI_START="0.10137165115218381" LOG_EFFECT_SIZE="0.2579641111288616" NO="1" P_CHI2="0.3375923934500864" P_Z="0.0012432569830404337" STUDIES="3" TAU2="0.010017205354779466" TOTAL_1="222" TOTAL_2="224" WEIGHT="26.42884113985088" Z="3.2287657221283763">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="3.018777320903423" CI_START="0.9952520921766138" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" LOG_CI_END="0.4798310786177918" LOG_CI_START="-0.002066900787518284" LOG_EFFECT_SIZE="0.23888208891513676" ORDER="888" O_E="0.0" SE="0.28306925853614895" STUDY_ID="STD-Goodman-1996" TOTAL_1="80" TOTAL_2="80" VAR="0.08012820512820513" WEIGHT="10.899362323553278"/>
<DICH_DATA CI_END="2.632165957234215" CI_START="1.123941289442319" EFFECT_SIZE="1.72" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="25" LOG_CI_END="0.42031326793541046" LOG_CI_START="0.05074362587968734" LOG_EFFECT_SIZE="0.23552844690754887" ORDER="889" O_E="0.0" SE="0.21708703714276412" STUDY_ID="STD-Hollander-2002" TOTAL_1="124" TOTAL_2="124" VAR="0.04712678169542385" WEIGHT="14.08894267293745"/>
<DICH_DATA CI_END="57.251558094143675" CI_START="1.0566319795352757" EFFECT_SIZE="7.777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7577873104439088" LOG_CI_START="0.023923750705955493" LOG_EFFECT_SIZE="0.8908555305749319" ORDER="890" O_E="0.0" SE="1.0184800377531154" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" VAR="1.0373015873015872" WEIGHT="1.4405361433601571"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.004984734054409319" CI_END="3.977269728349112" CI_START="1.7470851949862687" DF="2.0" EFFECT_SIZE="2.636025238662519" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="26" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.5995850447353949" LOG_CI_START="0.24231408346620473" LOG_EFFECT_SIZE="0.42094956410079976" NO="2" P_CHI2="0.9975107363423198" P_Z="3.863361780870515E-6" STUDIES="3" TAU2="0.0" TOTAL_1="222" TOTAL_2="224" WEIGHT="21.554701695247086" Z="4.618600862574789">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="5.574056440103889" CI_START="1.236195771256233" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="8" LOG_CI_END="0.7461713618479672" LOG_CI_START="0.09208725363598415" LOG_EFFECT_SIZE="0.41912930774197565" ORDER="891" O_E="0.0" SE="0.3842122429322725" STUDY_ID="STD-Goodman-1996" TOTAL_1="80" TOTAL_2="80" VAR="0.1476190476190476" WEIGHT="7.450082630156128"/>
<DICH_DATA CI_END="4.411905717495806" CI_START="1.5618250799591231" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="16" LOG_CI_END="0.644626222986462" LOG_CI_START="0.19363239249748934" LOG_EFFECT_SIZE="0.41912930774197565" ORDER="892" O_E="0.0" SE="0.26491600848468805" STUDY_ID="STD-Hollander-2002" TOTAL_1="124" TOTAL_2="124" VAR="0.0701804915514593" WEIGHT="11.697620296299485"/>
<DICH_DATA CI_END="12.588552354372556" CI_START="0.6129417557719358" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.099975790421133" LOG_CI_START="-0.2125807919557073" LOG_EFFECT_SIZE="0.44369749923271273" ORDER="893" O_E="0.0" SE="0.7710022337480251" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" VAR="0.5944444444444443" WEIGHT="2.4069987687914733"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.881391293420904E-32" CI_END="6.6731709547962526" CI_START="0.513901907269786" DF="0.0" EFFECT_SIZE="1.8518518518518519" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" ID="CMP-003.06.03" LOG_CI_END="0.8243322508471222" LOG_CI_START="-0.28911977049305926" LOG_EFFECT_SIZE="0.2676062401770315" NO="3" P_CHI2="0.0" P_Z="0.346135002497871" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="20" WEIGHT="3.2200267183933886" Z="0.9421126060804245">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="6.6731709547962526" CI_START="0.513901907269786" EFFECT_SIZE="1.8518518518518519" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8243322508471222" LOG_CI_START="-0.28911977049305926" LOG_EFFECT_SIZE="0.2676062401770315" ORDER="894" O_E="0.0" SE="0.6540472290116194" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" VAR="0.42777777777777776" WEIGHT="3.2200267183933886"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8626089204931802" CI_END="2.407473073702245" CI_START="0.3804286356204142" DF="1.0" EFFECT_SIZE="0.9570118581926924" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" I2="46.31186455741763" ID="CMP-003.06.04" LOG_CI_END="0.3815614384724068" LOG_CI_START="-0.41972680029438236" LOG_EFFECT_SIZE="-0.019082680910987776" NO="4" P_CHI2="0.17232418907886204" P_Z="0.9256230549257228" STUDIES="2" TAU2="0.2295973529664006" TOTAL_1="98" TOTAL_2="100" WEIGHT="12.555150691429445" Z="0.0933530919449612">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.2895109209008202" CI_START="0.36303999968786305" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.11042502454055557" LOG_CI_START="-0.44004552183253987" LOG_EFFECT_SIZE="-0.16481024864599217" ORDER="895" O_E="0.0" SE="0.32334912381270703" STUDY_ID="STD-Goodman-1996" TOTAL_1="80" TOTAL_2="80" VAR="0.10455465587044535" WEIGHT="9.335123973036056"/>
<DICH_DATA CI_END="6.6731709547962526" CI_START="0.513901907269786" EFFECT_SIZE="1.8518518518518519" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8243322508471222" LOG_CI_START="-0.28911977049305926" LOG_EFFECT_SIZE="0.2676062401770315" ORDER="896" O_E="0.0" SE="0.6540472290116194" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" VAR="0.42777777777777776" WEIGHT="3.2200267183933886"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.004207731872393622" CI_END="3.7904231327626814" CI_START="1.5947547298179572" DF="1.0" EFFECT_SIZE="2.458616525402993" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="24" I2="0.0" ID="CMP-003.06.05" LOG_CI_END="0.5786876938642658" LOG_CI_START="0.20269389888068465" LOG_EFFECT_SIZE="0.3906907963724753" NO="5" P_CHI2="0.9482798697834458" P_Z="4.638118472339708E-5" STUDIES="2" TAU2="0.0" TOTAL_1="204" TOTAL_2="204" WEIGHT="19.36247599606711" Z="4.073151739191664">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="4.859554936094734" CI_START="1.2861260099309966" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="10" LOG_CI_END="0.6865964960834684" LOG_CI_START="0.1092835212606068" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="897" O_E="0.0" SE="0.3391164991562634" STUDY_ID="STD-Goodman-1996" TOTAL_1="80" TOTAL_2="80" VAR="0.115" WEIGHT="8.79534366275392"/>
<DICH_DATA CI_END="4.296302451552448" CI_START="1.3727988776819635" EFFECT_SIZE="2.4285714285714284" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="14" LOG_CI_END="0.6330948472763828" LOG_CI_START="0.13760691545165132" LOG_EFFECT_SIZE="0.3853508813640171" ORDER="898" O_E="0.0" SE="0.2910520638586665" STUDY_ID="STD-Hollander-2002" TOTAL_1="124" TOTAL_2="124" VAR="0.08471130387638928" WEIGHT="10.567132333313191"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1521192910380058" CI_END="4.595940025048056" CI_START="1.7420771166190663" DF="1.0" EFFECT_SIZE="2.8295727499023373" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="19" I2="0.0" ID="CMP-003.06.06" LOG_CI_END="0.6623743527054055" LOG_CI_START="0.24106737603377498" LOG_EFFECT_SIZE="0.4517208643695902" NO="6" P_CHI2="0.6965184250186431" P_Z="2.6351105704254207E-5" STUDIES="2" TAU2="0.0" TOTAL_1="204" TOTAL_2="204" WEIGHT="16.878803759012087" Z="4.202905122645299">
<NAME>Asthenia</NAME>
<DICH_DATA CI_END="5.174939980615271" CI_START="1.2620173802971104" EFFECT_SIZE="2.5555555555555554" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="9" LOG_CI_END="0.713905317174607" LOG_CI_START="0.10106533598192896" LOG_EFFECT_SIZE="0.40748532657826797" ORDER="899" O_E="0.0" SE="0.35998523855941134" STUDY_ID="STD-Goodman-1996" TOTAL_1="80" TOTAL_2="80" VAR="0.1295893719806763" WEIGHT="8.138089626158779"/>
<DICH_DATA CI_END="6.0454925137983215" CI_START="1.5896140766142701" EFFECT_SIZE="3.1" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="10" LOG_CI_END="0.7814316877132178" LOG_CI_START="0.20129169995532764" LOG_EFFECT_SIZE="0.4913616938342727" ORDER="900" O_E="0.0" SE="0.3407771005482389" STUDY_ID="STD-Hollander-2002" TOTAL_1="124" TOTAL_2="124" VAR="0.11612903225806454" WEIGHT="8.74071413285331"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9419086709230687" CI_END="8.731741182682136" CI_START="1.8522147463860628" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.021574291268325" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.9411008543162107" LOG_CI_START="0.26769133750994656" LOG_EFFECT_SIZE="0.6043960959130786" METHOD="MH" NO="7" P_CHI2="0.6244061305120489" P_Q="0.0" P_Z="4.3448526047003776E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="222" TOTAL_2="224" WEIGHT="100.0" Z="3.518199701139808">
<NAME>Fluvoxamine - sexual side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="258.3062776126808" CI_START="0.8710589695283282" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4121349609523244" LOG_CI_START="-0.05995244284096177" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="901" O_E="0.0" SE="1.4521163780181814" STUDY_ID="STD-Goodman-1996" TOTAL_1="80" TOTAL_2="80" VAR="2.108641975308642" WEIGHT="7.420460470235806"/>
<DICH_DATA CI_END="8.73186273581603" CI_START="1.5396994720609296" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="6" LOG_CI_END="0.9411069000162341" LOG_CI_START="0.18743596086089118" LOG_EFFECT_SIZE="0.5642714304385625" ORDER="902" O_E="0.0" SE="0.44271004039116574" STUDY_ID="STD-Hollander-2002" TOTAL_1="124" TOTAL_2="124" VAR="0.1959921798631476" WEIGHT="79.83529972769003"/>
<DICH_DATA CI_END="29.24514359023871" CI_START="0.3799301267517019" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4660537580397492" LOG_CI_START="-0.4202962674790739" LOG_EFFECT_SIZE="0.5228787452803376" ORDER="903" O_E="0.0" SE="1.1080513425729774" STUDY_ID="STD-Jenike-1990a" TOTAL_1="18" TOTAL_2="20" VAR="1.2277777777777776" WEIGHT="12.744239802074166"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.1765500513959735" CI_END="1.4204689758432476" CI_START="0.914127831695916" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1395131525695112" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="138" I2="76.0567935809662" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.1524317528303595" LOG_CI_START="-0.038993068250583005" LOG_EFFECT_SIZE="0.0567193422898882" METHOD="MH" NO="8" P_CHI2="0.04098718402020307" P_Q="0.0" P_Z="0.24544754689781778" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01937999446493117" TOTALS="YES" TOTAL_1="296" TOTAL_2="193" WEIGHT="100.0" Z="1.16147809345972">
<NAME>Paroxetine - overall adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.538158529966716" CI_START="1.0757072681481743" EFFECT_SIZE="1.2863157894736843" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="60" LOG_CI_END="0.18700109823634964" LOG_CI_START="0.03169410299902577" LOG_EFFECT_SIZE="0.10934760061768768" ORDER="905" O_E="0.0" SE="0.09122809778442921" STUDY_ID="STD-Kamijima-2004" TOTAL_1="95" TOTAL_2="94" VAR="0.008322565825365379" WEIGHT="45.64064727995682"/>
<DICH_DATA CI_END="1.1629170136895748" CI_START="0.9109940771526938" EFFECT_SIZE="1.029276693455798" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="78" LOG_CI_END="0.06554872437368137" LOG_CI_START="-0.04048444659260443" LOG_EFFECT_SIZE="0.012532138890538466" ORDER="904" O_E="0.0" SE="0.06228440949825758" STUDY_ID="STD-Zohar-1996" TOTAL_1="201" TOTAL_2="99" VAR="0.003879347666546639" WEIGHT="54.35935272004318"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="27.30624485932397" CI_END="2.358028900585505" CI_START="1.1681998769366788" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6597135510313576" ESTIMABLE="YES" EVENTS_1="405" EVENTS_2="127" I2="70.70267244282648" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.37254912361229" LOG_CI_START="0.06751715615318384" LOG_EFFECT_SIZE="0.2200331398827369" METHOD="MH" NO="9" P_CHI2="6.258395291660612E-4" P_Q="0.0" P_Z="0.004689564361638598" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1926941747582615" TOTALS="YES" TOTAL_1="1665" TOTAL_2="846" WEIGHT="100.00000000000001" Z="2.8276185815392894">
<NAME>Paroxetine - asthenia, headache, insomnia, somnolence, nausea and constipation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3377946142416333" CI_START="0.8996604928858368" DF="0.0" EFFECT_SIZE="1.4502487562189055" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="18" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="0.3688063537806444" LOG_CI_START="-0.045921350431556304" LOG_EFFECT_SIZE="0.16144250167454402" NO="1" P_CHI2="1.0" P_Z="0.1270287806171199" STUDIES="1" TAU2="0.0" TOTAL_1="201" TOTAL_2="99" WEIGHT="12.737782390746736" Z="1.5259240491648114">
<NAME>Asthenia</NAME>
<DICH_DATA CI_END="2.3377946142416333" CI_START="0.8996604928858368" EFFECT_SIZE="1.4502487562189055" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="18" LOG_CI_END="0.3688063537806444" LOG_CI_START="-0.045921350431556304" LOG_EFFECT_SIZE="0.16144250167454402" ORDER="906" O_E="0.0" SE="0.24361310638949185" STUDY_ID="STD-Zohar-1996" TOTAL_1="201" TOTAL_2="99" VAR="0.059347345604737874" WEIGHT="12.737782390746736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7069056568900285" CI_END="1.689274761530865" CI_START="0.5345811088376498" DF="1.0" EFFECT_SIZE="0.9502917316017362" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="48" I2="73.02332207615537" ID="CMP-003.09.02" LOG_CI_END="0.22770029356854013" LOG_CI_START="-0.27198639251649437" LOG_EFFECT_SIZE="-0.022143049473977123" NO="2" P_CHI2="0.05418799773520655" P_Z="0.8620956042693031" STUDIES="2" TAU2="0.12632409583432394" TOTAL_1="460" TOTAL_2="188" WEIGHT="26.88073502405278" Z="0.17370716765304495">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.047201537694405" CI_START="0.4989004413046795" EFFECT_SIZE="0.7228065503927573" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="29" LOG_CI_END="0.020030271254411248" LOG_CI_START="-0.3019861119034674" LOG_EFFECT_SIZE="-0.14097792032452805" ORDER="907" O_E="0.0" SE="0.1891540174737424" STUDY_ID="STD-Hollander-2003" TOTAL_1="259" TOTAL_2="89" VAR="0.035779242326456843" WEIGHT="14.05174431573546"/>
<DICH_DATA CI_END="2.0742680774236946" CI_START="0.8099275975825736" EFFECT_SIZE="1.296150824823252" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="19" LOG_CI_END="0.3168648836934188" LOG_CI_START="-0.0915538025729171" LOG_EFFECT_SIZE="0.11265554056025086" ORDER="908" O_E="0.0" SE="0.2399071580179484" STUDY_ID="STD-Zohar-1996" TOTAL_1="201" TOTAL_2="99" VAR="0.05755544446824886" WEIGHT="12.828990708317319"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11241583471859158" CI_END="2.5334117554002944" CI_START="1.1506732703441562" DF="1.0" EFFECT_SIZE="1.7073749411640042" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="26" I2="0.0" ID="CMP-003.09.03" LOG_CI_END="0.4037057814073643" LOG_CI_START="0.06095202473295142" LOG_EFFECT_SIZE="0.23232890307015788" NO="3" P_CHI2="0.737410372028255" P_Z="0.007882864038410198" STUDIES="2" TAU2="0.0" TOTAL_1="460" TOTAL_2="188" WEIGHT="23.37572653807443" Z="2.6570461955155564">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="3.348095111127227" CI_START="1.0146151699705095" EFFECT_SIZE="1.8431028431028431" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="11" LOG_CI_END="0.524797786731919" LOG_CI_START="0.006301351363241108" LOG_EFFECT_SIZE="0.2655495690475801" ORDER="909" O_E="0.0" SE="0.30456737273431006" STUDY_ID="STD-Hollander-2003" TOTAL_1="259" TOTAL_2="89" VAR="0.09276128453428015" WEIGHT="11.246763497792141"/>
<DICH_DATA CI_END="2.7223454294027856" CI_START="0.9509215415842972" EFFECT_SIZE="1.608955223880597" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="15" LOG_CI_END="0.4349432305533795" LOG_CI_START="-0.021855314253592547" LOG_EFFECT_SIZE="0.2065439581498935" ORDER="910" O_E="0.0" SE="0.2683257264088802" STUDY_ID="STD-Zohar-1996" TOTAL_1="201" TOTAL_2="99" VAR="0.07199869545285323" WEIGHT="12.12896304028229"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3781326379735797" CI_END="3.0603708191100303" CI_START="1.1226795169380368" DF="1.0" EFFECT_SIZE="1.8535953260757085" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="25" I2="27.43804388303217" ID="CMP-003.09.04" LOG_CI_END="0.48577405227770487" LOG_CI_START="0.050255799102611944" LOG_EFFECT_SIZE="0.2680149256901584" NO="4" P_CHI2="0.24041967458138902" P_Z="0.01585237957475799" STUDIES="2" TAU2="0.035950082120687184" TOTAL_1="354" TOTAL_2="183" WEIGHT="22.317421089942744" Z="2.412296604526935">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="4.45931132607507" CI_START="1.2975041976820565" EFFECT_SIZE="2.4054054054054053" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="10" LOG_CI_END="0.6492677936047389" LOG_CI_START="0.1131087715510966" LOG_EFFECT_SIZE="0.38118828257791776" ORDER="911" O_E="0.0" SE="0.31494246358427225" STUDY_ID="STD-Hollander-2003" TOTAL_1="259" TOTAL_2="89" VAR="0.09918875536853065" WEIGHT="10.999101723496638"/>
<DICH_DATA CI_END="2.6208951235865334" CI_START="0.8035662673839121" EFFECT_SIZE="1.4512280701754385" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="15" LOG_CI_END="0.41844964278599917" LOG_CI_START="-0.09497830263124739" LOG_EFFECT_SIZE="0.16173567007737585" ORDER="912" O_E="0.0" SE="0.30159011664740937" STUDY_ID="STD-Kamijima-2004" TOTAL_1="95" TOTAL_2="94" VAR="0.090956598459398" WEIGHT="11.318319366446106"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.613396346267056" CI_START="1.8186706054356165" DF="0.0" EFFECT_SIZE="3.957894736842105" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="7" I2="0.0" ID="CMP-003.09.05" LOG_CI_END="0.9351744317786127" LOG_CI_START="0.25975404749901376" LOG_EFFECT_SIZE="0.5974642396388132" NO="5" P_CHI2="1.0" P_Z="5.253335785639952E-4" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="9.170068450427543" Z="3.467494967572457">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="8.613396346267056" CI_START="1.8186706054356165" EFFECT_SIZE="3.957894736842105" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="7" LOG_CI_END="0.9351744317786127" LOG_CI_START="0.25975404749901376" LOG_EFFECT_SIZE="0.5974642396388132" ORDER="913" O_E="0.0" SE="0.39674527711066004" STUDY_ID="STD-Kamijima-2004" TOTAL_1="95" TOTAL_2="94" VAR="0.15740681490961445" WEIGHT="9.170068450427543"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.560699256171796" CI_START="1.2626135913599938" DF="0.0" EFFECT_SIZE="4.287719298245614" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" I2="0.0" ID="CMP-003.09.06" LOG_CI_END="1.1631822318317413" LOG_CI_START="0.1012704599643093" LOG_EFFECT_SIZE="0.6322263458980252" NO="6" P_CHI2="1.0" P_Z="0.019606589361472103" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="5.518266506755773" Z="2.3337925068075904">
<NAME>Constipation</NAME>
<DICH_DATA CI_END="14.560699256171796" CI_START="1.2626135913599938" EFFECT_SIZE="4.287719298245614" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.1631822318317413" LOG_CI_START="0.1012704599643093" LOG_EFFECT_SIZE="0.6322263458980252" ORDER="914" O_E="0.0" SE="0.6237722313429768" STUDY_ID="STD-Kamijima-2004" TOTAL_1="95" TOTAL_2="94" VAR="0.38909179659459614" WEIGHT="5.518266506755773"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="132.29303793948802" CI_START="0.3627135959255313" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.927083333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="2.1215369895841656" LOG_CI_START="-0.44043616505709304" LOG_EFFECT_SIZE="0.8405504122635361" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.1984158739366476" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.2860779061968823">
<NAME>Paroxetine - sexual adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="132.29303793948802" CI_START="0.3627135959255313" EFFECT_SIZE="6.927083333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1215369895841656" LOG_CI_START="-0.44043616505709304" LOG_EFFECT_SIZE="0.8405504122635361" ORDER="915" O_E="0.0" SE="1.504915713007923" STUDY_ID="STD-Kamijima-2004" TOTAL_1="95" TOTAL_2="94" VAR="2.2647713032581454" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6642169988979783" CI_END="1.3669212660146628" CI_START="1.0762865757852542" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2129299273935679" ESTIMABLE="YES" EVENTS_1="330" EVENTS_2="149" I2="18.127119630134978" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.13574350014198294" LOG_CI_START="0.031927923478479954" LOG_EFFECT_SIZE="0.08383571181023142" METHOD="MH" NO="11" P_CHI2="0.30008012070420576" P_Q="0.0" P_Z="0.0015480772438555557" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.003039572442117747" TOTALS="YES" TOTAL_1="380" TOTAL_2="218" WEIGHT="100.0" Z="3.1655167952093817">
<NAME>Sertraline - overall adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7455562334837849" CI_START="1.0079596752275835" EFFECT_SIZE="1.326442721791559" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.24193384426925998" LOG_CI_START="0.003443157926518555" LOG_EFFECT_SIZE="0.12268850109788926" ORDER="916" O_E="0.0" SE="0.14009060970566337" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" VAR="0.019625378927704502" WEIGHT="16.40761488395179"/>
<DICH_DATA CI_END="1.3496690441056713" CI_START="1.059449383836927" EFFECT_SIZE="1.1957867858282796" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="65" LOG_CI_END="0.13022728705818398" LOG_CI_START="0.025080212726452753" LOG_EFFECT_SIZE="0.07765374989231837" ORDER="917" O_E="0.0" SE="0.061763911948871174" STUDY_ID="STD-Greist-1992b" TOTAL_1="241" TOTAL_2="84" VAR="0.0038147808192279115" WEIGHT="54.25424970969929"/>
<DICH_DATA CI_END="1.3094041214253411" CI_START="0.3156132620635045" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.11707370355517462" LOG_CI_START="-0.5008447560330008" LOG_EFFECT_SIZE="-0.1918855262389131" ORDER="918" O_E="0.0" SE="0.3629683619078001" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" VAR="0.13174603174603175" WEIGHT="2.759031987721986"/>
<DICH_DATA CI_END="1.5494239941049346" CI_START="1.02804578050385" EFFECT_SIZE="1.2620930232558139" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="50" LOG_CI_END="0.19017027709003503" LOG_CI_START="0.01201245490974421" LOG_EFFECT_SIZE="0.10109136599988962" ORDER="919" O_E="0.0" SE="0.10465078664414565" STUDY_ID="STD-Kronig-1999" TOTAL_1="86" TOTAL_2="81" VAR="0.010951787145238492" WEIGHT="26.579103418626943"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.93815199858035" CI_END="2.5085694345640435" CI_START="1.4032937728915473" CI_STUDY="95" CI_TOTAL="95" DF="19.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8762355572768021" ESTIMABLE="YES" EVENTS_1="501" EVENTS_2="125" I2="45.618188389666315" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.39942612634470853" LOG_CI_START="0.14714859803495506" LOG_EFFECT_SIZE="0.2732873621898318" METHOD="MH" NO="12" P_CHI2="0.01420828903098359" P_Q="0.0" P_Z="2.172500373006037E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.16012248522349287" TOTALS="YES" TOTAL_1="2055" TOTAL_2="1093" WEIGHT="99.99999999999999" Z="4.246382076998613">
<NAME>Sertraline - nausea, insomnia, dyspepsia, constipation, sedation, forgetfulness, headache and diarrhoea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.308137217260507" CI_END="7.6331835339051075" CI_START="0.8877868455959466" DF="3.0" EFFECT_SIZE="2.60319802001702" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="22" I2="67.77013563533461" ID="CMP-003.12.01" LOG_CI_END="0.8827057047769813" LOG_CI_START="-0.05169129423678085" LOG_EFFECT_SIZE="0.4155072052701001" NO="1" P_CHI2="0.02546259519988958" P_Z="0.08131411016404269" STUDIES="4" TAU2="0.6981109290550446" TOTAL_1="380" TOTAL_2="218" WEIGHT="17.953762866336664" Z="1.7431116720320146">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="90.38941596261338" CI_START="1.6680664738011812" EFFECT_SIZE="12.279069767441861" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9561175802747137" LOG_CI_START="0.22221335363373784" LOG_EFFECT_SIZE="1.0891654669542257" ORDER="920" O_E="0.0" SE="1.0185039256932553" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" VAR="1.0373502466525721" WEIGHT="1.833862230322137"/>
<DICH_DATA CI_END="3.2119464109639924" CI_START="1.09664375955182" EFFECT_SIZE="1.8767954037663581" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="13" LOG_CI_END="0.5067682907732753" LOG_CI_START="0.040065571615591294" LOG_EFFECT_SIZE="0.27341693119443333" ORDER="921" O_E="0.0" SE="0.2741434874489422" STUDY_ID="STD-Greist-1992b" TOTAL_1="241" TOTAL_2="84" VAR="0.07515465171066832" WEIGHT="9.333673655858457"/>
<DICH_DATA CI_END="2.21559756982024" CI_START="0.007612506378517477" EFFECT_SIZE="0.12987012987012986" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.34549088011869794" LOG_CI_START="-2.118472330463662" LOG_EFFECT_SIZE="-0.8864907251724818" ORDER="922" O_E="0.0" SE="1.4473441867106782" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" VAR="2.0948051948051947" WEIGHT="0.973867159589014"/>
<DICH_DATA CI_END="11.28178815455374" CI_START="1.8116640631483898" EFFECT_SIZE="4.52093023255814" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="5" LOG_CI_END="1.0523779404370504" LOG_CI_START="0.2580776695842883" LOG_EFFECT_SIZE="0.6552278050106692" ORDER="923" O_E="0.0" SE="0.46657591094866524" STUDY_ID="STD-Kronig-1999" TOTAL_1="86" TOTAL_2="81" VAR="0.2176930806775768" WEIGHT="5.812359820567059"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.315529547437517" CI_END="4.555114288085841" CI_START="1.0900606009265874" DF="2.0" EFFECT_SIZE="2.2283066705819774" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="27" I2="62.374397844065236" ID="CMP-003.12.02" LOG_CI_END="0.6584992779198522" LOG_CI_START="0.03745064281807404" LOG_EFFECT_SIZE="0.3479749603689632" NO="2" P_CHI2="0.07010489631354255" P_Z="0.028067291908481697" STUDIES="3" TAU2="0.24720302848002515" TOTAL_1="370" TOTAL_2="209" WEIGHT="21.45888649154471" Z="2.196344541464616">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="2.9311694775600183" CI_START="0.5581456420410191" EFFECT_SIZE="1.2790697674418605" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4670409296773462" LOG_CI_START="-0.2532524618480315" LOG_EFFECT_SIZE="0.10689423391465734" ORDER="924" O_E="0.0" SE="0.42310390369179873" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" VAR="0.17901691331923889" WEIGHT="6.475213508853013"/>
<DICH_DATA CI_END="3.113926249568116" CI_START="1.1659001310997308" EFFECT_SIZE="1.9053941908713692" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="15" LOG_CI_END="0.49330832249514084" LOG_CI_START="0.06666135113495654" LOG_EFFECT_SIZE="0.2799848368150487" ORDER="925" O_E="0.0" SE="0.2506145429135414" STUDY_ID="STD-Greist-1992b" TOTAL_1="241" TOTAL_2="84" VAR="0.06280764911976328" WEIGHT="9.850619887246365"/>
<DICH_DATA CI_END="15.57907020570017" CI_START="2.049906731614902" EFFECT_SIZE="5.651162790697675" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="4" LOG_CI_END="1.1925415344287493" LOG_CI_START="0.31173410160870213" LOG_EFFECT_SIZE="0.7521378180187257" ORDER="926" O_E="0.0" SE="0.5173906461056064" STUDY_ID="STD-Kronig-1999" TOTAL_1="86" TOTAL_2="81" VAR="0.2676930806775768" WEIGHT="5.133053095445334"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.307547266495157" CI_END="59.74123909160013" CI_START="0.32397968556099266" DF="1.0" EFFECT_SIZE="4.399425855258921" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="5" I2="69.76611611480763" ID="CMP-003.12.03" LOG_CI_END="1.7762742260529067" LOG_CI_START="-0.48948222042719736" LOG_EFFECT_SIZE="0.6433960028128547" NO="3" P_CHI2="0.06896241807901715" P_Z="0.2656555539151978" STUDIES="2" TAU2="2.625874712738489" TOTAL_1="284" TOTAL_2="128" WEIGHT="6.6865078184783755" Z="1.1131231649096844">
<NAME>Dyspepsia</NAME>
<DICH_DATA CI_END="355.4676266945377" CI_START="1.297651907407131" EFFECT_SIZE="21.477272727272727" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.550800054606931" LOG_CI_START="0.11315820943921964" LOG_EFFECT_SIZE="1.3319791320230756" ORDER="927" O_E="0.0" SE="1.4318828863732538" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" VAR="2.0502886002886003" WEIGHT="0.9934803662638294"/>
<DICH_DATA CI_END="4.2443680635663545" CI_START="0.6594682990837847" EFFECT_SIZE="1.6730290456431536" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="5" LOG_CI_END="0.6278130380579553" LOG_CI_START="-0.18080607633275436" LOG_EFFECT_SIZE="0.22350348086260047" ORDER="928" O_E="0.0" SE="0.4749868705222743" STUDY_ID="STD-Greist-1992b" TOTAL_1="241" TOTAL_2="84" VAR="0.22561252716854374" WEIGHT="5.6930274522145465"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.531983507816143" CI_START="0.3385661147916875" DF="0.0" EFFECT_SIZE="2.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-003.12.04" LOG_CI_END="1.333084038500738" LOG_CI_START="-0.4703565101827632" LOG_EFFECT_SIZE="0.43136376415898736" NO="4" P_CHI2="1.0" P_Z="0.34844744975606046" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.7124880713255064" Z="0.9376050046167843">
<NAME>Constipation</NAME>
<DICH_DATA CI_END="21.531983507816143" CI_START="0.3385661147916875" EFFECT_SIZE="2.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.333084038500738" LOG_CI_START="-0.4703565101827632" LOG_EFFECT_SIZE="0.43136376415898736" ORDER="929" O_E="0.0" SE="1.0593499054713802" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" VAR="1.122222222222222" WEIGHT="1.7124880713255064"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.061218706322501" CI_END="2.6229017078388406" CI_START="0.6496828819530877" DF="2.0" EFFECT_SIZE="1.3053943238073367" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="20" I2="34.66654323425858" ID="CMP-003.12.05" LOG_CI_END="0.4187820158884669" LOG_CI_START="-0.18729857601014988" LOG_EFFECT_SIZE="0.11574171993915855" NO="5" P_CHI2="0.21640384537664237" P_Z="0.4541109974698635" STUDIES="3" TAU2="0.13729270714530675" TOTAL_1="337" TOTAL_2="174" WEIGHT="16.064676813772046" Z="0.7485790029304183">
<NAME>Sedation</NAME>
<DICH_DATA CI_END="1.913463094210626" CI_START="0.5714087759653833" EFFECT_SIZE="1.045643153526971" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="12" LOG_CI_END="0.2818200902159957" LOG_CI_START="-0.24305309380264414" LOG_EFFECT_SIZE="0.019383498206675735" ORDER="930" O_E="0.0" SE="0.3083131064567126" STUDY_ID="STD-Greist-1992b" TOTAL_1="241" TOTAL_2="84" VAR="0.0950569716129882" WEIGHT="8.60570847689898"/>
<DICH_DATA CI_END="4.164618053273272" CI_START="0.04862390678080086" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6195751774205822" LOG_CI_START="-1.313150149869895" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="931" O_E="0.0" SE="1.1352924243950933" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" VAR="1.2888888888888888" WEIGHT="1.5155160643051426"/>
<DICH_DATA CI_END="5.772993205866037" CI_START="0.9603999001415496" EFFECT_SIZE="2.354651162790698" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.7614010463854098" LOG_CI_START="-0.01754789377117045" LOG_EFFECT_SIZE="0.37192657630711967" ORDER="932" O_E="0.0" SE="0.4575584633074155" STUDY_ID="STD-Kronig-1999" TOTAL_1="86" TOTAL_2="81" VAR="0.20935974734424348" WEIGHT="5.9434522725679235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="59.57376743870334" CI_START="0.12485388869486465" DF="0.0" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.12.06" LOG_CI_END="1.7750550657040625" LOG_CI_START="-0.9035979265811878" LOG_EFFECT_SIZE="0.43572856956143735" NO="6" P_CHI2="1.0" P_Z="0.523706034306008" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.8331183377178537" Z="0.6376431033323103">
<NAME>Forgetfulness</NAME>
<DICH_DATA CI_END="59.57376743870334" CI_START="0.12485388869486465" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7750550657040625" LOG_CI_START="-0.9035979265811878" LOG_EFFECT_SIZE="0.43572856956143735" ORDER="933" O_E="0.0" SE="1.573454027214515" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" VAR="2.4757575757575756" WEIGHT="0.8331183377178537"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.304192394622438" CI_END="2.028572178427435" CI_START="0.7356916446936868" DF="2.0" EFFECT_SIZE="1.2216397187088894" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="30" I2="13.20169250329821" ID="CMP-003.12.07" LOG_CI_END="0.3071904649045644" LOG_CI_START="-0.1333041762451615" LOG_EFFECT_SIZE="0.08694314432970142" NO="7" P_CHI2="0.31597413167084376" P_Z="0.4391080126499106" STUDIES="3" TAU2="0.045778717231859264" TOTAL_1="294" TOTAL_2="137" WEIGHT="16.596902792004233" Z="0.7737003616848142">
<NAME>Headache</NAME>
<DICH_DATA CI_END="2.1263910537771453" CI_START="0.25122869014589216" EFFECT_SIZE="0.7308970099667774" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.327643136424375" LOG_CI_START="-0.5999307659676492" LOG_EFFECT_SIZE="-0.13614381477163712" ORDER="934" O_E="0.0" SE="0.5448615018299438" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" VAR="0.2968740561763818" WEIGHT="4.805288040258208"/>
<DICH_DATA CI_END="2.159937737072397" CI_START="0.9835887387058032" EFFECT_SIZE="1.4575631837042626" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="22" LOG_CI_END="0.33444123224555183" LOG_CI_START="-0.007186452224827191" LOG_EFFECT_SIZE="0.16362739001036233" ORDER="935" O_E="0.0" SE="0.20067379294221221" STUDY_ID="STD-Greist-1992b" TOTAL_1="241" TOTAL_2="84" VAR="0.04026997117381386" WEIGHT="10.958496414028172"/>
<DICH_DATA CI_END="6.619307493189261" CI_START="0.013872654299429408" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8208125562647377" LOG_CI_START="-1.8578404360205125" LOG_EFFECT_SIZE="-0.5185139398778874" ORDER="936" O_E="0.0" SE="1.573454027214515" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" VAR="2.4757575757575756" WEIGHT="0.8331183377178537"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.619983844856473" CI_END="4.226510489103005" CI_START="1.1088973119994956" DF="2.0" EFFECT_SIZE="2.164894020617175" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="20" I2="44.75113465377089" ID="CMP-003.12.08" LOG_CI_END="0.6259819511192891" LOG_CI_START="0.04489133073272277" LOG_EFFECT_SIZE="0.335436640926006" NO="8" P_CHI2="0.1636555261821232" P_Z="0.023648486332399632" STUDIES="3" TAU2="0.15731733580173973" TOTAL_1="370" TOTAL_2="209" WEIGHT="18.69365680882061" Z="2.2627924535168247">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="2.6714836675593974" CI_START="0.39193668803005555" EFFECT_SIZE="1.0232558139534884" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4267525234148589" LOG_CI_START="-0.4067840816016571" LOG_EFFECT_SIZE="0.009984220906600923" ORDER="937" O_E="0.0" SE="0.4896235278594408" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" VAR="0.2397311990335246" WEIGHT="5.4920089554974325"/>
<DICH_DATA CI_END="6.068468597845968" CI_START="1.5327152695787007" EFFECT_SIZE="3.0497925311203318" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="8" LOG_CI_END="0.783079108963933" LOG_CI_START="0.18546148405472013" LOG_EFFECT_SIZE="0.4842702965093265" ORDER="938" O_E="0.0" SE="0.351043551126625" STUDY_ID="STD-Greist-1992b" TOTAL_1="241" TOTAL_2="84" VAR="0.12323157478759138" WEIGHT="7.7500213504697255"/>
<DICH_DATA CI_END="7.42066472164542" CI_START="1.0759022973310097" EFFECT_SIZE="2.8255813953488373" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.870442809862914" LOG_CI_START="0.031772834846575095" LOG_EFFECT_SIZE="0.45110782235474445" ORDER="939" O_E="0.0" SE="0.49263889480792805" STUDY_ID="STD-Kronig-1999" TOTAL_1="86" TOTAL_2="81" VAR="0.24269308067757678" WEIGHT="5.451626502853452"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.037903216712794" CI_END="48.30537026419168" CI_START="0.6828187675666798" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.7431536102256135" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="4" I2="72.82092494290386" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="1.6839954153572403" LOG_CI_START="-0.16569455062315827" LOG_EFFECT_SIZE="0.7591504323670409" METHOD="MH" NO="13" P_CHI2="0.011522722122598306" P_Q="0.0" P_Z="0.1076560845543127" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="3.35585763100996" TOTALS="YES" TOTAL_1="380" TOTAL_2="218" WEIGHT="100.0" Z="1.6088182707946617">
<NAME>Sertraline - sexual side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="62.69979205523282" CI_START="1.0687652270282577" EFFECT_SIZE="8.186046511627907" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7972661004891743" LOG_CI_START="0.028882315307914724" LOG_EFFECT_SIZE="0.9130742078985445" ORDER="940" O_E="0.0" SE="1.0387573890563855" STUDY_ID="STD-Chouinard-1990" TOTAL_1="43" TOTAL_2="44" VAR="1.0790169133192389" WEIGHT="26.61900062873674"/>
<DICH_DATA CI_END="413.20273975416063" CI_START="1.5910713194598052" EFFECT_SIZE="25.640495867768596" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="0" LOG_CI_END="2.6161631924607702" LOG_CI_START="0.20168964724786467" LOG_EFFECT_SIZE="1.4089264198543174" ORDER="941" O_E="0.0" SE="1.4182737122948663" STUDY_ID="STD-Greist-1992b" TOTAL_1="241" TOTAL_2="84" VAR="2.0115003229866613" WEIGHT="21.994420587500436"/>
<DICH_DATA CI_END="2.8157110328062926" CI_START="0.12785402898436074" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4495880825378574" LOG_CI_START="-0.89328558177057" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="942" O_E="0.0" SE="0.7888106377466155" STUDY_ID="STD-Jenike-1990b" TOTAL_1="10" TOTAL_2="9" VAR="0.6222222222222222" WEIGHT="29.675605477841412"/>
<DICH_DATA CI_END="302.78395804019203" CI_START="1.0591648011688506" EFFECT_SIZE="17.908045977011493" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.481132861847917" LOG_CI_START="0.02496353958793708" LOG_EFFECT_SIZE="1.253048200717927" ORDER="943" O_E="0.0" SE="1.442766018129743" STUDY_ID="STD-Kronig-1999" TOTAL_1="86" TOTAL_2="81" VAR="2.081573783069954" WEIGHT="21.71097330592141"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot 1.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuoAAAGQCAMAAADP6LWuAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot 2.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuoAAAGQCAMAAADP6LWuAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA
JFUAJKoAJP8ASQAASVUASaoASf8AawAAa1UAa6oAa/8AkgAAklUAkqoAkv8AtgAAtlUAtqoAtv8A
2wAA21UA26oA2/8A/wAA/1UA/6oA//8kAAAkAFUkAKokAP8kJAAkJFUkJKokJP8kSQAkSVUkSaok
Sf8kawAka1Uka6oka/8kkgAkklUkkqokkv8ktgAktlUktqoktv8k2wAk21Uk26ok2/8k/wAk/1Uk
/6ok//9JAABJAFVJAKpJAP9JJABJJFVJJKpJJP9JSQBJSVVJSapJSf9JawBJa1VJa6pJa/9JkgBJ
klVJkqpJkv9JtgBJtlVJtqpJtv9J2wBJ21VJ26pJ2/9J/wBJ/1VJ/6pJ//9rAABrAFVrAKprAP9r
JABrJFVrJKprJP9rSQBrSVVrSaprSf9rawBra1Vra6pra/9rkgBrklVrkqprkv9rtgBrtlVrtqpr
tv9r2wBr21Vr26pr2/9r/wBr/1Vr/6pr//+SAACSAFWSAKqSAP+SJACSJFWSJKqSJP+SSQCSSVWS
SaqSSf+SawCSa1WSa6qSa/+SkgCSklWSkqqSkv+StgCStlWStqqStv+S2wCS21WS26qS2/+S/wCS
/1WS/6qS//+2AAC2AFW2AKq2AP+2JAC2JFW2JKq2JP+2SQC2SVW2Saq2Sf+2awC2a1W2a6q2a/+2
kgC2klW2kqq2kv+2tgC2tlW2tqq2tv+22wC221W226q22/+2/wC2/1W2/6q2///bAADbAFXbAKrb
AP/bJADbJFXbJKrbJP/bSQDbSVXbSarbSf/bawDba1Xba6rba//bkgDbklXbkqrbkv/btgDbtlXb
tqrbtv/b2wDb21Xb26rb2//b/wDb/1Xb/6rb////AAD/AFX/AKr/AP//JAD/JFX/JKr/JP//SQD/
SVX/Sar/Sf//awD/a1X/a6r/a///kgD/klX/kqr/kv//tgD/tlX/tqr/tv//2wD/21X/26r/2///
/wD//1X//6r////30rcGAAAOg0lEQVR42u3dCZKjvBJGUfqP3gih/S9JwU5evHYxCRCDXbax8Lnd
noWQxEeSSqdVf5oK+Ab+MwQgdYDUAVIHSB0gdYDUAVIHSB0gdZA6QOrAFaUebszeeqDutJYwry1s
Fl/dcdhsZaZcyL4duvvpY7aabi/tQ7fP8ItRaTcKex3d6fxPU3ZbELIH5cgWYeXohKP76d/u9zcM
31g8bB+xkCuwGJGQDsbifmjFv9vfbBvj7dM4f+feQ7qsZavC7eK5zQ5tcKSyuNGFrll966b7jL/a
/cPt7YfrrtG6Y7PslnHo/z0CmN26+7YFcVp4p1npgZg3s619eT+cHLfX/+2Y5f6kCJNXW4ZwOUBh
fub1/6qh2nnxYYfJnvsP5nZpeN23a7LZfCf95kNnfj5N+pduODsX4mKvcWFUQtLQallpSK4jY/vC
mm2qJhYq6fxP02KYlljcLwa53Szb1MHc5rdsBZN2ZOxYVa2NXt/Mfr9do2OYdScZ1tEO549FNTZ4
EGFcP13DsNe/q1eeOLMAw6vuzNo9v//VHhfn9ng/r3ZaPMRxg4lFqKrJ+RqXdupni3GzKkzLTOrv
HpPis9J9s7qHbp8z6zgxJP2++6eL3vRWJjE8MTtCs0qS1md6u2rVcrY819R82ZDb4bxjoVobvSOW
cH7sqvSama9t3ua8hGeXjjUHptVBt8PZleCo33Brdsy4f3HoSYiTt5PiB+uPGUcxEel44Tvsu8RW
1nHei/Eh9mdA3sOb1BzH3oRpszLbxnSEjg5D2powPu/bNx/k/UHY23LS89FQh/zo3eHsxBCX4zOt
rS8Vq4wDtH0SrUm9Smv8hbseU/cu7nqF8V5vcGxlWNbfHahMTw6eQ7OX/UPvaB453ROxxHsKP9bi
OHke4mPHbm/LfM/jzueHJuu7rQmbnvzvgo1hMvfqXh2bjYX1wMdsUhdWit8xTjHGdLadqeh47CCk
piXky4W5+QkHYhlhLSpSZfcWNkaiddPjWGdMJgExjO9MBzmG3aaubJleIGM+MhSWI9M3M9lvVjsh
3ghLjUyPRV8qPKD0Vat+62icmMoYliGAPV/9tkW/XfvYvUqDGOm1Pia7GYrGsH5JSD+9XexC71b/
fNDWuVXD4IPHxY4XvRg+jpkycT5APzX3bUjKDH7VtOFD+yeV9ZVkHK1xWONkm1xj5n3bauralulx
mh2modXV6vb9wdy5wAyVdbJfOXL9UZvEHGOm/6lI/1zuZ9TPjP/t1hXiE5rx3ojl+/b/lMHJbRMe
mgv4tnT3wvTBIi109B4athh+edb9sTgGvgNWHaQOkDpQHCvBxrD/rcP+3CJMM7K6cF33dX5VPfJl
Q1jdarumRT7CnX3rvyPumj0OUEj6hAKlfiSPIR7RS5LTsJkieHwe/mio6a4vYjNR7G7HY97MLG1F
NKZIB2Yj/23MYJvluE3yuFcN5GqKYDXJpFtkUmYy4LaTACflklzKTPJf8i1mmPW5y3lcGaBJwh6r
XqgDMzHL+VS9WY5b+wXlhoE8kiK4liGXy17cTQIcy43JDOvJf/Pr2SQRcUx6ywZ351/eoTSpz8Q6
T9W7N4dtJ0Vwkkk3y5AbnyffM48ezYZVDbl2pFvHqQu/zFgMiQszzVFcdA2FS31p9ZIjfNcBPpIi
mM+QG57HbDPW59VxtxP5Nt4/h+Crl+irH8h/6+V0/Nva3RTBWSZd8mOV7J62kwBjjGuGPUy3niZu
7mcsjgM0JOwFOirWqh9J1cuVmtrnxea7KYLZHLxJ3lzSliNJgPnX2Upzb6a9HZUfq0y6Jgfm0zme
A3PZC/SRn+/i+3z171I6a/2VVh243rQUIHWA1IECp6VpyO3hEMT0l7NDUuBD88Q+qTCpZXvFm3h4
+hni0Vkqrif1EJ9wzOeZJr9M/5svb/I0Tc5Wu6H1b5J6mK7u1CY99QY6xDHxPD6wQuasquF5X+mQ
Dd5nW8X1E6marrgQ0oXtxqr7pVHGbgw1h5jspf8qita/yYGZmbncooRhLZdxw5+pYrWajZikEh5e
AHB63Zivo7hYxTBk97G8/uA7pb4wzzGR7mFPppovBPmTQBizp9ajCwBmVhOspomMy3UT4/j+Y4sN
4npS33dNdqd9cb6w4H7Vd2UMxrUp7d5qn/H+faE0NjIb49R0H/irDkcDKsOSght1ZhYAPBLxSX9Q
lFQ060Z23cTwy2V1UKJVT5IFw7hyXm41vi1HuptuhnQd6Lidjbi9AODWfqrZsojTtQxn3ZilMGYT
OXExTs2B+ZW/8KqNOTF89Q/j4aDgdroipbPqwPWmpQCpA6QOkDpA6gCpA6QOkDpA6iB14PJs5cDU
VdVMn2TL3D67Pfw8Nrf/mTJJoVouAj5L6nUr3eRJvszPXTO+XNJM5N7QOgp1YAZD3Z0TdX0T9r+7
eqJ/CsdnWfV6NMUHVF635erJBq32m3rq5MwKAedKvX7IojeJ2a77F73We6vPTU9G2UicLvXmnuPQ
Gm9HDV/iq6fGum5y9zf7Pvg0Tg18hq+e+uFt/LBZDTY2s1jj+OboqQMfQe4Hd486kqm5Xg9QMup8
9eKlPtX6ypWA0nEBqQMXn5YCpI68q2fSTuoAqQOkDpA68IM/vH4KormsOkDqAKkXh7g6qV8Sf2GJ
1L9C5uHnP0j92kIP45/qA6nzXPAGxNVPQVydVWfUQerlSdvfheTAXFXoYVXds/f90ItVL92kh4zA
4z84N6z6tYlbpwb/hlW//BR0eQVg5En9Avb7gPR9oUrqF70C/PffnpsPUv9ssx6PF4Vp6cVdmBB/
4+aDVS/Febm55fF//0vODUaeVb+km97d0zerzs0Hq34Vo26eyqqbuoJVZ2FgzJl1kPoHat0clAPz
TYa99ndyWHWA1AFSLwK5Lnz1bxG6Hx6R+teY9D6r0aSUAwOQOj8dpP75zNeBsb46qQOkfgGzLgJz
HiIwJ7kwz58NOI1I/UumvaL2pP6BNM9XOsPOVwf2pF6PITGxsU93X9pH4fuHpF43TVNT+kt4IK4e
Dk15af13DozfEZxvty1g+vxpad3dyPvjPJT1aWd0Gtxv1WtGvUSi4MvdVr3J/KGemtw/Y9qJpzow
SxpKfzZ3DucR/6Qtw7g/IvVb+IXKC/JhDMEmfzJC9pcGP9SFIeZXOzB4OndbEyr/NRIDQOoAqQOk
DpiWYmB1UirlnNS/Ar8l4sB8jdIrWQCkfimsA0PqjDpI/fJw0kkdIPULmnXG/TUINp5Cw4Vh1QFS
B0i9NMTVSR0gdYDUAVIHWsTVT8GSDKw6QOoAqReHuDqpA6QOkDpA6kCLuPopiKuz6gCpA6ReHOLq
pA6QOkDqAKkDLeLqpyCuzqoDpA6QenGIq5M6QOoAqQOkDrSIq5+CuDqrDpA6QOrFIa5O6sAJ09K6
nz7V5lG4stTrpr2NTwAODFCcVa+722jGGw7MszGcHyD1esOTAS4k9ZusGR3w1fEUxNU/wVefu+h1
w1fHtaXeybuhc3BgAFIHynFg8DK4hKw6QOoAqReHuDqpA6QOkDpA6kCLuPopiKuz6gCpA6ReHOLq
pA6QOkDqAKkDLeLqpyCuzqoDpA6QenGIq5M6QOoAqQOkDrSIq5+CuDqrDpA6QOrFIa5O6gCpA6QO
kDrQIq5+CuLqrDpA6gCpF4e4OqkDpA6QOkDqQIu4+imIq7PqAKkDpF4c4uqkDpA6QOrA76ReD54l
1xKl8/eI0pv2hqdhND/Kqg/qdlxwSated7eGwnFpq15vW3g8BZOfD7DqN7984bJQOq7sq1M6vkvq
9e2fCy6uNy2dOjO3OzYdV5c6XgXr8aG+OkDqAKljY65vmk/qAKkDpA6QOvCDuPopiKuz6gCpA6Re
HOLqpA6QOkDqAKkDLeLqpyCuzqoDpA6QenGIq5M6QOoAqeMkQiB1fIvYSR1bXGWZ41iQ1kkdX6J1
UseXaF1iwCnUBacGLJUdIqsOsOoo2GXZsfKsOq5IWIqf1EHpHJhvo6F0Vh2UTuooYJLKgcGE+iIu
TCyoraw6vgRSB6kDpA4Uh2npKVgHhlUHSB0g9eKwDgypA6QOkDpA6kCLuPopiKuz6sAZUu8jYrXY
GC7twAxKb9obnkbNhfkkqz5RtyODy1n1urslK2jWpI7rSb3Oxws4MLia1BuOJL5uWoqXwZZ8otTr
puGro3z+ZDTMgcEF8W3pKfhOjtQBUgdIHSB1oEVc/RSEuFh1gNQBUi8OcXVSB0gdIHWA1IEWcfVT
EFdn1QFSB0i9OMTVSR0gdYDUAVIHWsTVT0FcnVUHSB0g9eIQVyd1gNQBUgdIHWgRVz8FcXVWHSB1
gNSLQ1yd1AFSB0gdIHWgRVz9FMTVWXWA1AFSLw5xdVIHSB0gdYDUgRZx9VMQV2fVAVIHSL04xNVJ
HShc6u82Y6/YXyl1Xr0PrDpA6kD1JxPhNWXCfRTxNQGrji/h75vO0vrNZ35dSB+uMS58dYDUAVIH
XsEfOXZg1YEL8Xc5m+7sfP00ez/UWb8nApvu76k7rJvXtfVNPHtIukGpC4it/122uz2g9VPHoh2P
5iVqWd3f0w/qS9v6JpoXnDsndOOJDswrGv7usaibT67uCkNSgMDXHZizjsFrPZkiZVnAkBQ1KG/+
belbjUBThNUxJCc7MBc4rIWYWUNyRanX7873oPQCh+RVzL9Can25586o+zrrNzl3Qx+e7Zg+X5fv
GpKX+eoFBRt9WwoODEDqAKkDn4k1G7E6WU4nzT+z/GY5Ma+bUsKlpI4lzUzurdKbfJilFK1zYLA0
1NPH3qa3/1r1t8sc1VfIgcGXOzBNNcv4bY130zosrZHvvioxLUWx/kvTKrx/nORF/zz/sep1U1QK
HKuO+6esRWZ5surIuOpNPT5OPqmb7q3WVy/iNxmkjodPg6ZunxRl3OXA4JjCH/mMVUdp89S6fKWz
6vgWWHWQOkDqAKkDpA6QOkDqAKkDpA6QOr6T/wNey/WBtrBNdQAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>